Ikaros zinc finger family degraders and uses thereof

Abstract

The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and / or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and / or conditions through binding and degradation of an IKZF protein, such as IKZF2 and / or IKZF4, including cancer.

Description

IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF CROSS-REFERENCES TO RELATED APPLICATIONS

[0001] This application claims the benefit under 35 U.S.C. § 119(e) of U.S. provisional application no. 63 / 321,030, filed on March 17, 2022, and of U.S. provisional application no. 63 / 386,605, filed on December 8, 2022, which are hereby incorporated herein by reference in their entireties for all purposes. FIELD

[0002] The present disclosure relates to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and / or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the treatment and / or prophylaxis of diseases and / or conditions associated with one or more IKZF proteins, e.g., an IKZF2 and / or IKZF4 associated disease or condition where reduction of IKZF2 and / or IKZF4 protein levels can ameliorate the disease or disorder. SEQUENCE LISTING

[0003] The instant application contains a Sequence Listing which has been submitted electronically in .XML file format and is hereby incorporated by reference in its entirety. Said .XML copy, created on created on February 21, 2023, is named 1423-WO-PCT.xml and is 2,747 bytes in size. BACKGROUND

[0004] The IKAROS family of transcription factors includes five members: Ikaros (IKZF1), Helios (IKZF2), Aiolos (IKZF3), Eos (IKZF4), and Pegasus (IKZF5). Helios is about 50% identical with Ikaros, Aiolos, and Eos, and binds to the same DNA consensus site. When co- expressed in cells these four IKZF proteins can heterodimerize with each other. While Ikaros, Helios, and Aiolos are predominantly expressed in hematopoietic cells, Eos and Pegasus are more widely expressed across different tissues.

[0005] Regulatory T cells (Tregs) are a subset of CD4+ T cells that maintain normal immune tolerance and homeostasis. Treg activity can also repress antitumor immune responses. Helios is believed to be required to maintain a stable Treg phenotype, especially in the context of inflammatory tumor microenvironments. Genetic Helios knockout in Tregs has been shown to reduce Treg immunosuppressive activity and induce an effector T cell phenotype. A firstgeneration of small molecule Helios degraders has shown similar effects. As such Helios has emerged as a promising immuno-oncology target. Moreover, Helios degraders are expected to be useful for the treatment of chronic viral infections, which are also characterized by the presence of elevated levels of activated Tregs.

[0006] A need remains for Helios degraders with desirable selectivity, potency, metabolic stability, or reduced detrimental effects. SUMMARY

[0007] The present disclosure provides compounds useful as degraders of IKAROS Family Zinc Finger (IKZF) protein 2 (IKZF2; Helios). The disclosure further relates to the use of the compounds for the treatment and / or prophylaxis of diseases and / or conditions through binding and degradation of IKZF2 protein by said compounds.

[0008] In one embodiment, provided herein is a compound of Formula (I),or a pharmaceutically acceptable salt thereof, wherein: R1is -H; R2is -H, -F, or -Cl; R21is -H, -F, or -Cl; R3is -H, -F, or -Cl; R4aand R4bare each independently -H, halogen, -OH, or C1-6alkyl; Ring A is C3-10cycloalkyl or heterocyclyl; n is 0, 1, 2, 3, or 4;each R5is independently halogen, =O, =CH2, -CN, C1-6alkyl, C2-6alkenyl, C1-6haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C3-6cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, -O-(R51), or -N(R51)(R52); wherein each =CH2, alkyl, alkenyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclyl, aryl, or heteroaryl of R5is optionally substituted with one to four R5a, which may be the same or different; each R5ais independently halogen, -CN, C1-6alkyl, C6-10aryl, or -O(R51); wherein each R51and R52, which may be the same or different, is independently -H, C1-6alkyl, C3-10cycloalkyl, heterocyclyl, C6-10aryl, or heteroaryl; R6is -H, C1-8alkyl, C1-6haloalkyl, C3-12cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)N(R1a)(R1b), -S(O)(NR1a)(R1b), -C(O)R1c, -S(O2)R1c, or -C(O)OR1d, wherein the alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R6is each optionally substituted with one to four Z1, which may be the same or different; R7is -H, C1-8alkyl, C1-6haloalkyl, C3-12cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)N(R2a)(R2b), -S(O)(NR2a)(R2b), -C(O)R2c, S(O2)R2c, or -C(O)OR2d, wherein the alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R7is each optionally substituted with one to four Z2, which may be the same or different; or R6and R7together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z3, which may be the same or different; wherein the heterocyclyl formed by R6and R7is 3 to 20 membered heterocyclyl having 0 to 3 additional heteroatoms each independently N, O or S; each Z1, Z2, or Z3is independently deuterium, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkoxyalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, =O, imino, -NO2, -N3, -CN, -O-R3a, -C(O)-R3a, -C(O)O-R3a, -C(O)-N(R3a)(R3b), -N(R3a)(R3b), -N(R3a)2(R3b)+,-N(R3a)C(O)-R3b, -N(R3a)C(O)O-R3b, -N(R3a)C(O)N(R3b)(R3c), -N(R3a)S(O)2(R3b), -NR3aS(O)2N(R3b)(R3c), -NR3aS(O)2O(R3b), -OC(O)R3a, -OC(O)OR3a, -OC(O)-N(R3a)(R3b), -S-R3a, -S(O)R3a, -S(O)(NH)R3a, -S(O)2R3a, -S(O)2N(R3a)(R3b), -S(O)(NR3a)R3b, -S(O)(NR3a)N(R3b)(R3c), -SF5, or -Si(R3a)3;wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each Z1, Z2, or Z3is each optionally substituted with one to four Z1a, which may be the same or different; each Z1ais independently deuterium, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkoxyalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, =O, -NO2, -CN, -N3, -O-R3a, -C(O)R3a, -C(O)O-R3a, -C(O)N(R3a)(R3b), -N(R3a)(R3b), -N(R3a)2(R3b)+, -N(R3a)-C(O)R3b, -N(R3a)C(O)O(R3b), -N(R3a)C(O)N(R3b)(R3c), -N(R3a)S(O)2(R3b), -N(R3a)S(O)2-N(R3b)(R3c), -N(R3a)S(O)2O(R3b), -OC(O)R3a, -OC(O)OR3a, -OC(O)-N(R3a)(R3b), -S-R3a, -S(O)R3a, -S(O)(NH)R3a, -S(O)2R3a, -S(O)2N(R3a)(R3b), -S(O)(NR3a)R3b, or -Si(R3a)3; wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1ais each optionally substituted with one to four Z1b, which may be the same or different; each Z1bis independently C1-9alkyl, C1-8haloalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, oxo, -OH, -CN, -NO2, -NH2, -N3, -SH, -O(C1-9alkyl), -O(C1-8haloalkyl), -O(C2-6alkenyl), -O(C2-6alkynyl), -O(C3-15cycloalkyl), -O(heterocyclyl), -O(C6-10aryl), -O(heteroaryl), -NH(C1-9alkyl), -NH(C1-8haloalkyl), -NH(C2-6alkenyl), -NH(C2-6alkynyl), -NH(C3-15cycloalkyl), -NH(heterocyclyl), -NH(C6-10aryl), -NH(heteroaryl), -N(C1-9alkyl)2, -N(C1-8haloalkyl)2, -N(C2-6alkenyl)2, -N(C2-6alkynyl)2, -N(C3-15cycloalkyl)2, -N(heterocyclyl)2, -N(C6-10aryl)2, -N(heteroaryl)2, -N(C1-9alkyl)(C1-8haloalkyl), -N(C1-9alkyl)(C2-6alkenyl), -N(C1-9alkyl)(C2-6alkynyl), -N(C1-9alkyl)(C3-15cycloalkyl), -N(C1-9alkyl)(heterocyclyl), -N(C1-9alkyl)(C6-10aryl), -N(C1-9alkyl)(heteroaryl), -C(O)(C1-9alkyl), -C(O)(C1-8haloalkyl), -C(O)(C2-6alkenyl), -C(O)(C2-6alkynyl), -C(O)(C3-15cycloalkyl), -C(O)(heterocyclyl), -C(O)(C6-10aryl), -C(O)(heteroaryl), -C(O)O(C1-9alkyl), -C(O)O(C1-8haloalkyl), -C(O)O(C2-6alkenyl), -C(O)O(C2-6alkynyl), -C(O)O(C3-15cycloalkyl), -C(O)O(heterocyclyl), -C(O)O(C6-10aryl), -C(O)O(heteroaryl), -C(O)NH2, -C(O)NH(C1-9alkyl), -C(O)NH(C1-8haloalkyl), -C(O)NH(C2-6alkenyl), -C(O)NH(C2-6alkynyl), -C(O)NH(C3-15cycloalkyl), -C(O)NH(heterocyclyl), -C(O)NH(C6-10aryl), -C(O)NH(heteroaryl), -C(O)N(C1-9alkyl)2, -C(O)N(C1-8haloalkyl)2, -C(O)N(C2-6alkenyl)2, -C(O)N(C2-6alkynyl)2, -C(O)N(C3-15cycloalkyl)2, -C(O)N(heterocyclyl)2, -C(O)N(C6-10aryl)2,-C(O)N(heteroaryl)2, -NHC(O)(C1-9alkyl), -NHC(O)(C1-8haloalkyl), -NHC(O)(C2-6alkenyl), -NHC(O)(C2-6alkynyl), -NHC(O)(C3-15cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(C6-10aryl), -NHC(O)(heteroaryl), -NHC(O)O(C1-9alkyl), -NHC(O)O(C1-8haloalkyl), -NHC(O)O(C2-6alkenyl), -NHC(O)O(C2-6alkynyl), -NHC(O)O(C3-15cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(C6-10aryl), -NHC(O)O(heteroaryl), -NHC(O)NH(C1-9alkyl), -NHC(O)NH(C1-8haloalkyl), -NHC(O)NH(C2-6alkenyl), -NHC(O)NH(C2-6alkynyl), -NHC(O)NH(C3-15cycloalkyl), -NHC(O)NH(heterocyclyl), -NHC(O)NH(C6-10aryl), -NHC(O)NH(heteroaryl), -NHS(O)(C1-9alkyl), -N(C1-9alkyl)(S(O)(C1-9alkyl), -S(C1-9alkyl), -S(C1-8haloalkyl), -S(C2-6alkenyl), -S(C2-6alkynyl), -S(C3-15cycloalkyl), -S(heterocyclyl), -S(C6-10aryl), -S(heteroaryl), -S(O)N(C1-9alkyl)2, -S(O)(C1-9alkyl), -S(O)(C1-8haloalkyl), -S(O)(C2-6alkenyl), -S(O)(C2-6alkynyl), -S(O)(C3-15cycloalkyl), -S(O)(heterocyclyl), -S(O)(C6-10aryl), -S(O)(heteroaryl), -S(O)2(C1-9alkyl), -S(O)2(C1-8haloalkyl), -S(O)2(C2-6alkenyl), -S(O)2(C2-6alkynyl), -S(O)2(C3-15cycloalkyl), -S(O)2(heterocyclyl), -S(O)2(C6-10aryl), -S(O)2(heteroaryl), -S(O)(NH)(C1-9alkyl), -S(O)2NH(C1-9alkyl), or -S(O)2N(C1-9alkyl)2; wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1bis optionally substituted with one to three C1-9alkyl, C1-8haloalkyl, halogen, -OH, -NH2, -O(C1-9alkyl), -O(C1-8haloalkyl), -O(C3-15cycloalkyl), -O(heterocyclyl), -O(aryl), -O(heteroaryl), -NH(C1-9alkyl), -NH(C1-8haloalkyl), -NH(C3-15cycloalkyl), -NH(heterocyclyl), -NH(aryl), -NH(heteroaryl), -N(C1-9alkyl)2, -N(C3-15cycloalkyl)2, -NHC(O)(C1-8haloalkyl), -NHC(O)(C3-15cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(aryl), -NHC(O)(heteroaryl), -NHC(O)O(C1-9alkyl), -NHC(O)O(C1-8haloalkyl), -NHC(O)O(C2-6alkynyl), -NHC(O)O(C3-15cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(aryl), -NHC(O)O(heteroaryl), -NHC(O)NH(C1-9alkyl), S(O)2(C1-9alkyl), -S(O)2(C1-8haloalkyl), -S(O)2(C3-15cycloalkyl), -S(O)2(heterocyclyl), -S(O)2(aryl), -S(O)2(heteroaryl), -S(O)(NH)(C1-9alkyl), -S(O)2NH(C1-9alkyl), or -S(O)2N(C1-9alkyl)2; each R1a, R1b, R1c, R1d, R2a, R2b, R2c, R2d, R3a, R3b, and R3cis independently -H, C1-9alkyl, C2-6alkenyl, C2-6alkynyl, C3-15cycloalkyl, heterocyclyl, C6-10aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each R1a, R1b, R1c, R1d, R2a,R2b, R2c, R2d, R3a, R3b, and R3cis each optionally substituted with one to four Z1b, which may be the same or different; wherein each aryl of the compound of Formula (I) unless otherwise specified is C6-10aryl; wherein each heteroaryl of the compound of Formula (I) unless otherwise specified is 5 to 12 membered heteroaryl having one to four heteroatoms each independently N, O, or S; wherein each heterocyclyl of the compound of Formula (I) unless otherwise specified is 3 to 20 membered heterocyclyl having one to four heteroatoms each independently N, O, or S.

[0009] In some embodiments, provided herein are pharmaceutical compositions comprising a compound provided herein, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier. In some embodiments, the pharmaceutical compositions comprise a therapeutically effective amount of a compound provided herein, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

[0010] In some embodiments, the pharmaceutical compositions provided herein further comprise one or more (e.g., one, two, three, four, one or two, one to three, or one to four) additional therapeutic agents, or pharmaceutically acceptable salts thereof. In some embodiments, the pharmaceutical compositions further comprise a therapeutically effective amount of the one or more (e.g., one, two, three, four, one or two, one to three, or one to four) additional therapeutic agents, or pharmaceutically acceptable salts thereof.

[0011] In some embodiments, the present disclosure provides methods of degrading IKZF2 protein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound provided herein (e.g., a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (IVb), (V), (Va), (VI), or (VIa)), or pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein.

[0012] In some embodiments, the present disclosure provides methods of treating a patient having an IKZF2 protein mediated condition, comprising administering to the patient a therapeutically effective amount of a compound provided herein (e.g., a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (IVb), (V), (Va), (VI), or (VIa)), or pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein.

[0013] In some embodiments, the present disclosure provides methods of treating a cancer patient, comprising administering to the cancer patient a therapeutically effective amount of a compound provided herein (e.g., a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (IVb), (V), (Va), (VI), or (VIa)), or pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein.

[0014] In some embodimetns, the present disclosure provides uses of a compound provided herein (e.g., a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa- 2), (IVb), (V), (Va), (VI), or (VIa)), or pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of an IKFZ2 associated disease or condition.

[0015] In some embodimetns, the present disclosure provides uses of a compound provided herein (e.g., a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa- 2), (IVb), (V), (Va), (VI), or (VIa)), or pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of cancer.

[0016] In some embodimetns, the present disclosure provides a compound provided herein (e.g., a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (IVb), (V), (Va), (VI), or (VIa)), or pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound provided herein for pharmaceutical use.

[0017] In some embodimetns, the present disclosure provides a compound provided herein (e.g., a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (IVb), (V), (Va), (VI), or (VIa)), or pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound provided herein for the treatment of an IKFZ2 associated disease or condition.

[0018] In some embodimetns, the present disclosure provides a compound provided herein (e.g., a compound of Formula (I), (Ia), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (IVb), (V), (Va), (VI), or (VIa)), or pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound provided herein for the treatment of cancer.BRIEF DESCRIPTION OF THE DRAWINGS

[0019] FIG. 1A shows a timecourse for IKZF2 (Helios) degradation in HEK293 cells. The compound of Example 46 (Compound 46; solid circle) and Reference Compounds A-1 (Compound A-1; solid square) and B-4 (Compound B-4; solid triangle) were tested at a concentration of 12 nM. Percent IKZF2 remaining (normalized relative to a DMSO control) is plotted over time.

[0020] FIG. 1B shows a timecourse for IKZF2 (Helios) degradation in HEK293 cells. The compound of Example 2 (Compound 2; solid circle) and Reference Compounds B-3 (Compound B-3; solid square) and C-1 (Compound C-1; solid triangle) were tested at a concentration of 111 nM. Percent IKZF2 remaining (normalized relative to a DMSO control) is plotted over time.

[0021] FIG. 2A shows a plot of IKZF2 (Helios) degradation rate constants vs. compound concentrations observed in HEK293 cells for the compound of Example 46 (Compound 46; solid triangle) and Reference Compounds A-1 (Compound A-1; solid circle) and B-4 (Compound B-4; solid square).

[0022] FIG. 2B shows a plot of IKZF2 (Helios) degradation rate constants vs. compound concentrations observed in HEK293 cells for the compound of Example 2 (Compound 2; solid triangle) and Reference Compounds B-3 (Compound B-3; solid square) and C-1 (Compound C-1; solid circle).

[0023] FIG. 3A shows titration curves of IL-2 production in Jurkat cells IKZF2 (Helios) for the compounds of Example 328 (Compound 328; solid circle) and Example 84 (Compound 84; open square), and Reference Compounds A-1 (Compound A-1; solid triangle), and B-4 (Compound B-4; solid square).

[0024] FIG. 3B shows titration curves of IL-2 production in Jurkat cells IKZF2 (Helios) for the compounds of Example 287 (Compound 287; solid circle), Example 94 (Compound 94; open square), Example 283 (Compound 283; open triangle), and Example 46 (Compound 46; solid triangle).

[0025] FIG. 3C shows a bar diagram illustrating the Jurkat IL-2 production levels (relative to a DMSO control) achieved at saturating compound concentrations for the IKZF2 (Helios) degrader compounds of Examples 35, 46, 84, 94, 218, 283, 287, 328, and 369, and Reference Compounds A-1, B-2, and B-4.DETAILED DESCRIPTION

[0026] The present disclosure relates to degraders of IKAROS Family Zinc Finger (IKZF) proteins, such as IKZF2 (Helios). The disclosure also relates to compositions and methods relating to IKZF2 protein degraders and the use of such compounds for treatment and / or prophylaxis of IKZF2-mediated diseases and conditions. The disclosure also relates to compositions and methods of treating and / or preventing cancer or viral infections that include an IKZF2 protein degrader in combination with one or more additional therapeutic agents.

[0027] It is commonly believed that patients with certain IKZF2-mediated diseases, such as cancer and viral infections can benefit from the treatment with an IKZF2 protein degrader and optionally one or more additional therapeutic agents. Definitions and General Parameters

[0028] The description below is made with the understanding that the present disclosure is to be considered as an exemplification of the claimed subject matter and is not intended to limit the appended claims to the specific embodiments illustrated. The headings used throughout this disclosure are provided for convenience and are not to be construed to limit the claims in any way. Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.

[0029] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. It must be noted that as used herein and in the appended claims, the singular forms “a”, “and”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, e.g., reference to “the compound” includes a plurality of such compounds and reference to “the assay” includes reference to one or more assays and equivalents thereof known to those skilled in the art, and so forth.

[0030] As used in the present specification, the following terms and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.

[0031] A dashthat is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -CONH2is attached through the carbon atom. A dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A wavy line drawn through a line in a structure indicates a point of attachment of a group. Unless chemically or structurally required, no directionality is indicated or implied by the order in which a chemicalgroup is written or named. A solid line coming out of the center of a ring indicates that the point of attachment for a substituent on the ring can be at any ring atom. For example, Rain the below structure can be attached to any of the five carbon ring atoms or Racan replace the hydrogen attached to the nitrogen ring atom:.

[0032] The prefix “Cu-v” indicates that the following group has from u to v carbon atoms. For example, “C1-6alkyl” indicates that the alkyl group has from 1 to 6 carbon atoms. Likewise, the term “x-y membered” rings, wherein x and y are numerical ranges, such as “3 to12-membered heterocyclyl”, refers to a ring containing x-y atoms (e.g., 3-12), of which up to 80% may be heteroatoms, such as N, O, S, P, and the remaining atoms are carbon.

[0033] Also, certain commonly used alternative chemical names may or may not be used. For example, a divalent group such as a divalent “alkyl” group, a divalent “aryl” group, etc., may also be referred to as an “alkylene” group or an “alkylenyl” group, or alkylyl group, an “arylene” group or an “arylenyl” group, or arylyl group, respectively.

[0034] “A compound disclosed herein” or “a compound of the present disclosure” or “a compound provided herein” or “a compound described herein” refers to the compounds of Formula (I), (Ia), (Ib), or (Ic). Also included are the specific compounds of Examples 1 to 339 provided herein.

[0035] Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. In certain embodiments, the term “about” includes the indicated amount ± 10%. In other embodiments, the term “about” includes the indicated amount ± 5%. In certain other embodiments, the term “about” includes the indicated amount ± 1%. Also, to the term “about X” includes description of “X”. Also, the singular forms “a” and “the” include plural references unless the context clearly dictates otherwise. Thus, e.g., reference to “the compound” includes a plurality of such compounds and reference to “the assay” includes reference to one or more assays and equivalents thereof known to those skilled in the art.

[0036] “Alkyl” refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (i.e., C1-20alkyl), 1 to 8 carbon atoms (i.e., C1-8alkyl), 1 to 6 carbon atoms (i.e., C1-6alkyl), 1 to 4 carbon atoms (i.e., C1-4alkyl), or 1 to 3 carbon atoms (i.e., C1-3alkyl). Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbons is named by chemical name or identified by molecular formula, all positional isomers having that number of carbons may be encompassed; thus, for example, “butyl” includes n-butyl (i.e., -(CH2)3CH3), sec-butyl (i.e., -CH(CH3)CH2CH3), isobutyl (i.e., -CH2CH(CH3)2) and tert-butyl (i.e., -C(CH3)3); and “propyl” includes n-propyl (i.e., -(CH2)2CH3) and isopropyl (i.e., -CH(CH3)2).

[0037] “Alkenyl” refers to an aliphatic group containing at least one carbon-carbon double bond and having from 2 to 20 carbon atoms (i.e., C2-20alkenyl), 2 to 8 carbon atoms (i.e., C2-8alkenyl), 2 to 6 carbon atoms (i.e., C2-6alkenyl), or 2 to 4 carbon atoms (i.e., C2-4alkenyl). Examples of alkenyl groups include ethenyl, propenyl, butadienyl (including 1,2-butadienyl and 1,3- butadienyl).

[0038] “Alkynyl” refers to an aliphatic group containing at least one carbon-carbon triple bond and having from 2 to 20 carbon atoms (i.e., C2-20alkynyl), 2 to 8 carbon atoms (i.e., C2-8alkynyl), 2 to 6 carbon atoms (i.e., C2-6alkynyl), or 2 to 4 carbon atoms (i.e., C2-4alkynyl). The term “alkynyl” also includes those groups having one triple bond and one double bond.

[0039] “Acyl” refers to a group -C(=O)R, wherein R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein. Examples of acyl include formyl, acetyl, cylcohexylcarbonyl, cyclohexylmethyl- carbonyl, and benzoyl.

[0040] “Alkoxy” refers to an alkyl group having an oxygen atom that connects the alkyl group to the point of attachment: alkyl-O-. As for alkyl group, alkoxy groups will have any suitable number of carbon atoms, such as C1-6. Alkoxy groups include, for example, methoxy, ethoxy, propoxy, iso-propoxy, butoxy, 2-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, pentoxy, hexoxy, etc. The alkoxy groups can be further substituted with a variety of substituents described within. Alkoxy groups can be substituted or unsubstituted.

[0041] “Alkoxyalkyl” refers an alkoxy group linked to an alkyl group which is linked to the remainder of the compound. Alkoxyalkyl have any suitable number of carbon, such as from 2 to 6 (C2-6alkoxyalkyl), 2 to 5 (C2-5alkoxyalkyl), 2 to 4 (C2-4alkoxyalkyl), or 2 to 3 (C2-3alkoxyalkyl). The number of carbons refers to the total number of carbons in the alkoxy and the alkyl group. For example, in some embodiments, C6 alkoxyalkyl refers to ethoxy (C2 alkoxy) linked to a butyl (C4alkyl), and in other embodiments, n-propoxy (C3alkoxy) linked to isopropyl (C3alkyl). Alkoxy and alkyl are as defined above where the alkyl is divalent, and can include, but is not limited to, methoxymethyl (CH3OCH2-), methoxyethyl (CH3OCH2CH2-) and others.

[0042] “Amino” refers to the group -NRyRzwherein Ryand Rzare independently selected from the group consisting of hydrogen, alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; each of which may be optionally substituted.

[0043] “Imino” refers to a group containing a carbon-nitrogen double bond having the structurewherein R1, R2, and R3are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; each of which may be optionally substituted. Either one of R1, R2, and R3can serve as points of attachment.

[0044] “Aryl” as used herein refers to a single all carbon aromatic ring or a multicyclic all carbon ring system wherein at least one of the rings is aromatic. For example, in some embodiments, an aryl group has 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 12 carbon atoms. Aryl includes a phenyl radical. Aryl also includes multicyclicring systems (e.g., ring systems comprising 2, 3 or 4 rings) having 9 to 20 carbon atoms, e.g., 9 to 16 carbon atoms, in which at least one ring is aromatic and wherein the other rings may be aromatic or not aromatic (i.e., carbocycle). Such multicyclicring systems are optionally substituted with one or more (e.g., 1, 2 or 3) oxo groups on any carbocycle portion of the multicyclic ring system. The rings of the multicyclic ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is also to be understood that when reference is made to a certain atom-range membered aryl (e.g., 6-10 membered aryl), the atom range is for the total ring atoms of the aryl. For example, a 6-membered aryl would include phenyl and a 10-membered aryl would include naphthyl and 1,2,3,4-tetrahydronaphthyl. Non-limiting examples of aryl groups include, but are not limited to, phenyl, indenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, anthracenyl, and the like.

[0045] “Cyano” or “carbonitrile” refers to the group -CN.

[0046] “Cycloalkyl” refers to a saturated or partially saturated cyclic alkyl group having a single ring or multiple rings including fused, bridged, and spiro ring systems. The term “cycloalkyl” includes cycloalkenyl groups (i.e., the cyclic group having at least one double bond). As used herein, cycloalkyl has from 3 to 20 ring carbon atoms (i.e., C3-20cycloalkyl), 3 to 12 ring carbon atoms (i.e., C3-12cycloalkyl), 3 to 10 ring carbon atoms (i.e., C3-10cycloalkyl), 3 to 8 ring carbon atoms (i.e., C3-8cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C3-6cycloalkyl). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0047] “Fused” refers to a ring which is bound to an adjacent ring. In some embodiments the fused ring system is a heterocyclyl. In some embodiments the fused ring system is a oxabicyclohexanyl. In some embodiments the fused ring system.

[0048] “Bridged” refers to a ring fusion wherein non-adjacent atoms on a ring are joined by a divalent substituent, such as alkylenyl group, an alkylenyl group containing one or two heteroatoms, or a single heteroatom. Quinuclidinyl and admantanyl are examples of bridged ring systems. In some embodiments the bridged ring is a bicyclopentyl (e.g., bicyclo[1.1.1]pentyl), bicycloheptyl (e.g., bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl), or bicyclooctyl (e.g., bicyclo[2.2.2]octyl). In some embodiments, the bridged ring

[0049] “Spiro” refers to a ring substituent which is joined by two bonds at the same carbon atom. Examples of spiro groups include 1,1-diethylcyclopentane, dimethyl-dioxolane, and 4-benzyl-4- methylpiperidine, wherein the cyclopentane and piperidine, respectively, are the spiro substituents. In some embodiments the spiro substituent is a spiropentanyl (spiro[a.b]pentanyl), spirohexanyl, spiroheptanyl, spirooctyl (e.g., spiro[2.5]octyl), spirononanyl (e.g., spiro[3.5]nonanyl), spirodecanyl (e.g., spiro[4.5]decanyl), or spiroundecanyl (e.g., spiro[5.5]undecanyl). In some embodiments the spiro substituent is, , ,

[0050] “Halogen” or “halo” includes fluoro, chloro, bromo, and iodo.

[0051] “Haloalkyl” as used herein refers to an alkyl as defined herein, wherein one or more hydrogen atoms of the alkyl are independently replaced by a halo substituent, which may be thesame or different. For example, C1-4haloalkyl is a C1-4alkyl wherein one or more of the hydrogen atoms of the C1-4alkyl have been replaced by a halo substituent. Examples of haloalkyl groups include but are not limited to fluoromethyl, fluorochloromethyl, difluoromethyl, difluorochloromethyl, trifluoromethyl, 1,1,1-trifluoroethyl and pentafluoroethyl.

[0052] “Haloalkoxy” refers to an alkoxy group where some or all of the hydrogen atoms are substituted with halogen atoms. As for an alkyl group, haloalkoxy groups can have any suitable number of carbon atoms, such as C1-6. The alkoxy groups can be substituted with 1, 2, 3, or more halogens. When all the hydrogens are replaced with a halogen, for example by fluorine, the compounds are per-substituted, for example, perfluorinated. Haloalkoxy includes, but is not limited to, trifluoromethoxy, 2,2,2-trifluoroethoxy, perfluoroethoxy, etc.

[0053] The term “heteroaryl” as used herein refers to a single aromatic ring or a multicyclic ring. The term includes single aromatic rings of from about 1 to 6 carbon atoms and about 1-4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the rings. The sulfur and nitrogen atoms may also be present in an oxidized form provided the ring is aromatic. Such rings include but are not limited to pyridyl, pyrimidinyl, oxazolyl or furyl. The term also includes multicyclic ring systems (e.g. ring systems comprising 2 or 3 rings) wherein a heteroaryl group, as defined above, can be fused with one or more heteroaryls (e.g. naphthyridinyl), carbocycles (e.g. 5,6,7,8-tetrahydroquinolyl) or aryls (e.g. indazolyl) to form a multicyclic ring. Such multicyclic rings may be optionally substituted with one or more (e.g. 1, 2 or 3) oxo groups on the carbocycle portions of the multicyclic ring. It is to be understood that the point of attachment of a heteroaryl multicyclic ring, as defined above, can be at any position of the ring including a heteroaryl, aryl or a carbocycle portion of the ring. Exemplary heteroaryls include but are not limited to pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalyl, quinazolyl, 5,6,7,8-tetrahydroisoquinolinyl benzofuranyl, benzimidazolyl and thianaphthenyl.

[0054] “Heterocyclyl” or “heterocyclic ring” or “heterocycle” as used herein refers to a single saturated or partially unsaturated ring or a multicyclic ring. The term includes single saturated or partially unsaturated ring (e.g. 3, 4, 5, 6 or 7-membered ring) from about 1 to 6 carbon atoms and from about 1 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring. The ring may be substituted with one or more (e.g.1, 2 or 3) oxo groups and the sulfur and nitrogen atoms may also be present in their oxidized forms. Such rings include but are not limited to azetidinyl, tetrahydrofuranyl or piperidinyl. The term also includes multicyclic ringsystems (e.g. ring systems comprising 2 or 3 rings) wherein a heterocycle group (as defined above) can be connected to two adjacent atoms (fused heterocycle) with one or more heterocycles (e.g. decahydronapthyridinyl), heteroaryls (e.g. 1,2,3,4-tetrahydronaphthyridinyl), carbocycles (e.g. decahydroquinolyl) or aryls. It is to be understood that the point of attachment of a heterocycle multicyclic ring, as defined above, can be at any position of the ring including a heterocyle, heteroaryl, aryl or a carbocycle portion of the ring. Exemplary heterocycles include, but are not limited to aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydrofuranyl, dihydrooxazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1,2,3,4- tetrahydroquinolyl, benzoxazinyl, dihydrooxazolyl, chromanyl, 1,2-dihydropyridinyl, 2,3-dihydrobenzofuranyl, 1,3-benzodioxolyl and 1,4-benzodioxanyl. Exemplary fused bicyclic heterocycles include, but are not limited to

[0055] “Hydroxy” or “hydroxyl” refers to the group -OH.

[0056] “Oxo” refers to the group (=O) or (O).

[0057] “Sulfonyl” refers to the group -S(O)2Rc, where Rcis alkyl, heterocyclyl, cycloalkyl, heteroaryl, or aryl. Examples of sulfonyl are methylsulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl.

[0058] Whenever the graphical representation of a group terminates in a singly bonded nitrogen atom, that group represents an -NH2group unless otherwise indicated. Similarly, unless otherwise expressed, hydrogen atom(s) are implied and deemed present where necessary in view of the knowledge of one of skill in the art to complete valency or provide stability.

[0059] The terms “optional” or “optionally” mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. Also, the term “optionally substituted” means that any one or more hydrogen atoms on the designated atom or group may or may not be replaced by a moiety other than hydrogen.

[0060] The term “substituted” means that any one or more hydrogen atoms on the designated atom or group is replaced with one or more substituents other than hydrogen, provided that the designated atom’s normal valence is not exceeded. The one or more substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halo, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, hydroxy, hydrazino, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanate, thiol, thione, or combinations thereof. Polymers or similar indefinite structures arrived at by defining substituents with further substituents appended ad infinitum (e.g., a substituted aryl having a substituted alkyl which is itself substituted with a substituted aryl group, which is further substituted by a substituted heteroalkyl group, etc.) are not intended for inclusion herein. Unless otherwise noted, the maximum number of serial substitutions in compounds described herein is three. For example, serial substitutions of substituted aryl groups with two other substituted aryl groups are limited to ((substituted aryl)substituted aryl) substituted aryl. Similarly, the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluorines or heteroaryl groups having two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to the skilled artisan. When used to modify a chemical group, the term “substituted” may describe other chemical groups defined herein. For example, the term “substituted aryl” includes, but is not limited to, “alkylaryl.” Unless specified otherwise, where a group is described as optionally substituted, any substituents of the group are themselves unsubstituted.

[0061] In some embodiments, the term “substituted alkyl” refers to an alkyl group having one or more substituents including hydroxyl, halo, amino, alkoxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl. In additional embodiments, “substituted cycloalkyl” refers to a cycloalkyl group having one or more substituents including alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, amino, alkoxy, halo, oxo, and hydroxyl; “substituted heterocyclyl” refers to a heterocyclyl group having one or more substituents including alkyl, amino, haloalkyl, heterocyclyl, cycloalkyl, aryl, heteroaryl, alkoxy, halo, oxo, and hydroxyl; “substituted aryl” refers to an aryl group having one or more substituents including halo, alkyl, amino, haloalkyl, cycloalkyl, heterocyclyl, heteroaryl, alkoxy, and cyano; “substituted heteroaryl” refers to an heteroaryl group having one or more substituents including halo, amino, alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkoxy, and cyano and “substituted sulfonyl” refers to a group -S(O)2R, in which R is substituted with one or more substituents including alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl. In other embodiments, the one or more substituents may be further substituted with halo, alkyl, haloalkyl, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, orheteroaryl, each of which is substituted. In other embodiments, the substituents may be further substituted with halo, alkyl, haloalkyl, alkoxy, hydroxyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is unsubstituted.

[0062] In some embodiments, a substituted cycloalkyl, a substituted heterocyclyl, a substituted aryl, and / or a substituted heteroaryl includes a cycloalkyl, a heterocyclyl, an aryl, and / or a heteroaryl that has a substituent on the ring atom to which the cycloalkyl, heterocyclyl, aryl, and / or heteroaryl is attached to the rest of the compound. For example, in the below moiety, the cyclopropyl is substituted with a methyl group:.

[0063] The disclosures illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms “comprising,” “including,” “containing,” etc., shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the disclosure claimed.

[0064] The compounds of the present disclosure can be in the form of a pharmaceutically acceptable salt. The term “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids, including inorganic bases or acids and organic bases or acids. The compounds of the present disclosure can be in the form of a pharmaceutically acceptable salt. The term “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids, including inorganic bases or acids and organic bases or acids. In case the compounds of the present disclosure contain one or more acidic or basic groups, the disclosure also comprises their corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts. Thus, the compounds of the present disclosure which contain acidic groups can be present on these groups and can be used according to the disclosure, for example, as alkali metal salts, alkaline earth metal salts or ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine, amino acids, or other bases known to persons skilled in the art. The compounds of the present disclosure which contain one or morebasic groups, i.e., groups which can be protonated, can be present and can be used according to the disclosure in the form of their addition salts with inorganic or organic acids. Examples of suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to persons skilled in the art.

[0065] If the compounds of the present disclosure simultaneously contain acidic and basic groups in the molecule, the disclosure also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions). The respective salts can be obtained by customary methods which are known to the person skilled in the art like, for example, by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts.

[0066] The present disclosure also includes all salts of the compounds of the present disclosure which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts. Acids and bases useful for reaction with an underlying compound to form pharmaceutically acceptable salts (acid addition or base addition salts respectively) are known to one of skill in the art. Similarly, methods of preparing pharmaceutically acceptable salts from an underlying compound (upon disclosure) are known to one of skill in the art and are disclosed in for example, Berge, at al. Journal of Pharmaceutical Science, Jan. 1977 vol. 66, No.1, and other sources.

[0067] Furthermore, compounds disclosed herein may be subject to tautomerism. Where tautomerism, e.g., keto-enol tautomerism, of compounds or their prodrugs may occur, the individual forms, like, e.g., the keto and enol form, are each within the scope of the disclosure as well as their mixtures in any ratio. The same applies for stereoisomers, like, e.g., enantiomers, cis / trans isomers, diastereomers, conformers, and the like.

[0068] The term “protecting group” refers to a moiety of a compound that masks or alters the properties of a functional group or the properties of the compound as a whole. Chemical protecting groups and strategies for protection / deprotection are well known in the art. See e.g., Protective Groups in Organic Chemistry, Theodora W. Greene, John Wiley & Sons, Inc., New York, 1991. Protecting groups are often utilized to mask the reactivity of certain functionalgroups, to assist in the efficiency of desired chemical reactions, e.g., making and breaking chemical bonds in an ordered and planned fashion. The term “deprotecting” refers to removing the protecting group.

[0069] It will be appreciated by the skilled person that when lists of alternative substituents include members which, because of their valency requirements or other reasons, cannot be used to substitute a particular group, the list is intended to be read with the knowledge of the skilled person to include only those members of the list which are suitable for substituting the particular group.

[0070] Further the compounds of the present disclosure may be present in the form of solvates, such as those which include as solvate water, or pharmaceutically acceptable solvates, such as alcohols, in particular ethanol. A “solvate” is formed by the interaction of a solvent and a compound.

[0071] In certain embodiments, provided are optical isomers, racemates, or other mixtures thereof (e.g., scalemic mixtures) of the compounds described herein or a pharmaceutically acceptable salt or a mixture thereof. If desired, isomers can be separated by methods well known in the art, e.g., by liquid chromatography. In those situations, the single enantiomer or diastereomer, i.e., optically active form, can be obtained by asymmetric synthesis or by resolution. Resolution can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using for example, a chiral high-pressure liquid chromatography (HPLC) column.

[0072] A “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present invention contemplates various stereoisomers and mixtures thereof and includes “enantiomers,” which refers to two stereoisomers whose molecules are nonsuperimposeable mirror images of one another. “Diastereomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. Unless otherwise indicated, the description is intended to include individual stereoisomers as well as mixtures. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see, e.g., Chapter 4 of Advanced Organic Chemistry, 4th ed., J. March, John Wiley and Sons, New York, 1992).

[0073] Compounds disclosed herein and their pharmaceutically acceptable salts may, in some embodiments, include an asymmetric center and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as(R)- or (S)- or as (D)- or (L)- for amino acids. Some embodiments include all such possible isomers, as well as their racemic, scalemic, and optically pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high-pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centres of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included. Where compounds are represented in their chiral form, it is understood that the embodiment encompasses, but is not limited to, the specific diastereomerically or enantiomerically enriched form. Where chirality is not specified but is present, it is understood that the embodiment is directed to either the specific diastereomerically or enantiomerically enriched form; or a racemic or scalemic mixture of such compound(s). As used herein, “scalemic mixture” is a mixture of stereoisomers at a ratio other than 1:1. For example, in some embodiments a compoundis understood to encompass either the specific diastereomerically or enantiomerically enriched form; or a racemic or scalemic mixture of

[0074] Compositions provided herein that include a compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof may include racemic mixtures, or mixtures containing an enantiomeric excess of one enantiomer or single diastereomers or diastereomeric mixtures. All such isomeric forms of these compounds are expressly included herein the same as if each and every isomeric form were specifically and individually listed.

[0075] Any formula or structure given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can beincorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphoros, fluorine and chlorine, such as, but not limited to2H (deuterium, D),3H (tritium),11C,13C,14C,15N,18F,31P,32P,35S,36Cl and125I. Various isotopically labeled compounds of the present disclosure, for example those into which radioactive isotopes such as3H,13C and14C are incorporated. Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of patients. Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

[0076] The disclosure also includes “deuterated analogs” of compounds disclosed herein, in which from 1 to n hydrogens attached to a carbon atom is / are replaced by deuterium, in which n is the number of hydrogens in the molecule. Such compounds may exhibit increased resistance to metabolism and thus be useful for increasing the half-life of any compound of Formula (I) when administered to a mammal, e.g., a human. See, e.g., Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends Pharmacol. Sci. 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium.

[0077] Deuterium labelled or substituted therapeutic compounds of the disclosure may have beneficial DMPK (drug metabolism and pharmacokinetics) properties, relating to distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements and / or an improvement in therapeutic index. An18F labeled compound may be useful for PET or SPECT studies.

[0078] The concentration of such a heavier isotope, specifically deuterium, may be defined by an isotopic enrichment factor. In the compounds of this disclosure any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is designated specifically as “H” or “hydrogen”, the position is understood to have hydrogen at its natural abundance isotopic composition. Accordingly, in the compounds of this disclosure any atom specifically designated as a deuterium (D) is meant to represent deuterium.

[0079] Furthermore, the present disclosure provides pharmaceutical compositions comprising a compound of the present disclosure, or a prodrug compound thereof, or a pharmaceutically acceptable salt or solvate thereof as active ingredient together with a pharmaceutically acceptable carrier.

[0080] “Pharmaceutical composition” means one or more active ingredients, and one or more inert ingredients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present disclosure can encompass any composition made by admixing at least one compound of the present disclosure and a pharmaceutically acceptable carrier.

[0081] As used herein, “pharmaceutically acceptable carrier” includes excipients or agents such as solvents, diluents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like that are not deleterious to the disclosed compound or use thereof. The use of such carriers and agents to prepare compositions of pharmaceutically active substances is well known in the art (see, e.g., Remington’s Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, PA 17th Ed. (1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G.S. Banker & C.T. Rhodes, Eds.).

[0082] “IC50” or “EC50” refers to the inhibitory concentration required to achieve 50% of the maximum desired effect. In many cases here the maximum desired effect is the degradation of IKZF2 protein. This term is obtained using an in vitro protein degradation assay, such as a HiBiT protein tagging assay, evaluating the concentration-dependent degradation of IKZF2 protein. “Dmax” refers to the maximum protein (e.g., IKZF2 or IKZF1 protein) degradation at the highest compound concentration tested in the assay.

[0083] “Treatment” or “treating” is an approach for obtaining beneficial or desired results including clinical results. Beneficial or desired clinical results may include one or more of the following: a) inhibiting the disease or condition (e.g., decreasing one or more symptoms resulting from the disease or condition, and / or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and / or preventing or delaying the spread (e.g., metastasis) of the disease or condition); and / or c) relieving the disease, that is, causing the regression of clinical symptoms (e.g., ameliorating the disease state, providing partial or total remission of thedisease or condition, enhancing effect of another medication, delaying the progression of the disease, increasing the quality of life, and / or prolonging survival. In some embodiments, the term “treatment” or “treating” means administering a compound or pharmaceutically acceptable salt of Formula (I), (Ia), (Ib), or (Ic) for the purpose of: (i) delaying the onset of a disease, that is, causing the clinical symptoms of the disease not to develop or delaying the development thereof; (ii) inhibiting the disease, that is, arresting the development of clinical symptoms; and / or (iii) relieving the disease, that is, causing the regression of clinical symptoms or the severity thereof.

[0084] “Prevention” or “preventing” means any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop. Compounds may, in some embodiments, be administered to a subject (including a human) who is at risk or has a family history of the disease or condition.

[0085] As used herein, an “IKZF associated disease or condition” (e.g., IKZF2 or IKZF4 associated disease or condition) means a reduction of IKZF protein levels (e.g., IKZF2 or IKZF4 protein levels) can ameliorate the disease or disorder. In some embodiments, in an IKZF associated disease or condition degradation of IKZF2 protein can ameliorate the disease or disorder. In some embodiments, in an IKZF associated disease or condition degradation of IKZF2 protein and one or more additional IKZF proteins (e.g., IKZF4 protein) can ameliorate the disease or disorder. In some embodiments, in an IKZF associated disease or condition degradation of IKZF4 protein can ameliorate the disease or disorder.

[0086] “Subject” refers to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation or experiment. The methods described herein may be useful in human therapy and / or veterinary applications. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.

[0087] The term “therapeutically effective amount” or “effective amount” of a compound described herein or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof means an amount sufficient to effect treatment when administered to a subject, to provide a therapeutic benefit such as amelioration of symptoms or slowing of disease progression. For example, a therapeutically effective amount may be an amount sufficient to decrease a symptom of a disease or condition responsive to IKZF2 degraders. The therapeutically effective amount may vary depending on the subject, and disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, and the manner of administering, which can readily be determined by one or ordinary skill in the art.

[0088] As used herein, a “degrader” or “protein degrader” refers to any agent that is capable of binding to and inducing the degradation of a protein. Generally, protein degraders are believed to induce targeted protein degradation through recruitment of the cellular ubiquitinylation and proteasomal protein degradation machinery. For example, as used herein, an “IKZF2 degrader” or “IKZF2 protein degrader” refers to any agent that is capable of binding to and inducing the degradation of IKZF2 protein. In some embodiments, the IKZF2 degrader is IKZF2 selective. In some embodiments, the IKZF2 degrader can induce degradation of IKZF2 protein and one or more additional IKZF2 proteins (e.g., IKZF1 or IKZF4).

[0089] IKZF2, also known as Helios, is an IKAROS family zinc finger transcription factor commonly believed to be required to maintain a stable Treg cell phenotype, especially in inflammatory tumor microenvironments. In humans IKZF2 or Helios protein is encoded by the IKZF2 gene. Exemplary reference sequences for IKZF2 (NCBI Gene ID: 22807 (human); 22779 (mouse)) include the NCBI Reference Sequences NP_001072994 (human protein), NP_035900 (mouse protein), NM_001079526 (human mRNA), and NM_0011770 (mouse mRNA). Related family members include IKZF1 (Ikaros; NCBI Gene ID: 10320 (human); 22778 (mouse)) and IKZF4 (Eos; NCBI Gene ID: 64375 (human); 22781 (mouse). The activity of an IKZF (e.g., IKZF2) degrader can be measured by methods known in the art, such as those described and cited in Wang et al., 2021 Nature Chemical Biology 17, 711-717. In some embodiments IKZF protein degradation is measured using a HiBiT protein tagging assay, such as the Nano Glo® HiBiT Extracellular Detection System (Promega).

[0090] Spalt-like protein 4 (SALL4) is a member of the Spalt-like (SALL) family of zinc finger transcription factors. In humans SALL4 protein is encoded by the SALL4 gene (NCBI Gene ID: 57167. SALL4 biology is described, e.g., in Donovan et al., 2018 eLife 7:e38430 and Matyskiela et al.2020 Nat Struct Mol Biol 27, 319–322. SALL4 degradation activity can be measured by any method known in the art. In some embodiments SALL4 protein degradation is measured using a HiBiT protein tagging assay, such as the Nano Glo® HiBiT Extracellular Detection System (Promega). List of Abbreviations and AcronymsCompounds

[0091] In one aspect, the present disclosure provides a compound of Formula (I),or a pharmaceutically acceptable salt thereof, wherein: R1is -H; R2is -H, -F, or -Cl; R21is -H, -F, or -Cl; R3is -H, -F, or -Cl; R4aand R4bare each independently -H, halogen, -OH, or C1-6alkyl; Ring A is C3-10cycloalkyl or heterocyclyl; n is 0, 1, 2, 3, or 4; each R5is independently halogen, =O, =CH2, -CN, C1-6alkyl, C2-6alkenyl, C1-6haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C3-6cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, -O-(R51), or -N(R51)(R52); wherein each =CH2, alkyl, alkenyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclyl, aryl, or heteroaryl of R5is optionally substituted with one to four R5a, which may be the same or different; each R5ais independently halogen, -CN, C1-6alkyl, C6-10aryl, or -O(R51); wherein each R51and R52, which may be the same or different, is independently -H, C1-6alkyl, C3-10cycloalkyl, heterocyclyl, C6-10aryl, or heteroaryl;R6is -H, C1-8alkyl, C1-6haloalkyl, C3-12cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)N(R1a)(R1b), -S(O)(NR1a)(R1b), -C(O)R1c, -S(O2)R1c, or -C(O)OR1d, wherein the alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R6is each optionally substituted with one to four Z1, which may be the same or different; R7is -H, C1-8alkyl, C1-6haloalkyl, C3-12cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)N(R2a)(R2b), -S(O)(NR2a)(R2b), -C(O)R2c, S(O2)R2c, or -C(O)OR2d, wherein the alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R7is each optionally substituted with one to four Z2, which may be the same or different; or R6and R7together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z3, which may be the same or different; wherein the heterocyclyl formed by R6and R7is 3 to 20 membered heterocyclyl having 0 to 3 additional heteroatoms each independently N, O or S; each Z1, Z2, or Z3is independently deuterium, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkoxyalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, =O, imino, -NO2, -N3, -CN, -O-R3a, -C(O)-R3a, -C(O)O-R3a, -C(O)-N(R3a)(R3b), -N(R3a)(R3b), -N(R3a)2(R3b)+,-N(R3a)C(O)-R3b, -N(R3a)C(O)O-R3b, -N(R3a)C(O)N(R3b)(R3c), -N(R3a)S(O)2(R3b), -NR3aS(O)2N(R3b)(R3c), -NR3aS(O)2O(R3b), -OC(O)R3a, -OC(O)OR3a, -OC(O)-N(R3a)(R3b), -S-R3a, -S(O)R3a, -S(O)(NH)R3a, -S(O)2R3a, -S(O)2N(R3a)(R3b), -S(O)(NR3a)R3b, -S(O)(NR3a)N(R3b)(R3c), -SF5, or -Si(R3a)3; wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each Z1, Z2, or Z3is each optionally substituted with one to four Z1a, which may be the same or different; each Z1ais independently deuterium, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkoxyalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, =O, -NO2, -CN, -N3, -O-R3a, -C(O)R3a, -C(O)O-R3a, -C(O)N(R3a)(R3b), -N(R3a)(R3b), -N(R3a)2(R3b)+, -N(R3a)-C(O)R3b, -N(R3a)C(O)O(R3b), -N(R3a)C(O)N(R3b)(R3c), -N(R3a)S(O)2(R3b), -N(R3a)S(O)2-N(R3b)(R3c), -N(R3a)S(O)2O(R3b), -OC(O)R3a, -OC(O)OR3a, -OC(O)-N(R3a)(R3b), -S-R3a, -S(O)R3a, -S(O)(NH)R3a, -S(O)2R3a, -S(O)2N(R3a)(R3b), -S(O)(NR3a)R3b, or -Si(R3a)3;wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1ais each optionally substituted with one to four Z1b, which may be the same or different; each Z1bis independently C1-9alkyl, C1-8haloalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, oxo, -OH, -CN, -NO2, -NH2, -N3, -SH, -O(C1-9alkyl), -O(C1-8haloalkyl), -O(C2-6alkenyl), -O(C2-6alkynyl), -O(C3-15cycloalkyl), -O(heterocyclyl), -O(C6-10aryl), -O(heteroaryl), -NH(C1-9alkyl), -NH(C1-8haloalkyl), -NH(C2-6alkenyl), -NH(C2-6alkynyl), -NH(C3-15cycloalkyl), -NH(heterocyclyl), -NH(C6-10aryl), -NH(heteroaryl), -N(C1-9alkyl)2, -N(C1-8haloalkyl)2, -N(C2-6alkenyl)2, -N(C2-6alkynyl)2, -N(C3-15cycloalkyl)2, -N(heterocyclyl)2, -N(C6-10aryl)2, -N(heteroaryl)2, -N(C1-9alkyl)(C1-8haloalkyl), -N(C1-9alkyl)(C2-6alkenyl), -N(C1-9alkyl)(C2-6alkynyl), -N(C1-9alkyl)(C3-15cycloalkyl), -N(C1-9alkyl)(heterocyclyl), -N(C1-9alkyl)(C6-10aryl), -N(C1-9alkyl)(heteroaryl), -C(O)(C1-9alkyl), -C(O)(C1-8haloalkyl), -C(O)(C2-6alkenyl), -C(O)(C2-6alkynyl), -C(O)(C3-15cycloalkyl), -C(O)(heterocyclyl), -C(O)(C6-10aryl), -C(O)(heteroaryl), -C(O)O(C1-9alkyl), -C(O)O(C1-8haloalkyl), -C(O)O(C2-6alkenyl), -C(O)O(C2-6alkynyl), -C(O)O(C3-15cycloalkyl), -C(O)O(heterocyclyl), -C(O)O(C6-10aryl), -C(O)O(heteroaryl), -C(O)NH2, -C(O)NH(C1-9alkyl), -C(O)NH(C1-8haloalkyl), -C(O)NH(C2-6alkenyl), -C(O)NH(C2-6alkynyl), -C(O)NH(C3-15cycloalkyl), -C(O)NH(heterocyclyl), -C(O)NH(C6-10aryl), -C(O)NH(heteroaryl), -C(O)N(C1-9alkyl)2, -C(O)N(C1-8haloalkyl)2, -C(O)N(C2-6alkenyl)2, -C(O)N(C2-6alkynyl)2, -C(O)N(C3-15cycloalkyl)2, -C(O)N(heterocyclyl)2, -C(O)N(C6-10aryl)2, -C(O)N(heteroaryl)2, -NHC(O)(C1-9alkyl), -NHC(O)(C1-8haloalkyl), -NHC(O)(C2-6alkenyl), -NHC(O)(C2-6alkynyl), -NHC(O)(C3-15cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(C6-10aryl), -NHC(O)(heteroaryl), -NHC(O)O(C1-9alkyl), -NHC(O)O(C1-8haloalkyl), -NHC(O)O(C2-6alkenyl), -NHC(O)O(C2-6alkynyl), -NHC(O)O(C3-15cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(C6-10aryl), -NHC(O)O(heteroaryl), -NHC(O)NH(C1-9alkyl), -NHC(O)NH(C1-8haloalkyl), -NHC(O)NH(C2-6alkenyl), -NHC(O)NH(C2-6alkynyl), -NHC(O)NH(C3-15cycloalkyl), -NHC(O)NH(heterocyclyl), -NHC(O)NH(C6-10aryl), -NHC(O)NH(heteroaryl), -NHS(O)(C1-9alkyl), -N(C1-9alkyl)(S(O)(C1-9alkyl), -S(C1-9alkyl), -S(C1-8haloalkyl), -S(C2-6alkenyl), -S(C2-6alkynyl), -S(C3-15cycloalkyl), -S(heterocyclyl), -S(C6-10aryl), -S(heteroaryl), -S(O)N(C1-9alkyl)2, -S(O)(C1-9alkyl), -S(O)(C1-8haloalkyl), -S(O)(C2-6alkenyl), -S(O)(C2-6alkynyl), -S(O)(C3-15cycloalkyl),-S(O)(heterocyclyl), -S(O)(C6-10aryl), -S(O)(heteroaryl), -S(O)2(C1-9alkyl), -S(O)2(C1-8haloalkyl), -S(O)2(C2-6alkenyl), -S(O)2(C2-6alkynyl), -S(O)2(C3-15cycloalkyl), -S(O)2(heterocyclyl), -S(O)2(C6-10aryl), -S(O)2(heteroaryl), -S(O)(NH)(C1-9alkyl), -S(O)2NH(C1-9alkyl), or -S(O)2N(C1-9alkyl)2; wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1bis optionally substituted with one to three C1-9alkyl, C1-8haloalkyl, halogen, -OH, -NH2, -O(C1-9alkyl), -O(C1-8haloalkyl), -O(C3-15cycloalkyl), -O(heterocyclyl), -O(aryl), -O(heteroaryl), -NH(C1-9alkyl), -NH(C1-8haloalkyl), -NH(C3-15cycloalkyl), -NH(heterocyclyl), -NH(aryl), -NH(heteroaryl), -N(C1-9alkyl)2, -N(C3-15cycloalkyl)2, -NHC(O)(C1-8haloalkyl), -NHC(O)(C3-15cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(aryl), -NHC(O)(heteroaryl), -NHC(O)O(C1-9alkyl), -NHC(O)O(C1-8haloalkyl), -NHC(O)O(C2-6alkynyl), -NHC(O)O(C3-15cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(aryl), -NHC(O)O(heteroaryl), -NHC(O)NH(C1-9alkyl), S(O)2(C1-9alkyl), -S(O)2(C1-8haloalkyl), -S(O)2(C3-15cycloalkyl), -S(O)2(heterocyclyl), -S(O)2(aryl), -S(O)2(heteroaryl), -S(O)(NH)(C1-9alkyl), -S(O)2NH(C1-9alkyl), or -S(O)2N(C1-9alkyl)2; each R1a, R1b, R1c, R1d, R2a, R2b, R2c, R2d, R3a, R3b, and R3cis independently -H, C1-9alkyl, C2-6alkenyl, C2-6alkynyl, C3-15cycloalkyl, heterocyclyl, C6-10aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each R1a, R1b, R1c, R1d, R2a, R2b, R2c, R2d, R3a, R3b, and R3cis each optionally substituted with one to four Z1b, which may be the same or different; wherein each aryl of the compound of Formula (I) unless otherwise specified is C6-10aryl; wherein each heteroaryl of the compound of Formula (I) unless otherwise specified is 5 to 12 membered heteroaryl having one to four heteroatoms each independently N, O, or S; wherein each heterocyclyl of the compound of Formula (I) unless otherwise specified is 3 to 20 membered heterocyclyl having one to four heteroatoms each independently N, O, or S.

[0092] In some embodiments of the compound of Formula (I), or pharmaceutically acceptable salt thereof, R1is -H; R2is -H, -F, or -Cl; R21is -H; R3is -H, -F, or -Cl; R4aand R4bare each independently -H, halogen, -OH, or C1-6alkyl; Ring A is C3-10cycloalkyl or heterocyclyl; n is 0, 1, 2, 3, or 4; each R5is independently halogen, =O, -CN, C1-6alkyl, C1-6haloalkyl, C1-6haloalkoxy, C1-6alkoxy, C3-6cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, -O-(R51), or -N(R51)(R52); wherein each alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclyl, aryl, or heteroaryl of R5is optionally substituted with one to four R5a, which may be the same or different; each R5ais independently halogen, -CN, C1-6alkyl, C6-10aryl, or -O(R51); wherein each R51and R52, which may be the same or different, is independently -H, C1-6alkyl, C3-10cycloalkyl, heterocyclyl, C6-10aryl, or heteroaryl; R6is -H, C1-8alkyl, C1-6haloalkyl, C3-12cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)N(R1a)(R1b), -S(O)(NR1a)(R1b), -C(O)R1c, -S(O2)R1c, or -C(O)OR1d, wherein the alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R6is each optionally substituted with one to four Z1, which may be the same or different; R7is -H, C1-8alkyl, C1-6haloalkyl, C3-12cycloalkyl, heterocyclyl, aryl, heteroaryl -C(O)N(R2a)(R2b), -S(O)(NR2a)(R2b), -C(O)R2c, S(O2)R2c, or -C(O)OR2d, wherein the alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R7is each optionally substituted with one to four Z2, which may be the same or different; orR6and R7together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z3, which may be the same or different; wherein the heterocyclyl formed by R6and R7is 3 to 20 membered heterocyclyl having 0 to 3 additional heteroatoms each independently N, O or S; each Z1, Z2, or Z3is independently deuterium, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkoxyalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, =O, imino, -NO2, -N3, -CN, -O-R3a, -C(O)-R3a, -C(O)O-R3a, -C(O)-N(R3a)(R3b), -N(R3a)(R3b), -N(R3a)2(R3b)+,-N(R3a)C(O)-R3b, -N(R3a)C(O)O-R3b, -N(R3a)C(O)N(R3b)(R3c), -N(R3a)S(O)2(R3b), -NR3aS(O)2N(R3b)(R3c), -NR3aS(O)2O(R3b), -OC(O)R3a, -OC(O)OR3a, -OC(O)-N(R3a)(R3b), -S-R3a, -S(O)R3a, -S(O)(NH)R3a, -S(O)2R3a, -S(O)2N(R3a)(R3b), -S(O)(NR3a)R3b, -S(O)(NR3a)N(R3b)(R3c), -SF5, or -Si(R3a)3; wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each Z1, Z2, or Z3is each optionally substituted with one to four Z1a, which may be the same or different; each Z1ais independently deuterium, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkoxyalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, =O, -NO2, -CN, -N3, -O-R3a, -C(O)R3a, -C(O)O-R3a, -C(O)N(R3a)(R3b), -N(R3a)(R3b), -N(R3a)2(R3b)+, -N(R3a)-C(O)R3b, -N(R3a)C(O)O(R3b), -N(R3a)C(O)N(R3b)(R3c), -N(R3a)S(O)2(R3b), -N(R3a)S(O)2-N(R3b)(R3c), -N(R3a)S(O)2O(R3b), -OC(O)R3a, -OC(O)OR3a, -OC(O)-N(R3a)(R3b), -S-R3a, -S(O)R3a, -S(O)(NH)R3a, -S(O)2R3a, -S(O)2N(R3a)(R3b), -S(O)(NR3a)R3b, or -Si(R3a)3; wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1ais each optionally substituted with one to four Z1b, which may be the same or different;each Z1bis independently C1-9alkyl, C1-8haloalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, oxo, -OH, -CN, -NO2, -NH2, -N3, -SH, -O(C1-9alkyl), -O(C1-8haloalkyl), -O(C2-6alkenyl), -O(C2-6alkynyl), -O(C3-15cycloalkyl), -O(heterocyclyl), -O(C6-10aryl), -O(heteroaryl), -NH(C1-9alkyl), -NH(C1-8haloalkyl), -NH(C2-6alkenyl), -NH(C2-6alkynyl), -NH(C3-15cycloalkyl), -NH(heterocyclyl), -NH(C6-10aryl), -NH(heteroaryl), -N(C1-9alkyl)2, -N(C1-8haloalkyl)2, -N(C2-6alkenyl)2, -N(C2-6alkynyl)2, -N(C3-15cycloalkyl)2, -N(heterocyclyl)2, -N(C6-10aryl)2, -N(heteroaryl)2, -N(C1-9alkyl)(C1-8haloalkyl), -N(C1-9alkyl)(C2-6alkenyl), -N(C1-9alkyl)(C2-6alkynyl), -N(C1-9alkyl)(C3-15cycloalkyl), -N(C1-9alkyl)(heterocyclyl), -N(C1-9alkyl)(C6-10aryl), -N(C1-9alkyl)(heteroaryl), -C(O)(C1-9alkyl), -C(O)(C1-8haloalkyl), -C(O)(C2-6alkenyl), -C(O)(C2-6alkynyl), -C(O)(C3-15cycloalkyl), -C(O)(heterocyclyl), -C(O)(C6-10aryl), -C(O)(heteroaryl), -C(O)O(C1-9alkyl), -C(O)O(C1-8haloalkyl), -C(O)O(C2-6alkenyl), -C(O)O(C2-6alkynyl), -C(O)O(C3-15cycloalkyl), -C(O)O(heterocyclyl), -C(O)O(C6-10aryl), -C(O)O(heteroaryl), -C(O)NH2, -C(O)NH(C1-9alkyl), -C(O)NH(C1-8haloalkyl), -C(O)NH(C2-6alkenyl), -C(O)NH(C2-6alkynyl), -C(O)NH(C3-15cycloalkyl), -C(O)NH(heterocyclyl), -C(O)NH(C6-10aryl), -C(O)NH(heteroaryl), -C(O)N(C1-9alkyl)2, -C(O)N(C1-8haloalkyl)2, -C(O)N(C2-6alkenyl)2, -C(O)N(C2-6alkynyl)2, -C(O)N(C3-15cycloalkyl)2, -C(O)N(heterocyclyl)2, -C(O)N(C6-10aryl)2, -C(O)N(heteroaryl)2, -NHC(O)(C1-9alkyl), -NHC(O)(C1-8haloalkyl), -NHC(O)(C2-6alkenyl), -NHC(O)(C2-6alkynyl), -NHC(O)(C3-15cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(C6-10aryl), -NHC(O)(heteroaryl), -NHC(O)O(C1-9alkyl), -NHC(O)O(C1-8haloalkyl), -NHC(O)O(C2-6alkenyl), -NHC(O)O(C2-6alkynyl), -NHC(O)O(C3-15cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(C6-10aryl), -NHC(O)O(heteroaryl), -NHC(O)NH(C1-9alkyl), -NHC(O)NH(C1-8haloalkyl), -NHC(O)NH(C2-6alkenyl), -NHC(O)NH(C2-6alkynyl), -NHC(O)NH(C3-15cycloalkyl), -NHC(O)NH(heterocyclyl), -NHC(O)NH(C6-10aryl), -NHC(O)NH(heteroaryl), -NHS(O)(C1-9alkyl), -N(C1-9alkyl)(S(O)(C1-9alkyl), -S(C1-9alkyl), -S(C1-8haloalkyl), -S(C2-6alkenyl), -S(C2-6alkynyl), -S(C3-15cycloalkyl), -S(heterocyclyl), -S(C6-10aryl), -S(heteroaryl), -S(O)N(C1-9alkyl)2, -S(O)(C1-9alkyl), -S(O)(C1-8haloalkyl), -S(O)(C2-6alkenyl), -S(O)(C2-6alkynyl), -S(O)(C3-15cycloalkyl), -S(O)(heterocyclyl), -S(O)(C6-10aryl), -S(O)(heteroaryl), -S(O)2(C1-9alkyl), -S(O)2(C1-8haloalkyl), -S(O)2(C2-6alkenyl), -S(O)2(C2-6alkynyl), -S(O)2(C3-15cycloalkyl),-S(O)2(heterocyclyl), -S(O)2(C6-10aryl), -S(O)2(heteroaryl), -S(O)(NH)(C1-9alkyl), -S(O)2NH(C1-9alkyl), or -S(O)2N(C1-9alkyl)2; wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1bis optionally substituted with one to three C1-9alkyl, C1-8haloalkyl, halogen, -OH, -NH2, -O(C1-9alkyl), -O(C1-8haloalkyl), -O(C3-15cycloalkyl), -O(heterocyclyl), -O(aryl), -O(heteroaryl), -NH(C1-9alkyl), -NH(C1-8haloalkyl), -NH(C3-15cycloalkyl), -NH(heterocyclyl), -NH(aryl), -NH(heteroaryl), -N(C1-9alkyl)2, -N(C3-15cycloalkyl)2, -NHC(O)(C1-8haloalkyl), -NHC(O)(C3-15cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(aryl), -NHC(O)(heteroaryl), -NHC(O)O(C1-9alkyl), -NHC(O)O(C1-8haloalkyl), -NHC(O)O(C2-6alkynyl), -NHC(O)O(C3-15cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(aryl), -NHC(O)O(heteroaryl), -NHC(O)NH(C1-9alkyl), S(O)2(C1-9alkyl), -S(O)2(C1-8haloalkyl), -S(O)2(C3-15cycloalkyl), -S(O)2(heterocyclyl), -S(O)2(aryl), -S(O)2(heteroaryl), -S(O)(NH)(C1-9alkyl), -S(O)2NH(C1-9alkyl), or -S(O)2N(C1-9alkyl)2; each R1a, R1b, R1c, R1d, R2a, R2b, R2c, R2d, R3a, R3b, and R3cis independently -H, C1-9alkyl, C2-6alkenyl, C2-6alkynyl, C3-15cycloalkyl, heterocyclyl, C6-10aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each R1a, R1b, R1c, R1d, R2a, R2b, R2c, R2d, R3a, R3b, and R3cis each optionally substituted with one to four Z1b, which may be the same or different; wherein each aryl of the compound of Formula (I) unless otherwise specified is C6-10aryl; wherein each heteroaryl of the compound of Formula (I) unless otherwise specified is 5 to 12 membered heteroaryl having one to four heteroatoms each independently N, O, or S; wherein each heterocyclyl of the compound of Formula (I) unless otherwise specified is 3 to 20 membered heterocyclyl having one to four heteroatoms each independently N, O or S.

[0093] In some embodiments of the compound of Formula (I), or pharmaceutically acceptable salt thereof, R1is -H; R2is -H, -F, or -Cl; R3is -H, -F, or -Cl; R4aand R4bare each independently -H, halogen, -OH, or C1-6alkyl; Ring A is C3-10cycloalkyl or heterocyclyl; n is 0, 1, 2, 3, or 4; each R5is independently halogen, =O, -CN, C1-6alkyl, C1-6haloalkyl, C1-6haloalkoxy, C3-6cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, -O-(R51), or -N(R51)(R52); wherein each alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclyl, aryl, or heteroaryl of R5is optionally substituted with one to four R5a, which may be the same or different; each R5ais independently halogen, -CN, C1-6alkyl, C6-10aryl, or -O(R51); wherein each R51and R52, which may be the same or different, is independently -H, C1-6alkyl, C3-10cycloalkyl, heterocyclyl, C6-10aryl, or heteroaryl; R6is -H, C1-6alkyl, C1-6haloalkyl, C3-10cycloalkyl, heterocyclyl, -C(O)N(R1a)(R1b), -S(O)(NR1a)(R1b), -C(O)R1c, -S(O2)R1c, or -C(O)OR1d, wherein the alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R6is each optionally substituted with one to four Z1, which may be the same or different; R7is -H, C1-6alkyl, C1-6haloalkyl, C3-10cycloalkyl, heterocyclyl, -C(O)N(R2a)(R2b), -S(O)(NR2a)(R2b), -C(O)R2c, S(O2)R2c, or -C(O)OR2d, wherein the alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R7is each optionally substituted with one to four Z2, which may be the same or different; orR6and R7together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z3, which may be the same or different; wherein the heterocyclyl formed by R6and R7is 3 to 20 membered heterocyclyl having 0 to 3 additional heteroatoms each independently N, O or S; each Z1, Z2, or Z3is independently C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkoxyalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, =O, imino, -NO2, -N3, -CN, -O-R3a, -C(O)-R3a, -C(O)O-R3a, -C(O)-N(R3a)(R3b), -N(R3a)(R3b), -N(R3a)2(R3b)+,-N(R3a)C(O)-R3b, -N(R3a)C(O)O-R3b, -N(R3a)C(O)N(R3b)(R3c), -N(R3a)S(O)2(R3b), -NR3aS(O)2N(R3b)(R3c), -NR3aS(O)2O(R3b), -OC(O)R3a, -OC(O)OR3a, -OC(O)-N(R3a)(R3b), -S-R3a, -S(O)R3a, -S(O)(NH)R3a, -S(O)2R3a, -S(O)2N(R3a)(R3b), -S(O)(NR3a)R3b, -S(O)(NR3a)N(R3b)(R3c), -SF5, or -Si(R3a)3; wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each Z1, Z2, or Z3is each optionally substituted with one to four Z1a, which may be the same or different; each Z1ais independently C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkoxyalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, =O, -NO2, -CN, -N3, -O-R3a, -C(O)R3a, -C(O)O-R3a, -C(O)N(R3a)(R3b), -N(R3a)(R3b), -N(R3a)2(R3b)+, -N(R3a)-C(O)R3b, -N(R3a)C(O)O(R3b), -N(R3a)C(O)N(R3b)(R3c), -N(R3a)S(O)2(R3b), -N(R3a)S(O)2-N(R3b)(R3c), -N(R3a)S(O)2O(R3b), -OC(O)R3a, -OC(O)OR3a, -OC(O)-N(R3a)(R3b), -S-R3a, -S(O)R3a, -S(O)(NH)R3a, -S(O)2R3a, -S(O)2N(R3a)(R3b), -S(O)(NR3a)R3b, or -Si(R3a)3; wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1ais each optionally substituted with one to four Z1b, which may be the same or different;each Z1bis independently C1-9alkyl, C1-8haloalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, oxo, -OH, -CN, -NO2, -NH2, -N3, -SH, -O(C1-9alkyl), -O(C1-8haloalkyl), -O(C2-6alkenyl), -O(C2-6alkynyl), -O(C3-15cycloalkyl), -O(heterocyclyl), -O(C6-10aryl), -O(heteroaryl), -NH(C1-9alkyl), -NH(C1-8haloalkyl), -NH(C2-6alkenyl), -NH(C2-6alkynyl), -NH(C3-15cycloalkyl), -NH(heterocyclyl), -NH(C6-10aryl), -NH(heteroaryl), -N(C1-9alkyl)2, -N(C1-8haloalkyl)2, -N(C2-6alkenyl)2, -N(C2-6alkynyl)2, -N(C3-15cycloalkyl)2, -N(heterocyclyl)2, -N(C6-10aryl)2, -N(heteroaryl)2, -N(C1-9alkyl)(C1-8haloalkyl), -N(C1-9alkyl)(C2-6alkenyl), -N(C1-9alkyl)(C2-6alkynyl), -N(C1-9alkyl)(C3-15cycloalkyl), -N(C1-9alkyl)(heterocyclyl), -N(C1-9alkyl)(C6-10aryl), -N(C1-9alkyl)(heteroaryl), -C(O)(C1-9alkyl), -C(O)(C1-8haloalkyl), -C(O)(C2-6alkenyl), -C(O)(C2-6alkynyl), -C(O)(C3-15cycloalkyl), -C(O)(heterocyclyl), -C(O)(C6-10aryl), -C(O)(heteroaryl), -C(O)O(C1-9alkyl), -C(O)O(C1-8haloalkyl), -C(O)O(C2-6alkenyl), -C(O)O(C2-6alkynyl), -C(O)O(C3-15cycloalkyl), -C(O)O(heterocyclyl), -C(O)O(C6-10aryl), -C(O)O(heteroaryl), -C(O)NH2, -C(O)NH(C1-9alkyl), -C(O)NH(C1-8haloalkyl), -C(O)NH(C2-6alkenyl), -C(O)NH(C2-6alkynyl), -C(O)NH(C3-15cycloalkyl), -C(O)NH(heterocyclyl), -C(O)NH(C6-10aryl), -C(O)NH(heteroaryl), -C(O)N(C1-9alkyl)2, -C(O)N(C1-8haloalkyl)2, -C(O)N(C2-6alkenyl)2, -C(O)N(C2-6alkynyl)2, -C(O)N(C3-15cycloalkyl)2, -C(O)N(heterocyclyl)2, -C(O)N(C6-10aryl)2, -C(O)N(heteroaryl)2, -NHC(O)(C1-9alkyl), -NHC(O)(C1-8haloalkyl), -NHC(O)(C2-6alkenyl), -NHC(O)(C2-6alkynyl), -NHC(O)(C3-15cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(C6-10aryl), -NHC(O)(heteroaryl), -NHC(O)O(C1-9alkyl), -NHC(O)O(C1-8haloalkyl), -NHC(O)O(C2-6alkenyl), -NHC(O)O(C2-6alkynyl), -NHC(O)O(C3-15cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(C6-10aryl), -NHC(O)O(heteroaryl), -NHC(O)NH(C1-9alkyl), -NHC(O)NH(C1-8haloalkyl), -NHC(O)NH(C2-6alkenyl), -NHC(O)NH(C2-6alkynyl), -NHC(O)NH(C3-15cycloalkyl), -NHC(O)NH(heterocyclyl), -NHC(O)NH(C6-10aryl), -NHC(O)NH(heteroaryl), -NHS(O)(C1-9alkyl), -N(C1-9alkyl)(S(O)(C1-9alkyl), -S(C1-9alkyl), -S(C1-8haloalkyl), -S(C2-6alkenyl), -S(C2-6alkynyl), -S(C3-15cycloalkyl), -S(heterocyclyl), -S(C6-10aryl), -S(heteroaryl), -S(O)N(C1-9alkyl)2, -S(O)(C1-9alkyl), -S(O)(C1-8haloalkyl), -S(O)(C2-6alkenyl), -S(O)(C2-6alkynyl), -S(O)(C3-15cycloalkyl), -S(O)(heterocyclyl), -S(O)(C6-10aryl), -S(O)(heteroaryl), -S(O)2(C1-9alkyl), -S(O)2(C1-8haloalkyl), -S(O)2(C2-6alkenyl), -S(O)2(C2-6alkynyl), -S(O)2(C3-15cycloalkyl),-S(O)2(heterocyclyl), -S(O)2(C6-10aryl), -S(O)2(heteroaryl), -S(O)(NH)(C1-9alkyl), -S(O)2NH(C1-9alkyl), or -S(O)2N(C1-9alkyl)2; wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1bis optionally substituted with one to three C1-9alkyl, C1-8haloalkyl, halogen, -OH, -NH2, -O(C1-9alkyl), -O(C1-8haloalkyl), -O(C3-15cycloalkyl), -O(heterocyclyl), -O(aryl), -O(heteroaryl), -NH(C1-9alkyl), -NH(C1-8haloalkyl), -NH(C3-15cycloalkyl), -NH(heterocyclyl), -NH(aryl), -NH(heteroaryl), -N(C1-9alkyl)2, -N(C3-15cycloalkyl)2, -NHC(O)(C1-8haloalkyl), -NHC(O)(C3-15cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(aryl), -NHC(O)(heteroaryl), -NHC(O)O(C1-9alkyl), -NHC(O)O(C1-8haloalkyl), -NHC(O)O(C2-6alkynyl), -NHC(O)O(C3-15cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(aryl), -NHC(O)O(heteroaryl), -NHC(O)NH(C1-9alkyl), S(O)2(C1-9alkyl), -S(O)2(C1-8haloalkyl), -S(O)2(C3-15cycloalkyl), -S(O)2(heterocyclyl), -S(O)2(aryl), -S(O)2(heteroaryl), -S(O)(NH)(C1-9alkyl), -S(O)2NH(C1-9alkyl), or -S(O)2N(C1-9alkyl)2; each R1a, R1b, R1c, R1d, R2a, R2b, R2c, R2d, R3a, R3b, and R3cis independently -H, C1-9alkyl, C2-6alkenyl, C2-6alkynyl, C3-15cycloalkyl, heterocyclyl, C6-10aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each R1a, R1b, R1c, R1d, R2a, R2b, R2c, R2d, R3a, R3b, and R3cis each optionally substituted with one to four Z1b, which may be the same or different; wherein each aryl of the compound of Formula (I) unless otherwise specified is C6-10aryl; wherein each heteroaryl of the compound of Formula (I) unless otherwise specified is 5 to 12 membered heteroaryl having one to four heteroatoms each independently N, O, or S; wherein each heterocyclyl of the compound of Formula (I) unless otherwise specified is 3 to 20 membered heterocyclyl having one to four heteroatoms each independently N, O or S.

[0094] In some embodiments of the compound of Formula (I), or pharmaceutically acceptable salt thereof, R1is -H; R2is -H, -F, or -Cl; R3is -H, -F, or -Cl;R4aand R4bare each independently -H, halogen, -OH, or C1-6alkyl; Ring A is C3-10cycloalkyl or heterocyclyl; n is 0, 1, 2, 3, or 4; each R5is independently halogen, =O, -CN, C1-6alkyl, C1-6haloalkyl, C1-6haloalkoxy, C3-6cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, -O-(R51), or -N(R51)(R52); wherein each alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclyl, aryl, or heteroaryl of R5is optionally substituted with one to four R5a, which may be the same or different; each R5ais independently halogen, -CN, C1-6alkyl, C6-10aryl, or -O(R51); wherein each R51and R52, which may be the same or different, is independently -H, C1-6alkyl, C3-10cycloalkyl, heterocyclyl, C6-10aryl, or heteroaryl; R6is -H, C1-6alkyl, C1-6haloalkyl, C3-12cycloalkyl, heterocyclyl, -C(O)N(R1a)(R1b), -S(O)(NR1a)(R1b), -C(O)R1c, -S(O2)R1c, or -C(O)OR1d, wherein the alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R6is each optionally substituted with one to four Z1, which may be the same or different; R7is -H, C1-8alkyl, C1-6haloalkyl, C3-12cycloalkyl, heterocyclyl, aryl, heteroaryl -C(O)N(R2a)(R2b), -S(O)(NR2a)(R2b), -C(O)R2c, S(O2)R2c, or -C(O)OR2d, wherein the alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R7is each optionally substituted with one to four Z2, which may be the same or different; or R6and R7together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z3, which may be the same or different; wherein the heterocyclyl formed by R6and R7is 3 to 20 membered heterocyclyl having 0 to 3 additional heteroatoms each independently N, O or S; each Z1, Z2, or Z3is independently C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkoxyalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, =O, imino, -NO2, -N3, -CN, -O-R3a, -C(O)-R3a, -C(O)O-R3a, -C(O)-N(R3a)(R3b), -N(R3a)(R3b), -N(R3a)2(R3b)+,-N(R3a)C(O)-R3b, -N(R3a)C(O)O-R3b,-N(R3a)C(O)N(R3b)(R3c), -N(R3a)S(O)2(R3b), -NR3aS(O)2N(R3b)(R3c), -NR3aS(O)2O(R3b), -OC(O)R3a, -OC(O)OR3a, -OC(O)-N(R3a)(R3b), -S-R3a, -S(O)R3a, -S(O)(NH)R3a, -S(O)2R3a, -S(O)2N(R3a)(R3b), -S(O)(NR3a)R3b, -S(O)(NR3a)N(R3b)(R3c), -SF5, or -Si(R3a)3; wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each Z1, Z2, or Z3is each optionally substituted with one to four Z1a, which may be the same or different; each Z1ais independently C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkoxyalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, =O, -NO2, -CN, -N3, -O-R3a, -C(O)R3a, -C(O)O-R3a, -C(O)N(R3a)(R3b), -N(R3a)(R3b), -N(R3a)2(R3b)+, -N(R3a)-C(O)R3b, -N(R3a)C(O)O(R3b), -N(R3a)C(O)N(R3b)(R3c), -N(R3a)S(O)2(R3b), -N(R3a)S(O)2-N(R3b)(R3c), -N(R3a)S(O)2O(R3b), -OC(O)R3a, -OC(O)OR3a, -OC(O)-N(R3a)(R3b), -S-R3a, -S(O)R3a, -S(O)(NH)R3a, -S(O)2R3a, -S(O)2N(R3a)(R3b), -S(O)(NR3a)R3b, or -Si(R3a)3; wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1ais each optionally substituted with one to four Z1b, which may be the same or different; each Z1bis independently C1-9alkyl, C1-8haloalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, oxo, -OH, -CN, -NO2, -NH2, -N3, -SH, -O(C1-9alkyl), -O(C1-8haloalkyl), -O(C2-6alkenyl), -O(C2-6alkynyl), -O(C3-15cycloalkyl), -O(heterocyclyl), -O(C6-10aryl), -O(heteroaryl), -NH(C1-9alkyl), -NH(C1-8haloalkyl), -NH(C2-6alkenyl), -NH(C2-6alkynyl), -NH(C3-15cycloalkyl), -NH(heterocyclyl), -NH(C6-10aryl), -NH(heteroaryl), -N(C1-9alkyl)2, -N(C1-8haloalkyl)2, -N(C2-6alkenyl)2, -N(C2-6alkynyl)2, -N(C3-15cycloalkyl)2, -N(heterocyclyl)2, -N(C6-10aryl)2, -N(heteroaryl)2, -N(C1-9alkyl)(C1-8haloalkyl), -N(C1-9alkyl)(C2-6alkenyl), -N(C1-9alkyl)(C2-6alkynyl), -N(C1-9alkyl)(C3-15cycloalkyl), -N(C1-9alkyl)(heterocyclyl), -N(C1-9alkyl)(C6-10aryl), -N(C1-9alkyl)(heteroaryl), -C(O)(C1-9alkyl), -C(O)(C1-8haloalkyl), -C(O)(C2-6alkenyl), -C(O)(C2-6alkynyl), -C(O)(C3-15cycloalkyl), -C(O)(heterocyclyl), -C(O)(C6-10aryl), -C(O)(heteroaryl), -C(O)O(C1-9alkyl), -C(O)O(C1-8haloalkyl), -C(O)O(C2-6alkenyl), -C(O)O(C2-6alkynyl), -C(O)O(C3-15cycloalkyl), - C(O)O(heterocyclyl), -C(O)O(C6-10aryl), -C(O)O(heteroaryl), -C(O)NH2, -C(O)NH(C1-9alkyl), -C(O)NH(C1-8haloalkyl), -C(O)NH(C2-6alkenyl),-C(O)NH(C2-6alkynyl), -C(O)NH(C3-15cycloalkyl), -C(O)NH(heterocyclyl), -C(O)NH(C6-10aryl), -C(O)NH(heteroaryl), -C(O)N(C1-9alkyl)2, -C(O)N(C1-8haloalkyl)2, -C(O)N(C2-6alkenyl)2, -C(O)N(C2-6alkynyl)2, -C(O)N(C3-15cycloalkyl)2, -C(O)N(heterocyclyl)2, -C(O)N(C6-10aryl)2, -C(O)N(heteroaryl)2, -NHC(O)(C1-9alkyl), -NHC(O)(C1-8haloalkyl), -NHC(O)(C2-6alkenyl), -NHC(O)(C2-6alkynyl), -NHC(O)(C3-15cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(C6-10aryl), -NHC(O)(heteroaryl), -NHC(O)O(C1-9alkyl), -NHC(O)O(C1-8haloalkyl), -NHC(O)O(C2-6alkenyl), -NHC(O)O(C2-6alkynyl), -NHC(O)O(C3-15cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(C6-10aryl), -NHC(O)O(heteroaryl), -NHC(O)NH(C1-9alkyl), -NHC(O)NH(C1-8haloalkyl), -NHC(O)NH(C2-6alkenyl), -NHC(O)NH(C2-6alkynyl), -NHC(O)NH(C3-15cycloalkyl), -NHC(O)NH(heterocyclyl), -NHC(O)NH(C6-10aryl), -NHC(O)NH(heteroaryl), -NHS(O)(C1-9alkyl), -N(C1-9alkyl)(S(O)(C1-9alkyl), -S(C1-9alkyl), -S(C1-8haloalkyl), -S(C2-6alkenyl), -S(C2-6alkynyl), -S(C3-15cycloalkyl), -S(heterocyclyl), -S(C6-10aryl), -S(heteroaryl), -S(O)N(C1-9alkyl)2, -S(O)(C1-9alkyl), -S(O)(C1-8haloalkyl), -S(O)(C2-6alkenyl), -S(O)(C2-6alkynyl), -S(O)(C3-15cycloalkyl), -S(O)(heterocyclyl), -S(O)(C6-10aryl), -S(O)(heteroaryl), -S(O)2(C1-9alkyl), -S(O)2(C1-8haloalkyl), -S(O)2(C2-6alkenyl), -S(O)2(C2-6alkynyl), -S(O)2(C3-15cycloalkyl), -S(O)2(heterocyclyl), -S(O)2(C6-10aryl), -S(O)2(heteroaryl), -S(O)(NH)(C1-9alkyl), -S(O)2NH(C1-9alkyl), or -S(O)2N(C1-9alkyl)2; wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1bis optionally substituted with one to three C1-9alkyl, C1-8haloalkyl, halogen, -OH, -NH2, -O(C1-9alkyl), -O(C1-8haloalkyl), -O(C3-15cycloalkyl), -O(heterocyclyl), -O(aryl), -O(heteroaryl), -NH(C1-9alkyl), -NH(C1-8haloalkyl), -NH(C3-15cycloalkyl), -NH(heterocyclyl), -NH(aryl), -NH(heteroaryl), -N(C1-9alkyl)2, -N(C3-15cycloalkyl)2, -NHC(O)(C1-8haloalkyl), -NHC(O)(C3-15cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(aryl), -NHC(O)(heteroaryl), -NHC(O)O(C1-9alkyl), -NHC(O)O(C1-8haloalkyl), -NHC(O)O(C2-6alkynyl), -NHC(O)O(C3-15cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(aryl), -NHC(O)O(heteroaryl), -NHC(O)NH(C1-9alkyl), S(O)2(C1-9alkyl), -S(O)2(C1-8haloalkyl), -S(O)2(C3-15cycloalkyl), -S(O)2(heterocyclyl), -S(O)2(aryl), -S(O)2(heteroaryl), -S(O)(NH)(C1-9alkyl), -S(O)2NH(C1-9alkyl), or -S(O)2N(C1-9alkyl)2;each R1a, R1b, R1c, R1d, R2a, R2b, R2c, R2d, R3a, R3b, and R3cis independently -H, C1-9alkyl, C2-6alkenyl, C2-6alkynyl, C3-15cycloalkyl, heterocyclyl, C6-10aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each R1a, R1b, R1c, R1d, R2a, R2b, R2c, R2d, R3a, R3b, and R3cis each optionally substituted with one to four Z1b, which may be the same or different; wherein each heteroaryl of the compound of Formula (I) unless otherwise specified is 5 to 12 membered heteroaryl having one to four heteroatoms each independently N, O, or S; wherein each heterocyclyl of the compound of Formula (I) unless otherwise specified is 3 to 20 membered heterocyclyl having one to four heteroatoms each independently N, O or S.

[0095] In some embodiments of the compound of Formula (I), or pharmaceutically acceptable salt thereof, R1is -H; R2is -H or -F; R21is -H; R3is -H or -F; R4aand R4bare each independently -H -F, or -CH3; Ring A is a cyclopentyl, cyclohexyl, cycloheptyl, cyclohexenyl, or tetrahydropyranyl ring; n is 0, 1, or 2; each R5is independently -F, -OH, -CH3, =CH2, -CH2-OH, or -O-CH3; R6is -H, C1-6alkyl, C1-6haloalkyl, C3-10cycloalkyl, heterocyclyl, C6-10aryl, or heteroaryl, wherein each alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R6is optionally substituted with one to four Z1, which may be the same or different; R7is -H, C1-8alkyl, C1-6haloalkyl, C3-12cycloalkyl, heterocyclyl, C6-10aryl, or heteroaryl, wherein each alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R7is optionally substituted with one to four Z2, which may be the same or different; orR6and R7together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z3, which may be the same or different; wherein the heterocyclyl formed by R6and R7is 3 to 12 membered heterocyclyl having 0 to 3 additional heteroatoms each independently N, O, or S; each Z1, Z2, or Z3is independently deuterium, halogen, =O, -CN, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkoxyalkyl, C2-6alkenyl, C2-6alkynyl, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, or -O-R3a; wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each Z1, Z2, or Z3is optionally substituted with one to four Z1a, which may be the same or different; each Z1ais independently deuterium, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkoxyalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, -CN, -O-R3a, or -S(O)2R3a, wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1ais optionally substituted with one to four Z1b, which may be the same or different; each Z1bis independently C1-9alkyl, C1-8haloalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15 cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, or -CN, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1bis unsubstituted; each R3ais independently -H, C1-9alkyl, C6-10aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of R3ais optionally substituted with one to four Z1b, which may be the same or different; wherein each heteroaryl of the compound of Formula (I) or Formula (Ia) is 5 to 12 membered heteroaryl having one to four heteroatoms each independently N, O, or S; wherein each heterocyclyl of the compound of Formula (I) or Formula (Ia) is 3 to 20 membered heterocyclyl having one to four heteroatoms each independently N, O, or S.

[0096] In some embodiments of the compound of Formula (I), or pharmaceutically acceptable salt thereof, R1is -H; R2is -H or -F; R21is -H or -F; R3is -H or -F; R4ais -H, -F, or -CH3, and R4bis -H; Ring A isn is 0, 1, or 2; each R5is independently -F, -OH, -CH3, =CH2, -CH2-OH, or -O-CH3; R6is -H or C1-6alkyl optionally substituted with one Z1, wherein Z1is unsubstituted; R7is -H, C1-8alkyl, C3-12cycloalkyl, C6-10aryl, 4 to 12 membered heterocyclyl having 1 to 2 heteroatoms each independently selected from nitrogen,oxygen, and sulfur, or 5 to 12 membered heteroaryl having 1 to 3 heteroatoms each independently selected from nitrogen, oxygen, and sulfur, wherein each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl of R7is optionally substituted with one to four Z2, which may be the same or different; or R6and R7together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z3, which may be the same or different; wherein theheterocyclyl formed by R6and R7is 3 to 7 membered heterocyclyl optionally having an additional N; each Z1, Z2, or Z3is independently deuterium, halogen, =O, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C3-15cycloalkyl, C6-10aryl, heterocyclyl, heteroaryl or -O-R3a; wherein each alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1, Z2, or Z3is optionally substituted with one to four Z1a, which may be the same or different; each Z1ais independently deuterium, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, halogen, -CN, or -S(O)2R3a; wherein each alkyl of Z1ais optionally substituted with one to four Z1b, which may be the same or different; each Z1bis independently halogen, C3-15cycloalkyl, or C6-10aryl, wherein each cycloalkyl or aryl of Z1bis unsubstituted; each R3ais independently C1-9alkyl or C6-10aryl, wherein each alkyl or aryl of R3ais optionally substituted with one to four Z1b, which may be the same or different; wherein each heteroaryl of the compound of Formula (I) or Formula (Ia) is 5 to 6 membered heteroaryl having one or two heteroatoms each independently N or S; wherein each heterocyclyl of the compound of Formula (I) or Formula (Ia) is 3 to 7 membered heterocyclyl having one to two heteroatoms each independently N or O.

[0097] In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is a compound of Formula (Ia),or a pharmaceutically acceptable salt thereof.

[0098] In some embodiments, the compound of of Formula (I), or pharmaceutically acceptable salt thereof, is a compound of Formula (Ib),or a pharmaceutically acceptable salt thereof.

[0099] In some embodiments of the compound of Formula (I), Formula (Ia), or Formula (Ib), or pharmaceutically acceptable salt thereof, R1is -H; R2is -H or -F; R3is -H or -F; R4aand R4bare each independently -H -F, or -CH3; Ring A is a cyclopentyl, cyclohexyl, cycloheptyl, cyclohexenyl, or tetrahydropyranyl ring; n is 0, 1, or 2; each R5is independently -F, -OH, -CH3, =CH2, -CH2-OH, or -O-CH3; R6is -H, C1-6alkyl, C1-6haloalkyl, C3-10cycloalkyl, heterocyclyl, C6-10aryl, or heteroaryl,wherein each alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R6is optionally substituted with one to four Z1, which may be the same or different; R7is -H, C1-8alkyl, C1-6haloalkyl, C3-12cycloalkyl, heterocyclyl, C6-10aryl, or heteroaryl, wherein each alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R7is optionally substituted with one to four Z2, which may be the same or different; or R6and R7together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z3, which may be the same or different; wherein the heterocyclyl formed by R6and R7is 3 to 12 membered heterocyclyl having 0 to 3 additional heteroatoms each independently N, O, or S; each Z1, Z2, or Z3is independently deuterium, halogen, =O, -CN, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkoxyalkyl, C2-6alkenyl, C2-6alkynyl, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, or -O-R3a; wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each Z1, Z2, or Z3is optionally substituted with one to four Z1a, which may be the same or different; each Z1ais independently deuterium, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkoxyalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, -CN, -O-R3a, or -S(O)2R3a, wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1ais optionally substituted with one to four Z1b, which may be the same or different; each Z1bis independently C1-9alkyl, C1-8haloalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15 cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, or -CN, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1bis unsubstituted; each R3ais independently -H, C1-9alkyl, C6-10aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of R3ais optionally substituted with one to four Z1b, which may be the same or different;wherein each heteroaryl of the compound of Formula (I) or Formula (Ia) is 5 to 12 membered heteroaryl having one to four heteroatoms each independently N, O, or S; wherein each heterocyclyl of the compound of Formula (I) or Formula (Ia) is 3 to 20 membered heterocyclyl having one to four heteroatoms each independently N, O, or S.

[0100] In some embodiments of the compound of Formula (I), Formula (Ia), or Formula (Ib), or pharmaceutically acceptable salt thereof, R1is -H; R2is -H or -F; R3is -H or -F; R4aand R4bare each independently -H -F, or -CH3; Ring A is a cyclopentyl, cyclohexyl, cyclohexenyl, or tetrahydropyranyl ring; n is 0, 1, or 2; each R5is independently -F, -OH, -CH3, or -O-CH3; R6is -H, C1-6alkyl, C1-6haloalkyl, C3-10cycloalkyl, heterocyclyl, C6-10aryl, or heteroaryl, wherein each alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R6is optionally substituted with one to four Z1, which may be the same or different; R7is -H, C1-8alkyl, C1-6haloalkyl, C3-12cycloalkyl, heterocyclyl, C6-10aryl, or heteroaryl, wherein each alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R7is optionally substituted with one to four Z2, which may be the same or different; or R6and R7together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z3, which may be the same or different; wherein the heterocyclyl formed by R6and R7is 3 to 12 membered heterocyclyl having 0 to 3 additional heteroatoms each independently N, O, or S; each Z1, Z2, or Z3is independently deuterium, halogen, =O, -CN, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkoxyalkyl, C2-6alkenyl, C2-6alkynyl, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, or -O-R3a;wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each Z1, Z2, or Z3is optionally substituted with one to four Z1a, which may be the same or different; each Z1ais independently deuterium, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkoxyalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, -CN, -O-R3a, or -S(O)2R3a, wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1ais optionally substituted with one to four Z1b, which may be the same or different; each Z1bis independently C1-9alkyl, C1-8haloalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, or -CN, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1bis unsubstituted; each R3ais independently -H, C1-9alkyl, C6-10aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of R3ais optionally substituted with one to four Z1b, which may be the same or different; wherein each heteroaryl of the compound of Formula (I) or Formula (Ia) is 5 to 12 membered heteroaryl having one to four heteroatoms each independently N, O, or S; wherein each heterocyclyl of the compound of Formula (I) or Formula (Ia) is 3 to 20 membered heterocyclyl having one to four heteroatoms each independently N, O, or S.

[0101] In some embodiments, in the compound of Formula (I), Formula (Ia) or Formula (Ib), or pharmaceutically acceptable salt thereof, R1is -H; R2is -H or -F; R3is -H or -F; R4aand R4bare each independently -H or -F; Ring A is a cyclohexyl, cyclohexenyl, or tetrahydropyranyl ring; n is 0;R6is -H, C1-6alkyl, C1-6haloalkyl, C3-10cycloalkyl, heterocyclyl, C6-10aryl, or heteroaryl, wherein each alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R6is optionally substituted with one to four Z1, which may be the same or different; R7is -H, C1-6alkyl, C1-6haloalkyl, C3-10cycloalkyl, heterocyclyl, C6-10aryl, or heteroaryl, wherein each alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R7is optionally substituted with one to four Z2, which may be the same or different; or R6and R7together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z3, which may be the same or different; wherein the heterocyclyl formed by R6and R7is 3 to 12 membered heterocyclyl having 0 to 3 additional heteroatoms each independently N, O or S; each Z1, Z2, or Z3is independently halogen, =O, -CN, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkoxyalkyl, C2-6alkenyl, C2-6alkynyl, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, or -O-R3a; wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each Z1, Z2, or Z3is optionally substituted with one to four Z1a, which may be the same or different; each Z1ais independently -D, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkoxyalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, -CN, -O-R3a, or -S(O)2R3a; wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1ais optionally substituted with one to four Z1b, which may be the same or different; each Z1bis independently C1-9alkyl, C1-8haloalkyl, C2-6alkenyl, C2-6alkynyl, halogen, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, or -CN, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1bis unsubstituted; each R3ais independently -H, C1-9alkyl, C6-10aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of R3ais optionally substituted with one to four Z1b, which may be the same or different;wherein each heteroaryl of the compound of Formula (I) or Formula (Ia) is 5 to 12 membered heteroaryl having one to four heteroatoms each independently N, O, or S; and wherein each heterocyclyl of the compound of Formula (I) or Formula (Ia) is 3 to 20 membered heterocyclyl having one to four heteroatoms each independently N, O or S.

[0102] In some embodiments of the compound of Formula (I), Formula (Ia), or Formula (1b), or pharmaceutically acceptable salt thereof, R1is -H; R2is -H or -F; R3is -H or -F; R4ais -H, -F, or -CH3, and R4bis -H; Ring A is, , , ,n is 0, 1, or 2; each R5is independently -F, -OH, -CH3, =CH2, -CH2-OH, or -O-CH3; R6is -H or C1-6alkyl optionally substituted with one Z1, wherein Z1is unsubstituted; R7is -H, C1-8alkyl, C3-12cycloalkyl, C6-10aryl, 4 to 12 membered heterocyclyl having 1 to 2 heteroatoms each independently selected from nitrogen,oxygen, and sulfur, or 5 to 12 membered heteroaryl having 1 to 3 heteroatoms each independently selected from nitrogen, oxygen, and sulfur, wherein each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl of R7is optionally substituted with one to four Z2, which may be the same or different; orR6and R7together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z3, which may be the same or different; wherein the heterocyclyl formed by R6and R7is 3 to 7 membered heterocyclyl optionally having an additional N; each Z1, Z2, or Z3is independently deuterium, halogen, =O, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C3-15cycloalkyl, C6-10aryl, heterocyclyl, heteroaryl or -O-R3a; wherein each alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1, Z2, or Z3is optionally substituted with one to four Z1a, which may be the same or different; each Z1ais independently deuterium, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, halogen, -CN, or -S(O)2R3a; wherein each alkyl of Z1ais optionally substituted with one to four Z1b, which may be the same or different; each Z1bis independently halogen, C3-15cycloalkyl, or C6-10aryl, wherein each cycloalkyl or aryl of Z1bis unsubstituted; each R3ais independently C1-9alkyl or C6-10aryl, wherein each alkyl or aryl of R3ais optionally substituted with one to four Z1b, which may be the same or different; wherein each heteroaryl of the compound of Formula (I) or Formula (Ia) is 5 to 6 membered heteroaryl having one or two heteroatoms each independently N or S; wherein each heterocyclyl of the compound of Formula (I) or Formula (Ia) is 3 to 7 membered heterocyclyl having one to two heteroatoms each independently N or O.

[0103] In some embodiments of the compound of Formula (I), Formula (Ia), or Formula (Ib), or pharmaceutically acceptable salt thereof, R1is -H; R2is -H or -F; R3is -H or -F;R4ais -H, -F, or -CH3, and R4bis -H; Ring A is, , , ,n is 0, 1, or 2; each R5is independently -F, -OH, -CH3, or -O-CH3; R6is -H or C1-6alkyl optionally substituted with one Z1, wherein Z1is unsubstituted; R7is -H, C1-8alkyl, C3-12cycloalkyl, C6-10aryl, 4 to 12 membered heterocyclyl having 1 to 2 heteroatoms each independently selected from nitrogen,oxygen, and sulfur, or 5 to 12 membered heteroaryl having 1 to 3 heteroatoms each independently selected from nitrogen, oxygen, and sulfur, wherein each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl of R7is optionally substituted with one to four Z2, which may be the same or different; or R6and R7together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z3, which may be the same or different; wherein the heterocyclyl formed by R6and R7is 3 to 7 membered heterocyclyl optionally having an additional N; each Z1, Z2, or Z3is independently deuterium, halogen, =O, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C3-15cycloalkyl, C6-10aryl, heterocyclyl, heteroaryl or -O-R3a; wherein each alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1, Z2, or Z3is optionally substituted with one to four Z1a, which may be the same or different;each Z1ais independently deuterium, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, halogen, -CN, or -S(O)2R3a; wherein each alkyl of Z1ais optionally substituted with one to four Z1b, which may be the same or different; each Z1bis independently halogen, C3-15cycloalkyl, or C6-10aryl, wherein each cycloalkyl or aryl of Z1bis unsubstituted; each R3ais independently C1-9alkyl or C6-10aryl, wherein each alkyl or aryl of R3ais optionally substituted with one to four Z1b, which may be the same or different; wherein each heteroaryl of the compound of Formula (I) or Formula (Ia) is 5 to 6 membered heteroaryl having one or two heteroatoms each independently N or S; wherein each heterocyclyl of the compound of Formula (I) or Formula (Ia) is 3 to 7 membered heterocyclyl having one to two heteroatoms each independently N or O.

[0104] In some embodiments of the compound of Formula (I), Formula (Ia), or Formula (Ib), or pharmaceutically acceptable salt thereof, R1is -H; R2is -H or -F; R3is -H or -F; R4aand R4bare each -H; Ring A isn is 0; R6is -H or C1-6alkyl optionally substituted with one Z1, wherein Z1is unsubstituted; R7is -H, C1-6alkyl, C3-10cycloalkyl, or heterocyclyl, wherein each alkyl, cycloalkyl, or heterocyclyl of R7is optionally substituted with one to four Z2, which may be the same or different; orR6and R7together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z3, which may be the same or different; wherein the heterocyclyl formed by R6and R7is 3 to 7 membered heterocyclyl optionally having an additional N; each Z1, Z2, or Z3is independently halogen, =O, C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, C3-15cycloalkyl, heterocyclyl, C6-10aryl, heteroaryl, or -O-R3a; wherein each alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z1, Z2, or Z3is optionally substituted with one to four Z1a, which may be the same or different; each Z1ais independently C1-9alkyl, C1-8haloalkyl, C1-6alkoxy, halogen, -CN, or -S(O)2R3a; wherein each alkyl of Z1ais optionally substituted with one to four Z1b, which may be the same or different; each Z1bis independently halogen, C3-15cycloalkyl, or C6-10aryl; wherein each cycloalkyl or aryl of Z1bis unsubstituted; each R3ais independently C1-9alkyl or C6-10aryl, wherein each alkyl or aryl of R3ais optionally substituted with one to four Z1b, which may be the same or different; wherein each heteroaryl of the compound of Formula (I) or Formula (Ia) is 5 to 6 membered heteroaryl having one or two heteroatoms each independently N or S; wherein each heterocyclyl of the compound of Formula (I) or Formula (Ia) is 3 to 7 membered heterocyclyl having one to two heteroatoms each independently N or O.

[0105] In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIa)or pharmaceutically acceptable salt thereof.

[0106] In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIb)or pharmaceutically acceptable salt thereof.

[0107] In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIc)or pharmaceutically acceptable salt thereof.

[0108] In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is a compound of Formula (IId)or a pharmaceutically acceptable salt thereof.

[0109] In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIe)or a pharmaceutically acceptable salt thereof.

[0110] In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIf)or a pharmaceutically acceptable salt thereof.

[0111] In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIg)or a pharmaceutically acceptable salt thereof.

[0112] In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIh)or a pharmaceutically acceptable salt thereof.

[0113] In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIi)or a pharmaceutically acceptable salt thereof.

[0114] In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIj)or a pharmaceutically acceptable salt thereof.

[0115] In some embodiments, the compound of Formula (I), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIk)or a pharmaceutically acceptable salt thereof.

[0116] In some embodiments of the compounds of Formula (I), (Ia), (Ib), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), or (IIk), or pharmaceutically acceptable salt thereof, R4bis -F or -CH3. In some embodiments of the compounds of Formula (I), (Ia), (Ib), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), or (IIk), or pharmaceutically acceptable salt thereof, each R5is independently -F, -OH, -CH3, or - O-CH3. In some embodiments of the compounds of Formula (I), (Ia), (Ib), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), or (IIk), or pharmaceutically acceptable sal thereof, R6is -H.

[0117] In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), or (IIk), or pharmaceutically acceptable salt thereof, R6is C1-6alkyl or C1-6haloalkyl. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), or (IIk), or pharmaceutically acceptable salt thereof, R6is unsubstituted C1-6alkyl. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), or (IIk), or pharmaceutically acceptable salt thereof, R6is,In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), or (IIk), or pharmaceutically acceptable salt thereof, R6is -CH3or. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), or (IIk), or pharmaceutically acceptable salt thereof, R7is C1-6alkyl or C3-10cycloalkyl, each optionally substituted with one or two halogen or C6-10aryl of Z2. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), or (IIi), or pharmaceutically acceptable salt thereof,R7is C1-6alkyl or cyclohexyl, each optionally substituted with one or two -F or phenyl of Z2. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), or (IIk), or pharmaceutically acceptable salt thereof, R7is, ,,In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), or (IIk), or pharmaceutically acceptable salt thereof, R7is . Insome embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), or (IIk), or pharmaceutically acceptable salt thereof, R7is,

[0118] In some embodiments the compound of Formula (I) or (IIa), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIIa)or pharmaceutically acceptable salt thereof.

[0119] In some embodiments the compound of Formula (I), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIIa-1)or pharmaceutically acceptable salt thereof.

[0120] In some embodiments the compound of Formula (I), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIIa-2)or pharmaceutically acceptable salt thereof.

[0121] In some embodiments the compound of Formula (I), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIIa-3)In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), or (IIIa-3), or pharmaceutically acceptable salt thereof, R7is -H, C1-8alkyl, C3-12cycloalkyl, C6-10aryl, 4 to 12 membered heterocyclyl having 1 to 2 heteroatoms each independently selected from nitrogen,oxygen, and sulfur, or 5 to 12 membered heteroaryl having 1 to 3 heteroatoms each independently selected from nitrogen, oxygen, and sulfur, wherein each alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl of R7is optionally substituted with 1 to 3 Z2, which may be the same or different, wherein each Z2is independently, deuterium, halogen, =O, -CN, C1-8alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C3-10cycloalkyl, C6-10aryl, 5 to 12 membered heteroaryl having 1 to 3 heteroatoms each independently selected from nitrogen, oxygen, and sulfur, or-C(O)-R3a, wherein R3ais -H or unsubstituted C1-6alkyl, wherein each C1-6alkyl of Z2is optionally substituted with 1 to 3 Z1a, wherein each Z1ais independently cyano or C1-6alkoxy. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), or (IIIa-3), or pharmaceutically acceptable salt thereof, R7is -H, C1-8alkyl, C3-12cycloalkyl, C6-10aryl, 4 to 12 membered heterocyclyl having 1 to 2 heteroatoms each independently selected from nitrogen,oxygen, and sulfur, or 5 to 12 membered heteroaryl having 1 to 3 heteroatoms each independently selected from nitrogen, oxygen, and sulfur, wherein each alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl of R7is optionally substituted with 1 to 3 Z2, which may be the same or different, wherein each Z2is independently, deuterium, halogen, =O, - CN, C1-8alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C3-10cycloalkyl, C6-10aryl, or -C(O)- R3a, wherein R3ais -H or unsubstituted C1-6alkyl, wherein each C1-6alkyl of Z2is optionally substituted with 1 to 3 Z1a, wherein each Z1ais independently cyano or C1-6alkoxy. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), or (IIIa-3), or pharmaceutically acceptable salt thereof, R7is -H, C1-6alkyl, C3-12cycloalkyl, or 4 to 12 membered heterocyclyl having a heteroatom selected from nitrogen and oxygen, wherein each alkyl, cycloalkyl or heterocyclyl of R7is optionally substituted with 1 to 3 Z2, which may be the same or different, wherein each Z2is independently halogen, =O, C1-6alkyl, C1-8haloalkyl, C1-6alkoxy, or -C(O)-R3a, wherein R3ais -H or unsubstituted C1-6alkyl. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), or (IIIa-3), or pharmaceutically acceptable salt thereof, R7is -H, C1-8alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, spiro[2.3]hexyl, bicyclo[3.1.1]heptyl, spiro[3.3]heptyl, spiro[2.5]octyl, oxetanyl, oxepanyl, dioxanyl, oxaspiro[3.3]heptyl, oxaspiro[3.5]nonyl, oxabicyclo[3.2.1]octyl, (3aR,6aS)-hexahydro-1H-cyclopenta[c]furanyl, bicyclo[3.2.1]octyl,(1R,5S)bicyclo[3.1.0]hexyl, (1R,5S)bicyclo[3.2.0]heptyl, (3aR,6aS)-2- methyloctahydropentalenyl, (1R,5S)-6,6-dimethylbicyclo[3.1.0]hexyl, spiro[2.4]heptyl, 7,7- difluoro-spiro[3.5]nonanyl, (4s,7s)-1-oxaspiro[3.5]nonanyl, (4r,7r)-oxaspiro[3.5]nonanyl, oxabicyclo[2.2.1]heptanyl, 3-oxabicyclo[3.2.1]octanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidyl, tetrahydrothiopyranyl, -2,3-dihydro-1H-indyl, chromane, or 4,5,6,7-tetrahydro-1H- indazolyl, each optionally substituted with 1 to 3 Z2, which may be the same or different, wherein each Z2is independently deuterium, =O, -CN, -CH3, -CH2-O-CH3, -CH2-CN, -O-CH3, -O-CF3, - CF3, -O-C2H5, -O-C3H7, -C(O)-CH3, -F, cyclopropyl, phenyl, triazolyl, or pyridyl. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), or (IIIa-3), or pharmaceutically acceptable salt thereof, R7is-H, C1-8alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, spiro[2.3]hexyl, bicyclo[3.1.1]heptyl, spiro[3.3]heptyl, spiro[2.5]octyl, oxetanyl, oxepanyl, dioxanyl, oxaspiro[3.3]heptyl, oxaspiro[3.5]nonyl, oxabicyclo[3.2.1]octyl, (3aR,6aS)-hexahydro- 1H-cyclopenta[c]furanyl, bicyclo[3.2.1]octyl, (1R,5S)bicyclo[3.1.0]hexyl, (1R,5S)bicyclo[3.2.0]heptyl, (3aR,6aS)-2-methyloctahydropentalene, (1R,5S)-6,6- dimethylbicyclo[3.1.0]hexyl, spiro[2.4]heptyl, 7,7-difluoro-spiro[3.5]nonanyl, (4s,7s)-1- oxaspiro[3.5]nonanyl, (4r,7r)-oxaspiro[3.5]nonanyl, oxabicyclo[2.2.1]heptanyl, 3-oxabicyclo[3.2.1]octanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidyl, tetrahydrothiopyranyl, 2,3-dihydro-1H-indyl, chromane, or 4,5,6,7-tetrahydro-1H-indazolyl, each optionally substituted with 1 to 3 Z2, which may be the same or different, wherein each Z2is independently deuterium, =O, -CN, -CH3, -CH2-O-CH3, -CH2-CN, -O-CH3, -O-CF3, -CF3, -O- C2H5, -O-C3H7, -C(O)-CH3, -F, cyclopropyl, or phenyl. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), or (IIIa-3), or pharmaceutically acceptable salt thereof, R7is -H, C1-6alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, spiro[2.3]hexyl, bicyclo[3.1.1]heptyl, spiro[3.3]heptyl, spiro[2.5]octyl, oxetanyl, oxaspiro[3.3]heptyl, oxaspiro[3.5]nonyl, oxabicyclo[3.2.1]octyl, tetrahydrofuranyl, tetrahydropyranyl, piperidyl, or tetrahydrothiopyranyl, each optionally substituted with 1 to 3 Z2, which may be the same or different, wherein each Z2is independently =O, -CH3, -CF3, -O-C2H5, -C(O)-CH3, or -F. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), or (IIIa-3), or pharmaceutically acceptable salt thereof, R7is -H,,In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa- 1), (IIIa-2), or (IIIa-3), or pharmaceutically acceptable salt thereof, R7is -H,, ,, , , , In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), or (IIIa-3), or pharmaceutically acceptable salt thereof, R7is -H,, , , , , , ,

[0122] In some embodiments the compound of Formula (I), (IIa), (IId), or (IIIa), or pharmaceutically acceptable salt thereof, is a compound of Formula (IVa)wherein q is 1, 2, or 3, or a pharmaceutically acceptable salt thereof.

[0123] In some embodiments of the compound of Formula (IVa), or pharmaceutically acceptable salt thereof, q is 1 or 2. In some embodiments of the compound of Formula (IVa), or pharmaceutically acceptable salt thereof, q is 1.

[0124] In some embodiments the compound of Formula (I), (IIa), (IId), (IIIa), or (IVa), or pharmaceutically acceptable salt thereof, is a compound of Formula (IVa-1)or a pharmaceutically acceptable salt thereof.

[0125] In some embodiments the compound of Formula (I), (IIa), (IId), (IIIa), or (IVa), or pharmaceutically acceptable salt thereof, is a compound of Formula (IVa-2)or a pharmaceutically acceptable salt thereof.

[0126] In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIa), (IVa), (IVa-1), or (IVa-2), or pharmaceutically acceptable salt thereof, Z2is -O-R3a, C3-15cycloalkyl, 4 to 14 membered heterocyclyl having 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur, C6-10aryl, 5 to 14 membered heteroaryl having 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein each Z2is optionally substituted with one to four Z1a, which may be the same or different, wherein each Z1ais independently deuterium, cyano, halogen, C1-6alkyl, C1-8haloalkyl, C1-6alkoxy, or-S(O)2R3a, and each wherein each R3ais independently C1-9alkyl or C6-10aryl, wherein each alkyl or aryl of R3aoptionally substituted with one to four halogens. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIa), (IVa), (IVa-1), or (IVa-2), or pharmaceutically acceptable salt thereof, Z2is -O-R3a, cyclopropyl, cyclobutyl, cyclohexyl, bicyclo[1.1.1]pentyl, bicyclo[2.2.2]octyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,3-dioxolanyl, phenyl, naphthyl, thiazolyl, pyrazolyl, pyridyl, or pyrazinyl, each optionally substituted with 1 or 3 Z1a, wherein each Z1ais independently cyano, -F, -Cl, - OCH3, -CF3, or phenyl, and wherein each R3ais independently methyl, ethyl, or phenyl, wherein each phenyl of R3ais optionally substituted with -Cl. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIa), (IVa), (IVa-1), or (IVa-2), or pharmaceutically acceptable salt thereof, Z2is -O-R3a, cyclopropyl, cyclobutyl, cyclohexyl, bicyclo[1.1.1]pentyl, bicyclo[2.2.2]octyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,3-dioxolanyl, phenyl, naphthyl, thiazolyl, pyrazolyl, pyridyl, or pyrazinyl, each optionally substituted with 1 or 2 Z1a, wherein each Z1ais independently cyano, -F, -Cl, -OCH3, -CF3, and wherein each R3ais independently methyl, ethyl, or phenyl, wherein each phenyl of R3ais optionally substituted with -Cl. In some embodiments of the compound of Formula (I),(Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIa), (IVa), (IVa-1), or (IVa-2), or pharmaceutically acceptable salt thereof, Z2isIn some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIa), (IVa), (IVa-1), or (IVa-2), or pharmaceutically acceptable salt thereof, Z2is

[0127] In some embodiments the compound of Formula (I), (IIa), (IId), or (IIIa), or pharmaceutically acceptable salt thereof, is a compound of Formula (IVb)wherein each Z2may be the same or different, or a pharmaceutically acceptable salt thereof.

[0128] In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIa), or (IVb), or pharmaceutically acceptable salt thereof, each Z2, which may be the same or different, is independently C1-6alkyl, C3-15cycloalkyl, 4 to 14 membered heterocyclyl having 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur, C6-14 aryl, or C1-6alkoxy, each optionally substituted with 1 or 3 Z1a, wherein each Z1ais independently halogen, cyano, =O, C1-6haloalkyl, C3-10cycloalkyl, or C6-14aryl. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIa), or (IVb), or pharmaceutically acceptable salt thereof, each Z2, which may be the same or different, is independently C1-6alkyl, C3-15cycloalkyl, 4 to 14 membered heterocyclyl having 1 to 2 heteroatoms selected from nitrogen, oxygen, and sulfur, C6-14 aryl, or C1-6alkoxy, each optionally substituted with 1 or 3 Z1a, wherein each Z1ais independently halogen, cyano, C1-6haloalkyl, C3-10cycloalkyl, C6-14aryl. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIa), or (IVb), or pharmaceutically acceptable salt thereof, each Z2, which may be the same or different, is independently C1-6alkyl, C3-15cycloalkyl, C6-14aryl, or C1-6alkoxy. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIa), or (IVb), or pharmaceutically acceptable salt thereof, each Z2, which may be the same or different, is independently methyl, ethyl, ethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahyrdofuranyl, tetrahydropyranyl, bicyclo[1.1.1]pentanyl, phenyl, or thiopyranyl, each optionally substituted with 1 or 3 Z1a, wherein each Z1ais independently -F, -CH3, -CHF2, -CN, =O, or cyclopropyl. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIa), or (IVb), or pharmaceutically acceptable salt thereof, each Z2, which may be the same or different, is independently methyl, ethyl, ethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahyrdofuranyl, tetrahydropyranyl, bicyclo[1.1.1]pentanyl, or phenyl, each optionally substituted with 1 or 3 Z1a, wherein each Z1ais independently -F, -CH3, -CHF2, -CN, or cyclopropyl. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIa), or (IVb), or pharmaceutically acceptable salt thereof, each Z2, which may be the same or different, is independently -CH3, -C2H5,, ,In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIa), or (IVb), or pharmaceutically acceptable salt thereof, each Z2, which may be the same or different, is independently -CH3, -C2H5,, ,In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIa), or (IVb), or pharmaceutically acceptable salt thereof, each Z2, which may be the same or different, is independently

[0129] In some embodiments the compound of Formula (I), (IIa), or (IId), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIIb)wherein each p or q, which may be the same or different, is independently 1, 2, or 3, or a pharmaceutically acceptable salt thereof.

[0130] In some embodiments of the compound of Formula (IIIb), or pharmaceutically acceptable salt thereof, p and q are each 1. In some embodiments of the compound of Formula (IIIb), or pharmaceutically acceptable salt thereof, each Z1or Z2, which may be the same or different, is independently -H, C6-10aryl, or 4 to 10 membered heterocyclyl having 1 to 2 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein each aryl or heterocyclyl of Z1or Z2is unsubstituted. In some embodiments of the compound of Formula (IIIb), or pharmaceutically acceptable salt thereof, each Z1or Z2, which may be the same or different, is independently hydrogen, unsubstituted phenyl, or unsubstituted tetrahydropyranyl. In some embodiments of the compound of Formula (IIIb), or pharmaceutically acceptable salt thereof, each Z1or Z2, which may be the same or different, is independently

[0131] In some embodiments the compound of Formula (I), (IIa), or (IId), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIIc)or pharmaceutically acceptable salt thereof.

[0132] In some embodiments of the compound of Formula (IIIc), or pharmaceutically acceptable salt thereof, Z3is -H, C6-10aryl, or -O-R3a, wherein R3ais -H, C1-6alkyl or C6-10aryl, wherein the R3aalkyl or aryl is each optionally substituted with halogen, C3-10cycloalkyl, or C6-10aryl. In some embodiments of the compound of Formula (IIIc), or pharmaceutically acceptable salt thereof, Z3is methyl, phenyl, or -O-R3a, wherein R3ais methyl, ethyl, or phenyl, wherein the R3amethyl or phenyl is each optionally substituted with -Cl, cyclopropyl, or phenyl. In some embodiments of the compound of Formula (IIIc), or pharmaceutically acceptable salt thereof, Z3is

[0133] In some embodiments the compound of Formula (I), (IIa), or (IId), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIId)or pharmaceutically acceptable salt thereof.

[0134] In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIId), or pharmaceutically acceptable salt thereof, Z3is C1-6alkyl optionally substituted with one C6-10aryl of Z1a, wherein the C6-10aryl of Z1ais optionally substituted with one halogen of Z1b. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIId), or pharmaceutically acceptable salt thereof, Z3is methyl, optionally substituted with one phenyl of Z1a, wherein the phenyl of Z1ais optionally substituted with one -Cl of Z1b. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIId), or pharmaceutically acceptable salt thereof, Z3is.

[0135] In some embodiments the compound of Formula (I) or (IIa), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIIe)or pharmaceutically acceptable salt thereof.

[0136] In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIe), or pharmaceutically acceptable salt thereof, R7is C1-6alkyl. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIe), or pharmaceutically acceptable salt thereof, R7is

[0137] In some embodiments the compound of Formula (I), (IIc), or (IIf), or pharmaceutically acceptable salt thereof, is a compound of Formula (IIIf)or pharmaceutically acceptable salt thereof.

[0138] In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIf), or pharmaceutically acceptable salt thereof, R7is C1-8alkyl, C3-12cycloalkyl, or 4 to 12 membered heterocyclyl having 1 to 2 heteroatoms each independently selected from nitrogen, oxygen, and sulfur, wherein each alkyl, cycloalkyl, or heterocyclyl of R7is optionally substituted with 1 to 3 Z2, which may be the same or different, wherein each Z2is independently, deuterium, halogen, C3-10cycloalkyl, C1-8alkyl, C1-8haloalkyl, C1-6alkoxy, C1-6haloalkoxy, or 4 to 12 membered heterocyclyl having 1 to 2 heteroatoms each independently selected from nitrogen, oxygen, and sulfur, wherein each C1-6alkyl of Z2is optionally substituted with 1 to 3 Z1a, wherein each Z1ais independently halogen or C1-6alkoxy. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIf), or pharmaceutically acceptable salt thereof, R7is C1-8alkyl, cyclobutyl, cyclopentyl, cyclohexyl, spiro[3.3]heptanyl, spiro[2.5]octanyl, spiro[3.5]nonanyl, tetrahydrofuranyl,tetrahydropyranyl, oxepanyl, piperidyl, or tetrahydroindazolyl, each optionally substituted with 1 to 3 Z2, which may be the same or different, wherein each Z2is independently, deuterium, -F, - CH3, -CHF2, -CH2-CHF2, -CF3, CH2-CF3, -O-CH3, -O-CHF2, -CH2-O-CH3, -O-C3H7, cyclobutyl, oxetanyl, or tetrahydropyranyl, wherein each cyclobutyl, oxetanyl, or tetrahydropyranyl is optionally substituted with 1 to 3 -F. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIf), or pharmaceutically acceptable salt thereof, R7is C1-8alkyl, cyclobutyl, cyclopentyl, cyclohexyl, spiro[3.3]heptanyl, spiro[3.5]nonanyl, tetrahydrofuranyl, tetrahydropyranyl, oxepanyl, or piperidyl, each optionally substituted with 1 to 3 Z2, which may be the same or different, wherein each Z2is independently, deuterium, -F, -CH3, -CHF2, -CH2-CHF2, -CF3, CH2-CF3, -O-CH3, -O-CHF2, -CH2-O-CH3, -O-C3H7, cyclobutyl, oxetanyl, or tetrahydropyranyl, wherein each cyclobutyl, oxetanyl, or tetrahydropyranyl is optionally substituted with 1 to 3 -F. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIf), or pharmaceutically acceptable salt thereof, R7is C3-12cycloalkyl optionally substituted with 1 to 3 halogens. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIf), or pharmaceutically acceptable salt thereof, R7is cyclohexyl optionally substituted with 1 to 3 -F. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIf), or pharmaceutically acceptable salt thereof, R7is. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIf), or pharmaceutically acceptable salt thereof, R7is,In some embodiments of the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), or (IIIf), or pharmaceutically acceptable salt thereof, R7is.

[0139] In some embodiments of the compound of Formula (I), (Ia), or (IIa), or pharmaceutically acceptable salt thereof, R1is -D. In some embodiments of the compound of Formula (I), (Ia), (IIb), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa- 3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), or (IVa-2), or pharmaceutically acceptable salt thereof, R2is -H or -F. In some embodiments of the compound of Formula (I), (Ia), (IIb), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), or (IVa-2), or pharmaceutically acceptable salt thereof, R2is -H. In some embodiments of the compound of Formula (I), (Ia), (IIb), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), or (IVa-2), or pharmaceutically acceptable salt thereof, R2is -F. In some embodiments of the compound of Formula (I), (Ia), (IIb), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), or (IVa-2), or pharmaceutically acceptable salt thereof, R3is -H or -F. In someembodiments of the compound of Formula (I), (Ia), (IIb), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), or (IVa-2), or pharmaceutically acceptable salt thereof, R3is -H. In some embodiments of the compound of Formula (I), (Ia), (IIb), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), or (IVa-2), or pharmaceutically acceptable salt thereof, R3-F. In some embodiments of the compound of Formula (I), (Ia), (Ib), (IId), (IIe), (IIf), (IIg), (IIh), or (IIi), or pharmaceutically acceptable salt thereof, R4aand R4bare each -H.

[0140] In some embodiments the compound of Formula (I), or pharmaceutically acceptable salt thereof, is a compound of Formula (V)or pharmaceutically acceptable salt thereof, wherein R2is -H or -F; R21is -H or -F; R3is -H or -F; R7is C1-8alkyl or C3-12cycloalkyl, wherein each alkyl or cycloalkyl of R7is optionally substituted with one to four Z2, which may be the same or different; and each Z2is independently deuterium, halogen, C1-3alkyl, C1-3haloalkyl, or C6-10aryl.

[0141] In some embodiments the compound of Formula (V), or pharmaceutically acceptable salt thereof, is a compound of Formula (Va):,or pharmaceutically acceptable salt thereof.

[0142] In some embodiments of the compound of Formula (V) or (Va), or pharmaceutically acceptable salt thereof, R2is -H; R2ais -H; and R3is -H or -F. In some embodiments of the compound of Formula (V) or (Va), or pharmaceutically acceptable salt thereof, R7is C1-8alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, spiro[2.3]hexyl, bicyclo[3.1.1]heptyl, spiro[3.3]heptyl, spiro[2.5]octyl, bicyclo[3.2.1]octyl, (1R,5S)bicyclo[3.1.0]hexyl, (1R,5S)bicyclo[3.2.0]heptyl, spiro[2.4]heptyl, each optionally substituted with 1 to 3 Z2, which may be the same or different, wherein each Z2is independently deuterium, -CH3, -C2F, -CHF2, -CF3, -F, or phenyl. In some embodiments of the compound of Formula (V) or (Va), or pharmaceutically acceptable salt thereof, R7is C1-3alkyl or cyclohexyl, each optionally substituted with 1 to 2 Z2, which may be the same or different, wherein each Z2is independently -F or phenyl. In some embodiments of the compound of Formula (V) or (Va), or pharmaceutically acceptable salt thereof, R7is, , , , ,, , , , , , ,In some embodiments of the compound of Formula (V) or (Va), or pharmaceutically acceptable salt thereof, R7is.

[0143] In some embodiments the compound of Formula (V), or pharmaceutically acceptable salt thereof isor a pharmaceutically acceptable salt thereof.

[0144] In some embodiments the compound of Formula (V), or pharmaceutically acceptable salt thereof is, or a pharmaceutically acceptable salt thereof.

[0145] In some embodiments the compound of Formula (I), or pharmaceutically acceptable salt thereof, is a compound of Formula (VI)or pharmaceutically acceptable salt thereof, wherein R7is C3-12cycloalkyl, optionally substituted with one to four Z2, which may be the same or different; and each Z2is independently deuterium, halogen, C1-3alkyl, C1-3haloalkyl.

[0146] In some embodiments the compound of Formula (VI), or pharmaceutically acceptable salt thereof, is a compound of Formula (VIa):or a pharmaceutically acceptable salt thereof.

[0147] In some embodiments of the compound of Formula (VI) or (VIa), or pharmaceutically acceptable salt thereof, R7is cyclohexyl optionally substituted with 1 to 4 Z2, which may be the same or different, wherein each Z2is independently deuterium, -CH3, -C2F, -CHF2, -CF3, or -F. In some embodiments of

[0148] In some embodiments the compound of Formula (VI), or pharmaceutically acceptable salt thereof, is, or a pharmaceutically acceptable salt thereof.

[0149] In some embodiments the compound of Formula (VI), or pharmaceutically acceptable salt thereof, is, or a pharmaceutically acceptable salt thereof.

[0150] In some embodiments, the compound of Formula (I) or (IIa), or pharmaceutically acceptable salt thereof, is,, or a pharmaceutically acceptable salt thereof.

[0151] In some embodiments the compound of Formula (I) or (IIa), or pharmaceutically acceptable salt thereof, is,,,,,or a pharmaceutically acceptable salt thereof.

[0152] In some embodiments, the compound of Formula (I) or (IId), or pharmaceutically acceptable salt thereof, is, or a pharmaceutically acceptable salt thereof.

[0153] In some embodiments the compound of Formula (I), (IIk), or (IIIa-1), or pharmaceutically acceptable salt thereof, is,or a pharmaceutically acceptable salt thereof.

[0154] In some embodiments the compound of Formula (I) or (IIa), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0155] In some embodiments the compound of Formula (I) or (IIa), or pharmaceutically acceptable salt thereof, is, ,, or a pharmaceutically acceptable salt thereof.

[0156] In some embodiments the compound of Formula (I) or (IIb), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0157] In some embodiments the compound of Formula (I) or (IIc), or pharmaceutically acceptable salt thereof, is, or a pharmaceutically acceptable salt thereof.

[0158] In some embodiments the compound of Formula (I) or (IIc), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0159] In some embodiments the compound of Formula (I) or (IIc), or pharmaceutically acceptable salt thereof, is,or a pharmaceutically acceptable salt thereof.

[0160] In some embodiments, the compound of Formula (I) or (IIg), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0161] In some embodiments, the compound of Formula (I) or (IIh), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0162] In some embodiments, the compound of Formula (I) or (IIi), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0163] In some embodiments, the compound of Formula (I) or (IIj), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0164] In some embodiments, the compound of Formula (I) or (IIk), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0165] In some embodiments, the compound of Formula (I) or (IIa), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0166] In some embodiments, the compound of Formula (I), (Ia), or (IIa), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0167] In some embodiments, the compound of Formula (I), (Ib), or (IIa), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0168] In some embodiments, the compound of Formula (I) or (IIa), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0169] In some embodiments, the compound of Formula (I) or (IIa), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0170] In some embodiments, the compound of Formula (I) or (IIa), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0171] In some embodiments, the compound of Formula (I) or (IIa), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0172] In some embodiments, the compound of Formula (I) or (IIa), or pharmaceutically acceptable salt thereof, is, or a pharmaceutically acceptable salt thereof.

[0173] In some embodiments, the compound of Formula (I) or (IIa), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0174] In some embodiments, the compound of Formula (I) or (IIa), or pharmaceutically acceptable salt thereof, is, or a pharmaceutically acceptable salt thereof.

[0175] In some embodiments, the compound of Formula (I) or (IIa), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0176] In some embodiments, the compound of Formula (I), (Ia), or (IIc), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0177] In some embodiments, the compound of Formula (I), (Ib), or (IIc), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0178] In some embodiments, the compound of Formula (I), (Ia), or (IIc), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0179] In some embodiments, the compound of Formula (I), (Ib), or (IIc), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0180] In some embodiments, the compound of Formula (I), (Ia), or (IIc), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0181] In some embodiments, the compound of Formula (I), (Ib), or (IIc), or pharmaceutically acceptable salt thereof, isor a pharmaceutically acceptable salt thereof.

[0182] In some embodiments, the present disclosure provides a racemic mixture comprising the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a racemic mixture comprising the compound disclosed herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a scalemic mixture comprising the compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a scalemic mixture comprising the compound disclosed herein, or a pharmaceutically acceptable salt thereof.

[0183] One of skill in the art is aware that each and every embodiment of a group (e.g., R1) disclosed herein may be combined with any other embodiment of each of the remaining groups (e.g., R2, R3, Z1, Z2, etc.) to generate a complete compound of Formula (I), or any Formula described herein or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, each of which is deemed within the ambit of the present disclosure. Pharmaceutical Compositions and Modes of Administration

[0184] Furthermore, the present disclosure provides pharmaceutical compositions comprising at least one compound of the present disclosure, or a prodrug compound thereof, or a pharmaceutically acceptable salt or solvate thereof as active ingredient together with a pharmaceutically acceptable carrier.

[0185] The pharmaceutical composition of the present disclosure may additionally comprise one or more other compounds as active ingredients like a prodrug compound or other enzyme inhibitors.

[0186] The compositions are suitable for oral, rectal, topical, parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (nasal or buccal inhalation) or nasal administration, although the most suitable route in any given case will depend on the nature and severity of the conditions being treated and on the nature of the active ingredient. They may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy.

[0187] In practical use, the compounds of the present disclosure can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). In preparing the compositions for oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparations.

[0188] Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are employed. If desired, tablets may be coated by standard aqueous or non-aqueous techniques. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained. The active compounds can also be administered intranasally as, for example, liquid drops or spray.

[0189] The tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.

[0190] Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.

[0191] In some embodiments, the compounds of the present disclosure may also be used as salts with various countercations to yield an orally available formulation.

[0192] The compounds of the present disclosure may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

[0193] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

[0194] Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dose of a compound of the present disclosure. For example, oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like. In some embodiments, compounds of the present disclosure are administered orally. Kits

[0195] Provided herein are also kits that include a compound of the disclosure, or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof, and suitable packaging. In one embodiment, a kit further includes instructions for use. In one aspect, a kit includes a compound of the disclosure, or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, ordeuterated analog thereof, and a label and / or instructions for use of the compounds in the treatment of the indications, including the diseases or conditions, described herein.

[0196] Provided herein are also articles of manufacture that include a compound described herein or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof in a suitable container. The container may be a vial, jar, ampoule, preloaded syringe, and intravenous bag. Treatment Methods and Uses

[0197] The compounds or pharmaceutically acceptable salts thereof provided herein, or compositions comprising a compound or pharmaceutically acceptable salt thereof provided herein can be put to pharmaceutical use. In some embodiments the compounds or pharmaceutically acceptable salts thereof provided herein, or compositions comprising a compound or pharmaceutically acceptable salt thereof provided herein are for treating an IKFZ2 associated disease or condition. In some embodiments the compounds or pharmaceutically acceptable salts thereof provided herein, or compositions comprising a compound or pharmaceutically acceptable salt thereof provided herein are for treating cancer. In some embodiments, the compounds or pharmaceutically acceptable salts thereof provided herein, or compositions comprising a compound or pharmaceutically acceptable salt thereof provided herein can be used for the manufacture of a medicament for the treatment of an IKFZ2 associated disease or condition. In some embodiments, the compounds or pharmaceutically acceptable salts thereof provided herein, or compositions comprising a compound or pharmaceutically acceptable salt thereof provided herein can be used for the manufacture of a medicament for the treatment of cancer.

[0198] The disclosure further relates to the use of compounds or pharmaceutically acceptable salts thereof disclosed herein for the treatment and / or prophylaxis of diseases and / or conditions through binding and degradation of an IKZF protein (e.g., IKZF2 or IKZF4 protein) by said compounds. Further, the present disclosure relates to the use of said compounds or pharmaceutically acceptable salts thereof for the preparation of a medicament for the treatment and / or prophylaxis of an IKZF associated disease and / or condition through binding and degradation of an IKZF protein (e.g., IKZF2 or IKZF4 protein) by said compounds. In some embodiments the IKZF associated disease or condition is alleviated by selective degradation of IKZF2 protein. In some embodiments, the IKZF associated disease or condition is alleviated by degradation of IKZF2 protein. In some embodiments, the IKZF associated disease or condition is alleviated by degradation of IKZF2 protein and one or more additional IKZF2 proteins (e.g.,IKZF1 and / or IKZF4 proteins). In some embodiments, the IKZF associated disease or condition is alleviated by degradation of IKZF4 protein.

[0199] In some embodiments the IKZF associated disease and / or condition is an IKZF2 associated disease and / or condition. In some embodiments the IKZF2 associated disease or condition is alleviated by selective degradation of IKZF2 protein. In some embodiments the IKZF2 associated disease and / or condition is alleviated by degradation of IKZF2 protein and one or more additional IKZF proteins (e.g., IKZF1 and / or IKZF4 proteins).

[0200] Medicaments as referred to herein can be prepared by conventional processes, including the combination of a compound according to the present disclosure and a pharmaceutically acceptable carrier.

[0201] In some embodiments, provided herein is a method of treating and / or preventing an IKZF protein (e.g., IKZF2 protein) associated disease or condition in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa- 1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), or pharmaceutically acceptable salt thereof, or a composition comprising a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa- 1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), or a pharmaceutically acceptable salt thereof.

[0202] In some embodiments, provided herein is a method of degrading an IKZF protein (e.g., IKZF2 protein) comprising administering to a patient in need thereof (e.g., a patient having an IKZF protein associated disease or condition) a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), or a pharmaceutically acceptable salt thereof.

[0203] In some embodiments, provided herein is a method of reducing the proliferation of a cell comprising contacting the cell with a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe),(IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), or a pharmaceutically acceptable salt thereof, and reducing IKZF protein (e.g., IKZF2 protein) levels in the cell.

[0204] In some embodiments, provided herein is a method of reducing IKFZ protein (e.g., IKZF2 protein) levels in a patient in need thereof (e.g., a patient having an IKZF2 associated disease or condition) comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), or a pharmaceutically acceptable salt thereof.

[0205] In some embodiments, the IKZF protein (e.g., IKZF2 protein) associated disease or condition includes cancer. In some embodiments, the cancer is a hematological cancer. In some embodiments, the cancer includes a solid tumor. In some embodiments, the cancer includes a malignant tumor. In some embodiments the cancer includes a metastatic cancer. In some embodiments, the cancer is resistant or refractory to one or more anticancer therapies. In some embodiments, greater than about 50% of the cancer cells detectably express one or more cell surface immune checkpoint receptors (e.g., so-called “hot” cancer or tumor). In some embodiments, greater than about 1% and less than about 50% of the cancer cells detectably express one or more cell surface immune checkpoint receptors (e.g., so called “warm” cancer or tumor). In some embodiments, less than about 1% of the cancer cells detectably express one or more cell surface immune checkpoint receptors (e.g., so called “cold” cancer or tumor).

[0206] In some embodiments, the IKZF protein (e.g., IKZF2 protein) associated disease or condition is a hematological cancer, e.g., a leukemia (e.g., Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), B-cell ALL, Myelodysplastic Syndrome (MDS), myeloproliferative disease (MPD), Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), undifferentiated leukemia), a lymphoma (e.g., small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), T-cell lymphoma, B- cell lymphoma, diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), Waldestrom’s macroglobulinemia (WM)) and / or a myeloma (e.g., multiple myeloma (MM)).

[0207] In some embodiments, the IKZF protein (e.g., IKZF2 protein) associated disease or condition is an epithelial tumor (e.g., a carcinoma, a squamous cell carcinoma, a basal cellcarcinoma, a squamous intraepithelial neoplasia), a glandular tumor (e.g., an adenocarcinoma, an adenoma, an adenomyoma), a mesenchymal or soft tissue tumor (e.g., a sarcoma, a rhabdomyosarcoma, a leiomyosarcoma, a liposarcoma, a fibrosarcoma, a dermatofibrosarcoma, a neurofibrosarcoma, a fibrous histiocytoma, an angiosarcoma, an angiomyxoma, a leiomyoma, a chondroma, a chondrosarcoma, an alveolar soft-part sarcoma, an epithelioid hemangioendothelioma, a Spitz tumor, a synovial sarcoma), or a lymphoma.

[0208] In some embodiments, the IKZF protein (e.g., IKZF2 protein) associated disease or condition includes a solid tumor in or arising from a tissue or organ, such as: • bone (e.g., adamantinoma, aneurysmal bone cysts, angiosarcoma, chondroblastoma, chondroma, chondromyxoid fibroma, chondrosarcoma, chordoma, dedifferentiated chondrosarcoma, enchondroma, epithelioid hemangioendothelioma, fibrous dysplasia of the bone, giant cell tumour of bone, haemangiomas and related lesions, osteoblastoma, osteochondroma, osteosarcoma, osteoid osteoma, osteoma, periosteal chondroma, Desmoid tumor, Ewing sarcoma); • lips and oral cavity (e.g., odontogenic ameloblastoma, oral leukoplakia, oral squamous cell carcinoma, primary oral mucosal melanoma); salivary glands (e.g., pleomorphic salivary gland adenoma, salivary gland adenoid cystic carcinoma, salivary gland mucoepidermoid carcinoma, salivary gland Warthin's tumors); • esophagus (e.g., Barrett's esophagus, dysplasia and adenocarcinoma); • gastrointestinal tract, including stomach (e.g., gastric adenocarcinoma, primary gastric lymphoma, gastrointestinal stromal tumors (GISTs), metastatic deposits, gastric carcinoids, gastric sarcomas, neuroendocrine carcinoma, gastric primary squamous cell carcinoma, gastric adenoacanthomas), intestines and smooth muscle (e.g., intravenous leiomyomatosis), colon (e.g., colorectal adenocarcinoma), rectum, anus; • pancreas (e.g., serous neoplasms, including microcystic or macrocystic serous cystadenoma, solid serous cystadenoma, Von Hippel-Landau (VHL)-associated serous cystic neoplasm, serous cystadenocarcinoma; mucinous cystic neoplasms (MCN), intraductal papillary mucinous neoplasms (IPMN), intraductal oncocytic papillary neoplasms (IOPN), intraductal tubular neoplasms, cystic acinar neoplasms, including acinar cell cystadenoma, acinar cell cystadenocarcinoma, pancreatic adenocarcinoma, invasive pancreatic ductal adenocarcinomas, including tubular adenocarcinoma, adenosquamous carcinoma, colloid carcinoma, medullary carcinoma, hepatoid carcinoma,signet ring cell carcinoma, undifferentiated carcinoma, undifferentiated carcinoma with osteoclast-like giant cells, acinar cell carcinoma, neuroendocrine neoplasms, neuroendocrine microadenoma, neuroendocrine tumors (NET), neuroendocrine carcinoma (NEC), including small cell or large cell NEC, insulinoma, gastrinoma, glucagonoma, serotonin-producing NET, somatostatinoma, VIPoma, solid-pseudopapillary neoplasms (SPN), pancreatoblastoma); • gall bladder (e.g. carcinoma of the gallbladder and extrahepatic bile ducts, intrahepatic cholangiocarcinoma); • neuro-endocrine (e.g., adrenal cortical carcinoma, carcinoid tumors, phaeochromocytoma, pituitary adenomas); • thyroid (e.g., anaplastic (undifferentiated) carcinoma, medullary carcinoma, oncocytic tumors, papillary carcinoma, adenocarcinoma); • liver (e.g., adenoma, combined hepatocellular and cholangiocarcinoma, fibrolamellar carcinoma, hepatoblastoma, hepatocellular carcinoma, mesenchymal, nested stromal epithelial tumor, undifferentiated carcinoma; hepatocellular carcinoma, intrahepatic cholangiocarcinoma, bile duct cystadenocarcinoma, epithelioid hemangioendothelioma, angiosarcoma, embryonal sarcoma, rhabdomyosarcoma, solitary fibrous tumor, teratoma, York sac tumor, carcinosarcoma, rhabdoid tumor); • kidney (e.g., ALK-rearranged renal cell carcinoma, chromophobe renal cell carcinoma, clear cell renal cell carcinoma, clear cell sarcoma, metanephric adenoma, metanephric adenofibroma, mucinous tubular and spindle cell carcinoma, nephroma, nephroblastoma (Wilms tumor), papillary adenoma, papillary renal cell carcinoma, renal oncocytoma, renal cell carcinoma, succinate dehydrogenase-deficient renal cell carcinoma, collecting duct carcinoma); • breast (e.g., invasive ductal carcinoma, including without limitation, acinic cell carcinoma, adenoid cystic carcinoma, apocrine carcinoma, cribriform carcinoma, glycogen-rich / clear cell, inflammatory carcinoma, lipid-rich carcinoma, medullary carcinoma, metaplastic carcinoma, micropapillary carcinoma, mucinous carcinoma, neuroendocrine carcinoma, oncocytic carcinoma, papillary carcinoma, sebaceous carcinoma, secretory breast carcinoma, tubular carcinoma; lobular carcinoma, including without limitation, pleomorphic carcinoma, signet ring cell carcinoma; • peritoneum (e.g., mesothelioma; primary peritoneal cancer);• female sex organ tissues, including ovary (e.g., choriocarcinoma, epithelial tumors, germ cell tumors, sex cord-stromal tumors), Fallopian tubes (e.g., serous adenocarcinoma, mucinous adenocarcinoma, endometrioid adenocarcinoma, clear cell adenocarcinoma, transitional cell carcinoma, squamous cell carcinoma, undifferentiated carcinoma, Müllerian tumors, adenosarcoma, leiomyosarcoma, teratoma, germ cell tumors, choriocarcinoma, trophoblastic tumors), uterus (e.g., carcinoma of the cervix, endometrial polyps, endometrial hyperplasia, intraepithelial carcinoma (EIC), endometrial carcinoma (e.g., endometrioid carcinoma, serous carcinoma, clear cell carcinoma, mucinous carcinoma, squamous cell carcinoma, transitional carcinoma, small cell carcinoma, undifferentiated carcinoma, mesenchymal neoplasia), leiomyoma (e.g., endometrial stromal nodule, leiomyosarcoma, endometrial stromal sarcoma (ESS), mesenchymal tumors), mixed epithelial and mesenchymal tumors (e.g., adenofibroma, carcinofibroma, adenosarcoma, carcinosarcoma (malignant mixed mesodermal sarcoma - MMMT)), endometrial stromal tumors, endometrial malignant mullerian mixed tumours, gestational trophoblastic tumors (partial hydatiform mole, complete hydatiform mole, invasive hydatiform mole, placental site tumour)), vulva, vagina; • male sex organ tissues, including prostate, testis (e.g., germ cell tumors, spermatocytic seminoma), penis; • bladder (e.g., squamous cell carcinoma, urothelial carcinoma, bladder urothelial carcinoma); • brain, (e.g., gliomas (e.g., astrocytomas, including non-infiltrating, low-grade, anaplastic, glioblastomas; oligodendrogliomas, ependymomas), meningiomas, gangliogliomas, schwannomas (neurilemmomas), craniopharyngiomas, chordomas, Non-Hodgkin lymphomas (NHLs), indolent non-Hodgkin’s lymphoma (iNHL), refractory iNHL, pituitary tumors; • eye (e.g., retinoma, retinoblastoma, ocular melanoma, posterior uveal melanoma, iris hamartoma); • head and neck (e.g., nasopharyngeal carcinoma, Endolymphatic Sac Tumor (ELST), epidermoid carcinoma, laryngeal cancers including squamous cell carcinoma (SCC) (e.g., glottic carcinoma, supraglottic carcinoma, subglottic carcinoma, transglottic carcinoma), carcinoma in situ, verrucous, spindle cell and basaloid SCC, undifferentiated carcinoma, laryngeal adenocarcinoma, adenoid cystic carcinoma, neuroendocrine carcinomas,laryngeal sarcoma), head and neck paragangliomas (e.g., carotid body, jugulotympanic, vagal); • thymus (e.g., thymoma); • heart (e.g., cardiac myxoma); • lung (e.g., small cell carcinoma (SCLC), non-small cell lung carcinoma (NSCLC), including squamous cell carcinoma (SCC), adenocarcinoma and large cell carcinoma, carcinoids (typical or atypical), carcinosarcomas, pulmonary blastomas, giant cell carcinomas, spindle cell carcinomas, pleuropulmonary blastoma); • lymph (e.g., lymphomas, including Hodgkin’s lymphoma, non-Hodgkin’s lymphoma (NHL), indolent non-Hodgkin’s lymphoma (iNHL), refractory iNHL, Epstein-Barr virus (EBV)-associated lymphoproliferative diseases, including B cell lymphomas and T cell lymphomas (e.g., Burkitt lymphoma; large B cell lymphoma, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, indolent B-cell lymphoma, low grade B cell lymphoma, fibrin-associated diffuse large cell lymphoma; primary effusion lymphoma; plasmablastic lymphoma; extranodal NK / T cell lymphoma, nasal type; peripheral T cell lymphoma, cutaneous T cell lymphoma, angioimmunoblastic T cell lymphoma; follicular T cell lymphoma; systemic T cell lymphoma), lymphangioleiomyomatosis); • central nervous system (CNS) (e.g., gliomas including astrocytic tumors (e.g., pilocytic astrocytoma, pilomyxoid astrocytoma, subependymal giant cell astrocytoma, pleomorphic xanthoastrocytoma, diffuse astrocytoma, fibrillary astrocytoma, gemistocytic astrocytoma, protoplasmic astrocytoma, anaplastic astrocytoma, glioblastoma (e.g., giant cell glioblastoma, gliosarcoma, glioblastoma multiforme) and gliomatosis cerebri), oligodendroglial tumors (e.g., oligodendroglioma, anaplastic oligodendroglioma), oligoastrocytic tumors (e.g., oligoastrocytoma, anaplastic oligoastrocytoma), ependymal tumors (e.g., subependymom, myxopapillary ependymoma, ependymomas (e.g., cellular, papillary, clear cell, tanycytic), anaplastic ependymoma), optic nerve glioma, and non- gliomas (e.g., choroid plexus tumors, neuronal and mixed neuronal-glial tumors, pineal region tumors, embryonal tumors, medulloblastoma, meningeal tumors, primary CNS lymphomas, germ cell tumors, Pituitary adenomas, cranial and paraspinal nerve tumors, stellar region tumors); neurofibroma, meningioma, peripheral nerve sheath tumors, peripheral neuroblastic tumours (including without limitation neuroblastoma, ganglioneuroblastoma, ganglioneuroma), trisomy 19 ependymoma);• neuroendocrine tissues (e.g., paraganglionic system including adrenal medulla (pheochromocytomas) and extra-adrenal paraganglia ((extra-adrenal) paragangliomas); • skin (e.g., clear cell hidradenoma, cutaneous benign fibrous histiocytomas, cylindroma, hidradenoma, melanoma (including cutaneous melanoma, mucosal melanoma), pilomatricoma, Spitz tumors); and • soft tissues (e.g., aggressive angiomyxoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, angiofibroma, angiomatoid fibrous histiocytoma, synovial sarcoma, biphasic synovial sarcoma, clear cell sarcoma, dermatofibrosarcoma protuberans, desmoid-type fibromatosis, small round cell tumor, desmoplastic small round cell tumor, elastofibroma, embryonal rhabdomyosarcoma, Ewing's tumors / primitive neurectodermal tumors (PNET), extraskeletal myxoid chondrosarcoma, extraskeletal osteosarcoma, paraspinal sarcoma, inflammatory myofibroblastic tumor, lipoblastoma, lipoma, chondroid lipoma, liposarcoma / malignant lipomatous tumors, liposarcoma, myxoid liposarcoma, fibromyxoid sarcoma, lymphangioleiomyoma, malignant myoepithelioma, malignant melanoma of soft parts, myoepithelial carcinoma, myoepithelioma, myxoinflammatory fibroblastic sarcoma, undifferentiated sarcoma, pericytoma, rhabdomyosarcoma, non- rhabdomyosarcoma soft tissue sarcoma (NRSTS), soft tissue leiomyosarcoma, undifferentiated sarcoma, well-differentiated liposarcoma.

[0209] In some embodiments, the IKZF protein (e.g., IKZF2 protein) associated disease or condition is a cancer selected from a lung cancer, a colorectal cancer, a breast cancer, a prostate cancer, a cervical cancer, a pancreatic cancer and a head and neck cancer. In some embodiments, the cancer is metastatic.

[0210] In some embodiments, the IKZF protein (e.g., IKZF2 protein) associated disease or condition is a cancer selected from non-small lung cancer (NSCLC), melanoma, triple-negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, and gastrointestinal stromal tumor (GIST). In some embodiments, the cancer is metastatic. Dosage

[0211] The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.

[0212] When treating or preventing an IKZF protein (e.g., IKZF2 protein) associated disease or condition for which compounds of the present disclosure are indicated, generally satisfactory results are obtained when the compounds of the present disclosure are administered at a daily dosage of from about 0.1 milligram to about 300 milligram per kilogram of animal body weight. In some embodiments, the compounds of the present disclosure are given as a single daily dose or in divided doses two to six times a day, or in sustained release form. For most large mammals, the total daily dosage is from about 1 milligram to about 1000 milligrams, or from about 1 milligram to about 50 milligrams. In the case of a 70 kg adult human, the total daily dose will generally be from about 0.1 milligrams to about 200 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response. In some embodiments, the total daily dosage is from about 1 milligram to about 900 milligrams, about 1 milligram to about 800 milligrams, about 1 milligram to about 700 milligrams, about 1 milligram to about 600 milligrams, about 1 milligram to about 400 milligrams, about 1 milligram to about 300 milligrams, about 1 milligram to about 200 milligrams, about 1 milligram to about 100 milligrams, about 1 milligram to about 50 milligrams, about 1 milligram to about 20 milligram, or about 1 milligram to about 10 milligrams.

[0213] The compounds of the present application or the compositions thereof may be administered once, twice, three, or four times daily, using any suitable mode described above. Also, administration or treatment with the compounds may be continued for a number of days; for example, commonly treatment would continue for at least 7 days, 14 days, or 28 days, for one cycle of treatment. Treatment cycles are frequently alternated with resting periods of about 1 to 28 days, commonly about 7 days or about 14 days, between cycles. The treatment cycles, in other embodiments, may also be continuous.

[0214] In some embodiments, the methods provided herein comprise administering to the subject an initial daily dose of about 1 to 800 mg of a compound described herein and increasing the dose by increments until clinical efficacy is achieved. Increments of about 5, 10, 25, 50, or 100 mg can be used to increase the dose. The dosage can be increased daily, every other day, twice per week, or once per week. Combinations

[0215] In some embodiments, a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptablesalt thereof, is administered in combination with one or more additional therapeutic agents to treat or prevent a disease or condition disclosed herein. In some embodiments, the one or more additional therapeutic agents are one, two, three, or four additional therapeutic agents. In some embodiments, the one or more additional therapeutic agents are one additional therapeutic agent. In some embodiments, the one or more additional therapeutic agents are two additional therapeutic agents. In some embodiments, the one or more additional therapeutic agents are three additional therapeutic agents. In some embodiments, the one or more additional therapeutic agents are four additional therapeutic agents.

[0216] In some embodiments, the pharmaceutical compositions provided herein have a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents. In some embodiments, the one or more additional therapeutic agents are one, two, three, or four additional therapeutic agents. In some embodiments, the one or more additional therapeutic agents are one additional therapeutic agent. In some embodiments, the one or more additional therapeutic agents are two additional therapeutic agents. In some embodiments, the one or more additional therapeutic agents are three additional therapeutic agents. In some embodiments, the one or more additional therapeutic agents are four additional therapeutic agents.

[0217] In some embodiments the one or more additional therapeutic agents include, e.g., an inhibitory immune checkpoint blocker or inhibitor, a stimulatory immune checkpoint stimulator, agonist or activator, a chemotherapeutic agent, an anti-cancer agent, a radiotherapeutic agent, an anti-neoplastic agent, an anti-proliferation agent, an anti-angiogenic agent, an anti-inflammatory agent, an immunotherapeutic agent, a therapeutic antigen-binding molecule (e.g., a mono- and multi-specific antibody, or fragment thereof, in any format, such as DART®, Duobody®, BiTE®, BiKE, TriKE, XmAb®, TandAb®, scFv, Fab, Fab derivative), a bi-specific antibody, a non- immunoglobulin antibody mimetic (e.g., including adnectin, affibody, affilin, affimer, affitin, alphabody, anticalin, peptide aptamer, armadillo repeat protein (ARM), atrimer, avimer, designed ankyrin repeat protein (DARPin®), fynomer, knottin, Kunitz domain peptide, monobody, and nanoCLAMPs), an antibody-drug conjugate (ADC), antibody-peptide conjugate), an oncolytic virus, a gene modifier or editor, a cell comprising a chimeric antigen receptor (CAR), e.g., including a T-cell immunotherapeutic agent, an NK-cell immunotherapeutic agent, or amacrophage immunotherapeutic agent, a cell comprising an engineered T-cell receptor (TCR-T), or any combination thereof. Illustrative Targets

[0218] In some embodiments, the one or more additional therapeutic agents include, e.g., an inhibitor, agonist, antagonist, ligand, modulator, stimulator, blocker, activator or suppressor of a target (e.g., polypeptide or polynucleotide), such as: 2'-5'-oligoadenylate synthetase (OAS1; NCBI Gene ID: 4938); 5'-3' exoribonuclease 1 (XRN1; NCBI Gene ID: 54464); 5'-nucleotidase ecto (NT5E, CD73; NCBI Gene ID: 4907); ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL1, BCR-ABL, c-ABL, v-ABL; NCBI Gene ID: 25); absent in melanoma 2 (AIM2; NCBI Gene ID: 9447); acetyl-CoA acyltransferase 2 (ACAA2; NCBI Gene ID: 10499); acid phosphatase 3 (ACP3; NCBI Gene ID: 55); adenosine deaminase (ADA, ADA1; NCBI Gene ID: 100); adenosine receptors (e.g., ADORA1 (A1), ADORA2A (A2a, A2AR), ADORA2B (A2b, A2BR), ADORA3 (A3); NCBI Gene IDs: 134, 135, 136, 137); AKT serine / threonine kinase 1 (AKT1, AKT, PKB; NCBI Gene ID: 207); alanyl aminopeptidase, membrane (ANPEP, CD13; NCBI Gene ID: 290); ALK receptor tyrosine kinase (ALK, CD242; NCBI Gene ID: 238); alpha fetoprotein (AFP; NCBI Gene ID: 174); amine oxidase copper containing (e.g., AOC1 (DAO1), AOC2, AOC3 (VAP1); NCBI Gene IDs: 26, 314, 8639); androgen receptor (AR; NCBI Gene ID: 367); angiopoietins (ANGPT1, ANGPT2; NCBI Gene IDs: 284, 285); angiotensin II receptor type 1 (AGTR1; NCBI Gene ID: 185); angiotensinogen (AGT; NCBI Gene ID: 183); apolipoprotein A1 (APOA1; NCBI Gene ID: 335); apoptosis inducing factor mitochondria associated 1 (AIFM1, AIF; NCBI Gene ID: 9131); arachidonate 5-lipoxygenase (ALOX5; NCBI Gene ID: 240); asparaginase (ASPG; NCBI Gene ID: 374569); asteroid homolog 1 (ASTE1; NCBI Gene ID: 28990); ATM serine / threonine kinase (ATM; NCBI Gene ID: 472); ATP binding cassette subfamily B member 1 (ABCB1, CD243, GP170; NCBI Gene ID: 5243); ATP-dependent Clp- protease (CLPP; NCBI Gene ID: 8192); ATR serine / threonine kinase (ATR; NCBI Gene ID: 545); AXL receptor tyrosine kinase (AXL; NCBI Gene ID: 558); B and T lymphocyte associated (BTLA, CD272; NCBI Gene ID: 151888); baculoviral IAP repeat containing proteins (BIRC2 (cIAP1), BIRC3 (cIAP2), XIAP (BIRC4, IAP3), BIRC5 (survivin); NCBI Gene IDs: 329, 330, 331, 332); basigin (Ok blood group) (BSG, CD147; NCBI Gene ID: 682); B-cell lymphoma 2 (BCL2; NCBI Gene ID: 596); BCL2 binding component 3 (BBC3, PUMA; NCBI Gene ID: 27113); BCL2 like (e.g., BCL2L1 (Bcl-x), BCL2L2 (BIM); Bcl-x; NCBI Gene IDs: 598, 10018); beta 3-adrenergic receptor (ADRB3; NCBI Gene ID: 155); bone gamma-carboxyglutamate protein (BGLAP; NCBI Gene ID: 632); bone morphogenetic protein-10 ligand (BMP10; NCBIGene ID: 27302); bradykinin receptors (e.g., BDKRB1, BDKRB2; NCBI Gene IDs: 623, 624); B-RAF (BRAF; NCBI Gene ID: 273); breakpoint cluster region (BCR; NCBI Gene ID: 613); bromodomain and external domain (BET) bromodomain containing proteins (e.g., BRD2, BRD3, BRD4, BRDT; NCBI Gene IDs: 6046, 8019, 23476, 676); Bruton’s tyrosine kinase (BTK; NCBI Gene ID: 695); cadherins (e.g., CDH3 (p-cadherin), CDH6 (k-cadherin); NCBI Gene IDs: 1001, 1004); cancer / testis antigens (e.g., CTAG1A, CTAG1B, CTAG2; NCBI Gene IDs: 1485, 30848, 246100); cannabinoid receptors (e.g., CNR1 (CB1), CNR2 (CB2); NCBI Gene IDs: 1268, 1269); carbohydrate sulfotransferase 15 (CHST15; NCBI Gene ID: 51363); carbonic anhydrases (e.g., CA1, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9, CA10, CA11, CA12, CA13, CA14; NCBI Gene IDs: 759, 760, 761, 762, 763, 765, 766, 767, 768, 770, 771, 11238, 23632, 56934, 377677); carcinoembryonic antigen related cell adhesion molecules (e.g., CEACAM3 (CD66d), CEACAM5 (CD66e), CEACAM6 (CD66c); NCBI Gene IDs: 1048, 1084, 4680); casein kinases (e.g., CSNK1A1 (CK1), CSNK2A1 (CK2); NCBI Gene IDs: 1452, 1457); caspases (e.g., CASP3, CASP7, CASP8; NCBI Gene IDs: 836, 840, 841, 864); catenin beta 1 (CTNNB1; NCBI Gene ID: 1499); cathepsin G (CTSG; NCBI Gene ID: 1511); Cbl proto-oncogene B (CBLB, Cbl-b; NCBI Gene ID: 868); C-C motif chemokine ligand 21 (CCL21; NCBI Gene ID: 6366); C-C motif chemokine receptor 2 (CCR2; NCBI Gene ID: 729230); C-C motif chemokine receptors (e.g., CCR3 (CD193), CCR4 (CD194), CCR5 (CD195), CCR8 (CDw198); NCBI Gene IDs: 1232, 1233, 1234, 1237); CCAAT enhancer binding protein alpha (CEBPA, CEBP; NCBI Gene ID: 1050); cell adhesion molecule 1 (CADM1; NCBI Gene ID: 23705); cell division cycle 7 (CDC7; NCBI Gene ID: 8317); cellular communication network factor 2 (CCN2; NCBI Gene ID: 1490); cereblon (CRBN; NCBI Gene ID: 51185); checkpoint kinases (e.g., CHEK1 (CHK1), CHEK2 (CHK2); NCBI Gene IDs: 1111, 11200); cholecystokinin B receptor (CCKBR; NCBI Gene ID: 887); chorionic somatomammotropin hormone 1 (CSH1; NCBI Gene ID: 1442); claudins (e.g., CLDN6, CLDN18; NCBI Gene IDs: 9074, 51208); cluster of differentiation markers (e.g., CD1A, CD1C, CD1D, CD1E, CD2, CD3 alpha (TRA), CD beta (TRB), CD gamma (TRG), CD delta (TRD), CD4, CD8A, CD8B, CD19, CD20 (MS4A1), CD22, CD24, CD25 (IL2RA, TCGFR), CD28, CD33 (SIGLEC3), CD37, CD38, CD39 (ENTPD1), CD40 (TNFRSF5), CD44 (MIC4, PGP1), CD47 (IAP), CD48 (BLAST1), CD52, CD55 (DAF), CD58 (LFA3), CD74,CD79a, CD79b, CD80 (B7-1), CD84, CD86 (B7-2), CD96 (TACTILE), CD99 (MIC2), CD115 (CSF1R), CD116 (GMCSFR, CSF2RA), CD122 (IL2RB), CD123 (IL3RA), CD128 (IL8R1), CD132 (IL2RG), CD135 (FLT3), CD137 (TNFRSF9, 4-1BB), CD142 (TF, TFA), CD152 (CTLA4), CD160, CD182 (IL8R2), CD193 (CCR3), CD194 (CCR4), CD195 (CCR5), CD207, CD221 (IGF1R), CD222 (IGF2R), CD223 (LAG3), CD226 (DNAM1), CD244, CD247, CD248, CD276(B7-H3), CD331 (FGFR1), CD332 (FGFR2), CD333 (FGFR3), CD334 (FGFR4); NCBI Gene IDs: 909, 911, 912, 913, 914, 919, 920, 923, 925, 926, 930, 931, 933, 940, 941, 942, 945, 951, 952, 953, 958,960, 961, 962, 965, 972, 973, 974, 1043, 1232, 1233, 1234, 1237, 1436, 1438, 1493, 1604, 2152, 2260, 2261, 2263, 2322, 3480, 3482, 3559, 3560, 3561, 3563, 3577, 3579, 3604, 3902, 4267, 6955, 6957, 6964, 6965, 8832, 10666, 11126, 50489, 51744, 80381, 100133941); clusterin (CLU; NCBI Gene ID: 1191); coagulation factors (e.g., F7, FXA, ; NCBI Gene IDs: 2155, 2159); collagen type IV alpha chains (e.g., COL4A1, COL4A2, COL4A3, COL4A4, COL4A5; NCBI Gene IDs: 1282, 1284, 1285, 1286, 1287); collectin subfamily member 10 (COLEC10; NCBI Gene ID: 10584); colony stimulating factors (e.g., CSF1 (MCSF), CSF2 (GMCSF), CSF3 (GCSF); NCBI Gene IDs: 1435, 1437, 1440); complement factors (e.g., C3, C5; NCBI Gene IDs: 718, 727); COP9 signalosome subunit 5 (COPS5; NCBI Gene ID: 10987); C- type lectin domain family member (e.g., CLEC4C (CD303), CLEC9A (CD370), CLEC12A (CD371); CD371; NCBI Gene ID: 160364, 170482, 283420); C-X-C motif chemokine ligand 12 (CXCL12; NCBI Gene ID: 6387); C-X-C motif chemokine receptors (CXCR1 (IL8R1, CD128), CXCR2 (IL8R2, CD182), CXCR3 (CD182, CD183, IP-10R), CXCR4 (CD184); NCBI Gene ID: 2833, 3577, 3579, 7852); cyclin D1 (CCND1, BCL1; NCBI Gene ID: 595); cyclin dependent kinases (e.g., CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK12; NCBI Gene ID: 983, 1017, 1018, 1019, 1020, 1021, 1022, 1024, 1025, 8558, 51755); cyclin G1 (CCNG1; NCBI Gene ID: 900); cytochrome P450 family members (e.g., CYP2D6, CYP3A4, CYP11A1, CYP11B2, CYP17A1, CYP19A1, CYP51A1; NCBI Gene IDs: 1565, 1576, 1583, 1585, 1586, 1588, 1595); cytochrome P450 oxidoreductase (POR; NCBI Gene ID: 5447); cytokine inducible SH2 containing protein (CISH; NCBI Gene ID: 1154); cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152; NCBI Gene ID: 1493); DEAD-box helicases (e.g., DDX5, DDX6, DDX58; NCBI Gene IDs: 1655, 1656, 23586); delta like canonical Notch ligands (e.g., DLL3, DLL4; NCBI Gene IDs: 10683, 54567); diablo IAP-binding mitochondrial protein (DIABLO, SMAC; NCBI Gene ID: 56616); diacylglycerol kinases (e.g., DGKA, DGKZ; NCBI Gene IDs: 1606, 8525); dickkopf WNT signaling pathway inhibitors (e.g., DKK1, DKK3; NCBI Gene ID: 22943, 27122); dihydrofolate reductase (DHFR; NCBI Gene ID: 1719); dihydropyrimidine dehydrogenase (DPYD; NCBI Gene ID: 1806); dipeptidyl peptidase 4 (DPP4; NCBI Gene ID: 1803); discoidin domain receptor tyrosine kinases (e.g., DDR1 (CD167), DDR2; CD167; NCBI Gene ID: 780, 4921); DNA dependent protein kinase (PRKDC; NCBI Gene ID: 5591); DNA topoisomerases (e.g., TOP1, TOP2A, TOP2B, TOP3A, TOP3B; NCBI Gene ID: 7150, 7153, 7155, 7156, 8940); dopachrome tautomerase (DCT; NCBI Gene ID: 1638); dopamine receptor D2 (DRD2; NCBI Gene ID: 1318); DOT1 like histone lysine methyltransferase (DOT1L;NCBI Gene ID: 84444); ectonucleotide pyrophosphatase / phosphodiesterase 3 (ENPP3, CD203c; NCBI Gene ID: 5169); EMAP like 4 (EML4; NCBI Gene ID: 27436); endoglin (ENG; NCBI Gene ID: 2022); endoplasmic reticulum aminopeptidases (e.g., ERAP1, ERAP2; NCBI Gene ID: 51752, 64167); enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2; NCBI Gene ID: 2146); ephrin receptors (e.g., EPHA1, EPHA2EPHA3, EPHA4, EPHA5, EPHA7, EPHB4; NCBIGene ID:1969, 2041, 2042, 2043, 2044, 2045, 2050); ephrins (e.g., EFNA1, EFNA4, EFNB2; NCBI Gene ID: 1942, 1945, 1948); epidermal growth factor receptors (e.g., ERBB1 (HER1, EGFR), ERBB1 variant III (EGFRvIII), ERBB2 (HER2, NEU, CD340), ERBB3 (HER3), ERBB4 (HER4); NCBI Gene ID: 1956, 2064, 2065, 2066); epithelial cell adhesion molecule (EPCAM; NCBI Gene ID: 4072); epithelial mitogen (EPGN; NCBI Gene ID: 255324); eukaryotic translation elongation factors (e.g., EEF1A2, EEF2; NCBI Gene ID: 1917, 1938); eukaryotic translation initiation factors (e.g., EIF4A1, EIF5A; NCBI Gene ID: 1973, 1984); exportin-1 (XPO1; NCBI Gene ID: 7514); farnesoid X receptor (NR1H4, FXR; NCBI Gene ID: 9971); Fas ligand (FASLG, FASL, CD95L, CD178, TNFSF6; NCBI Gene ID: 356); fatty acid amide hydrolase (FAAH; NCBI Gene ID: 2166); fatty acid synthase (FASN; FAS; NCBI Gene ID: 2194); Fc fragment of Ig receptors (e.g., FCER1A, FCGRT, FCGR3A (CD16); NCBI Gene IDs: 2205, 2214, 2217); Fc receptor like 5 (FCRL5, CD307; NCBI Gene ID: 83416); fibroblast activation protein alpha (FAP; NCBI Gene ID: 2191); fibroblast growth factor receptors (e.g., FGFR1 (CD331), FGFR2 (CD332), FGFR3 (CD333), FGFR4 (CD334); NCBI Gene IDs: 2260, 2261, 2263, 2264); fibroblast growth factors (e.g., FGF1 (FGF alpha), FGF2 (FGF beta), FGF4, FGF5; NCBI Gene IDs: 2246, 2247, 2249, 2250); fibronectin 1 (FN1, MSF; NCBI Gene ID: 2335); fms related receptor tyrosine kinases (e.g., FLT1 (VEGFR1), FLT3 (STK1, CD135), FLT4 (VEGFR2); NCBI Gene IDs: 2321, 2322, 2324); fms related receptor tyrosine kinase 3 ligand (FLT3LG; NCBI Gene ID: 2323); focal adhesion kinase 2 (PTK2, FAK1; NCBI Gene ID: 5747); folate hydrolase 1 (FOLH1, PSMA; NCBI Gene ID: 2346); folate receptor 1 (FOLR1; NCBI Gene ID: 2348); forkhead box protein M1 (FOXM1; NCBI Gene ID: 2305); FURIN (FURIN, PACE; NCBI Gene ID: 5045); FYN tyrosine kinase (FYN, SYN; NCBI Gene ID: 2534); galectins (e.g., LGALS3, LGALS8 (PCTA1), LGALS9; NCBI Gene ID: 3958, 3964, 3965); glucocorticoid receptor (NR3C1, GR; NCBI Gene ID: 2908); glucuronidase beta (GUSB; NCBI Gene ID: 2990); glutamate metabotropic receptor 1 (GRM1; NCBI Gene ID: 2911); glutaminase (GLS; NCBI Gene ID: 2744); glutathione S-transferase Pi (GSTP1; NCBI Gene ID: 2950); glycogen synthase kinase 3 beta (GSK3B; NCBI Gene ID: 2932); glypican 3 (GPC3; NCBI Gene ID: 2719); gonadotropin releasing hormone 1 (GNRH1; NCBI Gene ID: 2796); gonadotropin releasing hormone receptor (GNRHR; NCBI Gene ID: 2798); GPNMB glycoprotein nmb (GPNMB,osteoactivin; NCBI Gene ID: 10457); growth differentiation factor 2 (GDF2, BMP9; NCBI Gene ID: 2658); growth factor receptor-bound protein 2 (GRB2, ASH; NCBI Gene ID: 2885); guanylate cyclase 2C (GUCY2C, STAR, MECIL, MUCIL, NCBI Gene ID: 2984); H19 imprinted maternally expressed transcript (H19; NCBI Gene ID: 283120); HCK proto-oncogene, Src family tyrosine kinase (HCK; NCBI Gene ID: 3055); heat shock proteins (e.g., HSPA5 (HSP70, BIP, GRP78), HSPB1 (HSP27), HSP90B1 (GP96); NCBI Gene IDs: 3309, 3315, 7184); heme oxygenases (e.g., HMOX1 (HO1), HMOX2 (HO1); NCBI Gene ID: 3162, 3163); heparanase (HPSE; NCBI Gene ID: 10855); hepatitis A virus cellular receptor 2 (HAVCR2, TIM3, CD366; NCBI Gene ID: 84868); hepatocyte growth factor (HGF; NCBI Gene ID: 3082); HERV-H LTR- associating 2 (HHLA2, B7-H7; NCBI Gene ID: 11148); histamine receptor H2 (HRH2; NCBI Gene ID: 3274); histone deacetylases (e.g., HDAC1, HDAC7, HDAC9; NCBI Gene ID: 3065, 9734, 51564); HRas proto-oncogene, GTPase (HRAS; NCBI Gene ID: 3265); hypoxia-inducible factors (e.g., HIF1A, HIF2A (EPAS1); NCBI Gene IDs: 2034, 3091); I-Kappa-B kinase (IKK beta; NCBI Gene IDs: 3551, 3553); IKAROS family zinc fingers (IKZF1 (LYF1), IKZF3; NCBI Gene ID: 10320, 22806); immunoglobulin superfamily member 11 (IGSF11; NCBI Gene ID: 152404); indoleamine 2,3-dioxygenases (e.g., IDO1, IDO2; NCBI Gene IDs: 3620, 169355); inducible T cell costimulator (ICOS, CD278; NCBI Gene ID: 29851); inducible T cell costimulator ligand (ICOSLG, B7-H2; NCBI Gene ID: 23308); insulin like growth factor receptors (e.g., IGF1R, IGF2R; NCBI Gene ID: 3480, 3482); insulin like growth factors (e.g., IGF1, IGF2; NCBI Gene IDs: 3479, 3481); insulin receptor (INSR, CD220; NCBI Gene ID: 3643); integrin subunits (e.g., ITGA5 (CD49e), ITGAV (CD51), ITGB1 (CD29), ITGB2 (CD18, LFA1, MAC1), ITGB7; NCBI Gene IDs: 3678, 3685, 3688, 3695, 3698); intercellular adhesion molecule 1 (ICAM1, CD54; NCBI Gene ID: 3383); interleukin 1 receptor associated kinase 4 (IRAK4; NCBI Gene ID: 51135); interleukin receptors (e.g., IL2RA (TCGFR, CD25), IL2RB (CD122), IL2RG (CD132), IL3RA, IL6R, IL13RA2 (CD213A2), IL22RA1; NCBI Gene IDs: 3598, 3559, 3560, 3561, 3563, 3570, 58985); interleukins (e.g., IL1A, IL1B, IL2, IL3, IL6 (HGF), IL7, IL8 (CXCL8), IL10 (TGIF), IL12A, IL12B, IL15, IL17A (CTLA8), IL18, IL23A, IL24, IL- 29 (IFNL1); NCBI Gene IDs: 3552, 3553, 3558, 3562, 3565, 3569, 3574, 3586, 3592, 3593, 3600, 3605, 3606, 11009, 51561, 282618); isocitrate dehydrogenases (NADP(+)1) (e.g., IDH1, IDH2; NCBI Gene IDs: 3417, 3418); Janus kinases (e.g., JAK1, JAK2, JAK3; NCBI Gene IDs: 3716, 3717, 3718); kallikrein related peptidase 3 (KLK3; NCBI Gene ID: 354); killer cell immunoglobulin like receptor, Ig domains and long cytoplasmic tails (e.g., KIR2DL1 (CD158A), KIR2DL2 (CD158B1), KIR2DL3 (CD158B), KIR2DL4 (CD158D), KIR2DL5A (CD158F), KIR2DL5B, KIR3DL1 (CD158E1), KIR3DL2 (CD158K), KIR3DP1 (CD158c), KIR2DS2(CD158J); NCBI Gene IDs: 3802, 3803, 3804, 3805, 3811, 3812, 57292, 553128, 548594, 100132285); killer cell lectin like receptors (e.g., KLRC1 (CD159A), KLRC2 (CD159c), KLRC3, KLRRC4, KLRD1 (CD94), KLRG1, KLRK1 (NKG2D, CD314); NCBI Gene IDs: 3821, 3822, 3823, 3824, 8302, 10219, 22914); kinase insert domain receptor (KDR, CD309, VEGFR2; NCBI Gene ID: 3791); kinesin family member 11 (KIF11; NCBI Gene ID: 3832); KiSS-1 metastasis suppressor (KISS1; NCBI Gene ID: 3814); KIT proto-oncogene, receptor tyrosine kinase (KIT, C-KIT, CD117; NCBI Gene ID: 3815); KRAS proto-oncogene, GTPase (KRAS; NCBI Gene ID: 3845); lactotransferrin (LTF; NCBI Gene ID: 4057); LCK proto-oncogene, Src family tyrosine kinase (LCK; NCBI Gene ID: 3932); LDL receptor related protein 1 (LRP1, CD91, IGFBP3R; NCBI Gene ID: 4035); leucine rich repeat containing 15 (LRRC15; NCBI Gene ID: 131578); leukocyte immunoglobulin like receptors (e.g., LILRB1 (ILT2, CD85J), LILRB2 (ILT4, CD85D); NCBI Gene ID: 10288, 10859); leukotriene A4 hydrolase (LTA4H; NCBI Gene ID: 4048); linker for activation of T-cells (LAT; NCBI Gene ID: 27040); luteinizing hormone / choriogonadotropin receptor (LHCGR; NCBI Gene ID: 3973); LY6 / PLAUR domain containing 3 (LYPD3; NCBI Gene ID: 27076); lymphocyte activating 3 (LAG3; CD223; NCBI Gene ID: 3902); lymphocyte antigens (e.g., LY9 (CD229), LY75 (CD205); NCBI Gene IDs: 4063, 17076); LYN proto- oncogene, Src family tyrosine kinase (LYN; NCBI Gene ID: 4067); lypmphocyte cytosolic protein 2 (LCP2; NCBI Gene ID: 3937); lysine demethylase 1A (KDM1A; NCBI Gene ID: 23028); lysophosphatidic acid receptor 1 (LPAR1, EDG2, LPA1, GPR26; NCBI Gene ID: 1902); lysyl oxidase (LOX; NCBI Gene ID: 4015); lysyl oxidase like 2 (LOXL2; NCBI Gene ID: 4017); macrophage migration inhibitory factor (MIF, GIF; NCBI Gene ID: 4282); macrophage stimulating 1 receptor (MST1R, CD136; NCBI Gene ID: 4486); MAGE family members (e.g., MAGEA1, MAGEA2, MAGEA2B, MAGEA3, MAGEA4, MAGEA5, MAGEA6, MAGEA10,MAGEA11, MAGEC1, MAGEC2,MAGED1, MAGED2; NCBI Gene IDs: 4100, 4101, 4102, 4103, 4104, 4105, 4109, 4110, 9500, 9947, 10916, 51438, 266740); major histocompatibility complexes (e.g., HLA-A, HLA-E, HLA-F, HLA-G; NCBI Gene IDs: 3105, 3133, 3134, 3135); major vault protein (MVP, VAULT1; NCBI Gene ID: 9961); MALT1 paracaspase (MALT1; NCBI Gene ID: 10892); MAPK activated protein kinase 2 (MAPKAPK2; NCBI Gene ID: 9261); MAPK interacting serine / threonine kinases (e.g., MKNK1, MKNK2; NCBI Gene IDs: 2872, 8569); matrix metallopeptidases (e.g., MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP20, MMP21,MMP24, MMP25, MMP26, MMP27, MMP28; NCBI Gene IDs: 4312, 4313, 4314, 4316, 4317, 4318, 4319, 4320, 4321, 4322, 4323, 4324, 4325, 4326, 4327, 9313, 10893, 56547, 64066, 64386, 79148, 118856); MCL1 apoptosis regulator, BCL2 familymember (MCL1; NCBI Gene ID: 4170); MDM2 proto-oncogene (MDM2; NCBI Gene ID: 4193); MDM4 regulator of p53 (MDM4; BMFS6; NCBI Gene ID: 4194); mechanistic target of rapamycin kinase (MTOR, FRAP1; NCBI Gene ID: 2475); melan-A (MLANA; NCBI Gene ID: 2315); melanocortin receptors (MC1R, MC2R; NCBI Gene IDs: 4157, 4148); MER proto- oncogene, tyrosine kinase (MERTK; NCBI Gene ID: 10461); mesothelin (MSLN; NCBI Gene ID: 10232); MET proto-oncogene, receptor tyrosine kinase (MET, c-Met, HGFR; NCBI Gene ID: 4233); methionyl aminopeptidase 2 (METAP2, MAP2; NCBI Gene ID: 10988); MHC class I polypeptide-related sequences (e.g., MICA, MICB; NCBI Gene IDs: 4277, 100507436); mitogen activated protein kinases (e.g., MAPK1 (ERK2), MAPK3 (ERK1), MAPK8 (JNK1), MAPK9 (JNK2), MAPK10 (JNK3), MAPK11 (p38 beta), MAPK12; NCBI Gene IDs: 5594, 5595, 5599, 5600, 5601, 5602, 819251); mitogen-activated protein kinase kinase kinases (e.g., MAP3K5 (ASK1), MAP3K8 (TPL2, AURA2); NCBI Gene IDs: 4217, 1326); mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1, HPK1; NCBI Gene ID: 11184); mitogen-activated protein kinase kinases (e.g., MAP2K1 (MEK1), MAP2K2 (MEK2), MAP2K7 (MEK7); NCBI Gene IDs: 5604, 5605, 5609); MPL proto-oncogene, thrombopoietin receptor (MPL; NCBI Gene ID: 4352); mucins (e.g., MUC1 (including splice variants thereof (e.g., including MUC1 / A, C, D, X, Y, Z and REP)), MUC5AC, MUC16 (CA125); NCBI Gene IDs: 4582, 4586, 94025); MYC proto-oncogene, bHLH transcription factor (MYC; NCBI Gene ID: 4609); myostatin (MSTN, GDF8; NCBI Gene ID: 2660); myristoylated alanine rich protein kinase C substrate (MARCKS; NCBI Gene ID: 4082); natriuretic peptide receptor 3 (NPR3; NCBI Gene ID: 4883); natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1, B7-H6; NCBI Gene ID: 374383); necdin, MAGE family member (NDN; NCBI Gene ID: 4692); nectin cell adhesion molecules (e.g., NECTIN2 (CD112, PVRL2), NECTIN4 (PVRL4); NCBI Gene IDs: 5819, 81607); neural cell adhesion molecule 1 (NCAM1, CD56; NCBI Gene ID: 4684); neuropilins (e.g., NRP1 (CD304, VEGF165R), NRP2 (VEGF165R2); NCBI Gene IDs: 8828, 8829); neurotrophic receptor tyrosine kinases (e.g., NTRK1 (TRKA), NTRK2 (TRKB), NTRK3 (TRKC); NCBI Gene IDs: 4914, 4915, 4916); NFKB activating protein (NKAP; NCBI Gene ID: 79576); NIMA related kinase 9 (NEK9; NCBI Gene ID: 91754); NLR family pyrin domain containing 3 (NLRP3, NALP3; NCBI Gene ID: 114548); notch receptors (e.g., NOTCH1, NOTCH2, NOTCH3, NOTCH4; NCBI Gene IDs: 4851, 4853, 4854, 4855); NRAS proto-oncogene, GTPase (NRAS; NCBI Gene ID: 4893); nuclear factor kappa B (NFKB1, NFKB2; NCBI Gene IDs: 4790, 4791); nuclear factor, erythroid 2 like 2 (NFE2L2; NRF2; NCBI Gene ID: 4780); nuclear receptor subfamily 4 group A member 1 (NR4A1; NCBI Gene ID: 3164); nucleolin (NCL; NCBI Gene ID: 4691); nucleophosmin 1 (NPM1; NCBI Gene ID: 4869); nucleotide binding oligomerization domain containing 2 (NOD2;NCBI Gene ID: 64127); nudix hydrolase 1 (NUDT1; NCBI Gene ID: 4521); O-6-methylguanine- DNA methyltransferase (MGMT; NCBI Gene ID: 4255); opioid receptor delta 1 (OPRD1; NCBI Gene ID: 4985); ornithine decarboxylase 1 (ODC1; NCBI Gene ID: 4953); oxoglutarate dehydrogenase (OGDH; NCBI Gene ID: 4967); parathyroid hormone (PTH; NCBI Gene ID: 5741); PD-L1 (CD274; NCBI Gene ID: 29126); periostin (POSTN; NCBI Gene ID: 10631); peroxisome proliferator activated receptors (e.g., PPARA (PPAR alpha), PPARD (PPAR delta), PPARG (PPAR gamma); NCBI Gene IDs: 5465, 5467, 5468); phosphatase and tensin homolog (PTEN; NCBI Gene ID: 5728); phosphatidylinositol-4,5-bisphosphate 3-kinases (PIK3CA (PI3K alpha), PIK3CB (PI3K beta), PIK3CD (PI3K delta), PIK3CG (PI3K gamma); NCBI Gene IDs: 5290, 5291, 5293, 5294); phospholipases (e.g., PLA2G1B, PLA2G2A, PLA2G2D, PLA2G3, PLA2G4A, PLA2G5, PLA2G7, PLA2G10, PLA2G12A, PLA2G12B, PLA2G15; NCBI Gene IDs: 5319, 5320, 5321, 5322, 7941, 8399, 50487, 23659, 26279, 81579, 84647); Pim proto- oncogene, serine / threonine kinases (e.g., PIM1, PIM2, PIM3; NCBI Gene IDs: 5292, 11040, 415116); placenta growth factor (PGF; NCBI Gene ID: 5228); plasminogen activator, urokinase (PLAU, u-PA, ATF; NCBI Gene ID: 5328); platelet derived growth factor receptors (e.g., PDGFRA (CD140A, PDGFR2), FDGFRB (CD140B, PDGFR1); NCBI Gene IDs: 5156, 5159); plexin B1 (PLXNB1; NCBI Gene ID: 5364); poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155; NCBI Gene ID: 5817); polo like kinase 1 (PLK1; NCBI Gene ID: 5347); poly(ADP-ribose) polymerases (e.g., PARP1, PARP2, PARP3; NCBI Gene IDs: 142, 10038, 10039); polycomb protein EED (EED; NCBI Gene ID: 8726); porcupine O-acyltransferase (PORCN; NCBI Gene ID: 64840); PRAME nuclear receptor transcriptional regulator (PRAME; NCBI Gene ID: 23532); premelanosome protein (PMEL; NCBI Gene ID: 6490); progesterone receptor (PGR; NCBI Gene ID: 5241); programmed cell death 1 (PDCD1, PD-1, CD279; NCBI Gene ID: 5133); programmed cell death 1 ligand 2 (PDCD1LG2, CD273, PD-L2; NCBI Gene ID: 80380); prominin 1 (PROM1, CD133; NCBI Gene ID: 8842); promyelocytic leukemia (PML; NCBI Gene ID: 5371); prosaposin (PSAP; NCBI Gene ID: 5660); prostaglandin E receptor 4 (PTGER4; NCBI Gene ID: 5734); prostaglandin E synthase (PTGES; NCBI Gene ID: 9536); prostaglandin-endoperoxide synthases (PTGS1 (COX1), PTGS2 (COX2); NCBI Gene ID: 5742, 5743); proteasome 20S subunit beta 9 (PSMB9; NCBI Gene ID: 5698); protein arginine methyltransferases (e.g., PRMT1, PRMT5; NCBI Gene ID: 3276, 10419); protein kinase N3 (PKN3; NCBI Gene ID: 29941); protein phosphatase 2A (PPP2CA; NCBI Gene ID: 5515); protein tyrosine kinase 7 (inactive) (PTK7; NCBI Gene ID: 5754); protein tyrosine phosphatase receptors (PTPRB (PTPB), PTPRC (CD45R); NCBI Gene ID: 5787, 5788); prothymosin alpha (PTMA; NCBI Gene ID: 5757); purine nucleoside phosphorylase (PNP; NCBI Gene ID: 4860);purinergic receptor P2X 7 (P2RX7; NCBI Gene ID: 5027); PVR related immunoglobulin domain containing (PVRIG, CD112R; NCBI Gene ID: 79037); Raf-1 proto-oncogene, serine / threonine kinase (RAF1, c-Raf; NCBI Gene ID: 5894); RAR-related orphan receptor gamma (RORC; NCBI Gene ID: 6097); ras homolog family member C (RHOC); NCBI Gene ID: 389); Ras homolog, mTORC1 binding (RHEB; NCBI Gene ID: 6009); RB transcriptional corepressor 1 (RB1; NCBI Gene ID: 5925); receptor-interacting serine / threonine protein kinase 1 (RIPK1; NCBI Gene ID: 8737); ret proto-oncogene (RET; NCBI Gene ID: 5979); retinoic acid early transcripts (e.g., RAET1E, RAET1G, RAET1L; NCBI Gene IDs: 135250, 154064, 353091); retinoic acid receptors alpha (e.g., RARA, RARG; NCBI Gene IDs: 5914, 5916); retinoid X receptors (e.g., RXRA, RXRB, RXRG; NCBI Gene IDs: 6256, 6257, 6258); Rho associated coiled-coil containing protein kinases (e.g., ROCK1, ROCK2; NCBI Gene IDs: 6093, 9475); ribosomal protein S6 kinase B1 (RPS6KB1, S6K-beta 1; NCBI Gene ID: 6198); ring finger protein 128 (RNF128, GRAIL; NCBI Gene ID: 79589); ROS proto-oncogene 1, receptor tyrosine kinase (ROS1; NCBI Gene ID: 6098); roundabout guidance receptor 4 (ROBO4; NCBI Gene ID: 54538); RUNX family transcription factor 3 (RUNX3; NCBI Gene ID: 864); S100 calcium binding protein A9 (S100A9; NCBI Gene ID: 6280); secreted frizzled related protein 2 (SFRP2; NCBI Gene ID: 6423); secreted phosphoprotein 1 (SPP1; NCBI Gene ID: 6696); secretoglobin family 1A member 1 (SCGB1A1; NCBI Gene ID: 7356); selectins (e.g., SELE, SELL (CD62L), SELP (CD62); NCBI Gene IDs: 6401, 6402, 6403); semaphorin 4D (SEMA4D; CD100; NCBI Gene ID: 10507); sialic acid binding Ig like lectins (SIGLEC7 (CD328), SIGLEC9 (CD329), SIGLEC10; NCBI Gene ID: 27036, 27180, 89790); signal regulatory protein alpha (SIRPA, CD172A; NCBI Gene ID: 140885); signal transducer and activator of transcription (e.g., STAT1, STAT3, STAT5A, STAT5B ; NCBI Gene IDs: 6772, 6774, 6776, 6777); sirtuin-3 (SIRT3; NCBI Gene ID: 23410); signaling lymphocytic activation molecule (SLAM) family members (e.g., SLAMF1 (CD150), SLAMF6 (CD352), SLAMF7 (CD319), SLAMF8 (CD353), SLAMF9; NCBI Gene IDs: 56833, 57823, 89886, 114836); SLIT and NTRK like family member 6 (SLITRK6; NCBI Gene ID: 84189); smoothened, frizzled class receptor (SMO; NCBI Gene ID: 6608); soluble epoxide hydrolase 2 (EPHX2; NCBI Gene ID: 2053); solute carrier family members (e.g., SLC3A2 (CD98), SLC5A5, SLC6A2, SLC10A3, SLC34A2, SLC39A6, SLC43A2 (LAT4), SLC44A4; NCBI Gene IDs: 6520, 6528, 6530, 8273, 10568, 25800, 80736, 124935); somatostatin receptors (e.g., SSTR1, SSTR2, SSTR3, SSTR4, SSTR5; NCBI Gene IDs: 6751, 6752, 6753, 6754, 6755); sonic hedgehog signaling molecule (SHH; NCBI Gene ID: 6469); Sp1 transcription factor (SP1; NCBI Gene ID: 6667); sphingosine kinases (e.g., SPHK1, SPHK2; NCBI Gene IDs: 8877, 56848); sphingosine-1-phosphate receptor 1 (S1PR1, CD363; NCBI Gene ID: 1901); spleenassociated tyrosine kinase (SYK; NCBI Gene ID: 6850); splicing factor 3B factor 1 (SF3B1; NCBI Gene ID: 23451); SRC proto-oncogene, non-receptor tyrosine kinase (SRC; NCBI Gene ID: 6714); stabilin 1 (STAB1, CLEVER-1; NCBI Gene ID: 23166); STEAP family member 1 (STEAP1; NCBI Gene ID: 26872); steroid sulfatase (STS; NCBI Gene ID: 412); stimulator of interferon response cGAMP interactor 1 (STING1; NCBI Gene ID: 340061); superoxide dismutase 1 (SOD1, ALS1; NCBI Gene ID: 6647); suppressors of cytokine signaling (SOCS1 (CISH1), SOCS3 (CISH3); NCBI Gene ID: 8651, 9021); synapsin 3 (SYN3; NCBI Gene ID: 8224); syndecan 1 (SDC1, CD138, syndecan; NCBI Gene ID: 6382); synuclein alpha (SNCA, PARK1; NCBI Gene ID: 6622); T cell immunoglobulin and mucin domain containing 4 (TIMD4, SMUCKLER; NCBI Gene ID: 91937); T cell immunoreceptor with Ig and ITIM domains (TIGIT; NCBI Gene ID: 201633); tachykinin receptors (e.g., TACR1, TACR3; NCBI Gene ID: 6869, 6870); TANK binding kinase 1 (TBK1; NCBI Gene ID: 29110); tankyrase (TNKS; NCBI Gene ID: 8658); TATA-box binding protein associated factor, RNA polymerase I subunit B (TAF1B; NCBI Gene ID: 9014); T-box transcription factor T (TBXT; NCBI Gene ID: 6862); TCDD inducible poly(ADP-ribose) polymerase (TIPARP, PAPR7; NCBI Gene ID: 25976); tec protein tyrosine kinase (TEC; NCBI Gene ID: 7006); TEK receptor tyrosine kinase (TEK, CD202B, TIE2; NCBI Gene ID: 7010); telomerase reverse transcriptase (TERT; NCBI Gene ID: 7015); tenascin C (TNC; NCBI Gene ID: 3371); three prime repair exonucleases (e.g., TREX1, TREX2; NCBI Gene ID: 11277, 11219); thrombomodulin (THBD, CD141; NCBI Gene ID: 7056); thymidine kinases (e.g., TK1, TK2; NCBI Gene IDs: 7083, 7084); thymidine phosphorylase (TYMP; NCBI Gene ID: 1890); thymidylate synthase (TYMS; NCBI Gene ID: 7298); thyroid hormone receptor (THRA, THRB; NCBI Gene IDs: 7606, 7608); thyroid stimulating hormone receptor (TSHR; NCBI Gene ID: 7253); TNF superfamily members (e.g., TNFSF4 (OX40L, CD252),TNFSF5 (CD40L), TNFSF7 (CD70), TNFSF8 (CD153, CD30L), TNFSF9 (4-1BB-L, CD137L), TNFSF10 (TRAIL, CD253, APO2L), TNFSF11 (CD254, RANKL2, TRANCE), TNFSF13 (APRIL, CD256, TRAIL2), TNFSF13b (BAFF, BLYS, CD257), TNFSF14 (CD258, LIGHT), TNFSF18 (GITRL); NCBI Gene IDs: 944, 959, 970, 7292, 8600, 8740, 8741, 8743, 8744, 8995); toll like receptors (e.g., TLR1 (CD281), TLR2 (CD282), TLR3 (CD283), TLR4 (CD284), TLR5, TLR6 (CD286), TLR7, TLR8 (CD288), TLR9 (CD289), TLR10 (CD290); NCBI Gene IDs: 7096, 7097, 7098, 7099, 10333, 51284, 51311, 54106, 81793); transferrin (TF; NCBI Gene ID: 7018); transferrin receptor (TFRC, CD71; NCBI Gene ID: 7037); transforming growth factors (e.g., TGFA, TGFB1; NCBI Gene ID: 7039, 7040); transforming growth factor receptors (e.g., TGFBR1, TGFBR2, TGFBR3; NCBI Gene ID: 7046, 7048, 7049); transforming protein E7 (E7; NCBI Gene ID: 1489079); transglutaminase 5 (TGM5; NCBI Gene ID: 9333);transient receptor potential cation channel subfamily V member 1 (TRPV1, VR1; NCBI Gene ID: 7442); transmembrane and immunoglobulin domain containing 2 (TMIGD2, CD28H, IGPR1; NCBI Gene ID: 126259); triggering receptors expressed on myeloid cells (e.g., TREM1 (CD354), TREM2; NCBI Gene ID: 54209, 54210); trophinin (TRO, MAGED3; NCBI Gene ID: 7216); trophoblast glycoprotein (TPBG; NCBI Gene ID: 7162); tryptophan 2,3-dioxygenase (TDO2; NCBI Gene ID: 6999); tryptophan hydroxylases (e.g., TPH1, TPH2; NCBI Gene ID: 7166, 121278); tumor associated calcium signal transducer 2 (TACSTD2, TROP2, EGP1; NCBI Gene ID: 4070); tumor necrosis factor (TNF; NCBI Gene ID: 7124); tumor necrosis factor (TNF) receptor superfamily members (e.g., TNFRSF1A (CD120a), TNFRSF1B (CD120b), TNFRSF4 (OX40), TNFRSF5 (CD40),TNFRSF6 (CD95, FAS receptor), TNFRSF7 (CD27), TNFRSF8 (CD30), TNFRSF9 (CD137, 4-1BB), TNFRSF10A (CD261), TNFRSF10B (TRAIL, DR5, CD262), TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF11B (OPG), TNFRSF12A, TNFRSF13B, TNFR13C (, CD268, BAFFR), TNFRSF14 (CD270, LIGHTR), TNFRSF16, TNFRSF17 (CD269, BCMA), TNFRSF18 (GITR, CD357), TNFRSF19, TNFRSF21, TNFRSF25, ; NCBI Gene IDs: 355, 608, 939, 943, 958, 3604, 4804, 4982, 7132, 7133, 7293, 8718, 8764, 8784, 8792, 8793, 8794, 8795, 8797, 23495, 27242, 51330, 55504); tumor protein p53 (TP53; NCBI Gene ID: 7157); tumor suppressor 2, mitochondrial calcium regulator (TUSC2; NCBI Gene ID: 11334); TYRO3 protein tyrosine kinase (TYRO3; BYK; NCBI Gene ID: 7301); tyrosinase (TYR; NCBI Gene ID: 7299); tyrosine hydroxylase (TH; NCBI Gene ID: 7054); tyrosine kinase with immunoglobulin like and EGF like domains 1 (e.g., TIE1, TIE1; NCBI Gene ID: 7075); tyrosine-protein phosphatase non-receptor type 11 (PTPN11, SHP2; NCBI Gene ID: 5781); ubiquitin conjugating enzyme E2 I (UBE2I, UBC9; NCBI Gene ID: 7329); ubiquitin C- terminal hydrolase L5 (UCHL5; NCBI Gene ID: 51377); ubiquitin specific peptidase 7 (USP7; NCBI Gene ID: 7874); ubiquitin-like modifier activating enzyme 1 (UBA1; NCBI Gene ID: 7317); UL16 binding proteins (e.g., ULBP1, ULBP2, ULBP3; NCBI Gene ID: 79465, 80328, 80328); valosin-containing protein (VCP, CDC48; NCBI Gene ID: 7415); vascular cell adhesion molecule 1 (VCAM1, CD106; NCBI Gene ID: 7412); vascular endothelial growth factors (e.g., VEGFA, VEGFB; NCBI Gene ID: 7422, 7423); vimentin (VIM; NCBI Gene ID: 7431); vitamin D receptor (VDR; NCBI Gene ID: 7421); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7-H4; NCBI Gene ID: 79679); V-set immunoregulatory receptor (VSIR, VISTA, B7- H5; NCBI Gene ID: 64115); WEE1 G2 checkpoint kinase (WEE1; NCBI Gene ID: 7465); WRN RecQ like helicase (WRN; RECQ3; NCBI Gene ID: 7486); WT1 transcription factor (WT1; NCBI Gene ID: 7490); WW domain containing transcription regulator 1 (WWTR1; TAZ; NCBI Gene ID: 25937); X-C motif chemokine ligand 1 (XCL1, ATAC; NCBI Gene ID: 6375); X-C motifchemokine receptor 1 (XCR1, GPR5, CCXCR1; NCBI Gene ID: 2829); Yes1 associated transcriptional regulator (YAP1; NCBI Gene ID: 10413); or zeta chain associated protein kinase 70 (ZAP70; NCBI Gene ID: 7535).

[0219] In some embodiments, the one or more additional therapeutic agents include, e.g., an agent targeting 5'-nucleotidase ecto (NT5E or CD73; NCBI Gene ID: 4907); adenosine A2A receptor (ADORA2A; NCBI Gene ID: 135); adenosine A2B receptor (ADORA2B; NCBI Gene ID: 136); C-C motif chemokine receptor 8 (CCR8, CDw198; NCBI Gene ID: 1237); cytokine inducible SH2 containing protein (CISH; NCBI Gene ID: 1154); diacylglycerol kinase alpha (DGKA, DAGK, DAGK1 or DGK-alpha; NCBI Gene ID: 1606); fms like tyrosine kinase 3 (FLT3, CD135; NCBI Gene ID: 2322); integrin associated protein (IAP, CD47; NCBI Gene ID: 961); interleukine-2 (IL2; NCBI Gene ID:3558); interleukine 2 receptor (IL2RA, IL2RB, IL2RG; NCBI Gene IDs: 3559, 3560, 3561); Kirsten rat sarcoma virus (KRAS; NCBI Gene ID: 3845; including mutations, such as KRAS G12C or G12D); mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) (also called Hematopoietic Progenitor Kinase 1 (HPK1), NCBI Gene ID: 11184); myeloid cell leukemia sequence 1 apoptosis regulator (MCL1; NCBI Gene ID: 4170); phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta (PIK3CD; NCBI Gene ID: 5293); programmed death-ligand 1 (PD-L1, CD274; NCBI Gene ID 29126); programmed cell death protein 1 (PD-1, CD279; NCBI Gene ID: 5133); proto-oncogen c-KIT (KIT, CD117; NCBI Gene ID: 3815); signal-regulatory protein alpha (SIRPA, CD172A; NCBI Gene ID: 140885); TCDD inducible poly(ADP-ribose) polymerase (TIPARP, PARP7; NCBI Gene ID: 25976); T cell immunoreceptor with Ig and ITIM domains (TIGIT; NCBI Gene ID: 201633); triggering receptor expressed on myeloid cells 1 (TREM1; NCBI Gene ID: 54210); triggering receptor expressed on myeloid cells 2 (TREM2; NCBI Gene ID: 54209); tumor-associated calcium signal transducer 2 (TACSTD2, TROP2, EGP1; NCBI Gene ID: 4070); tumor necrosis factor receptor superfamily, member 4 (TNFRSF4, CD134, OX40; NCBI Gene ID:7293); tumor necrosis factor receptor superfamily, member 9 (TNFRSF9, 4-1BB, CD137; NCBI Gene ID: 3604); tumor necrosis factor receptor superfamily, member 18 (TNFRSF18, CD357, GITR; NCBI Gene ID: 8784); WRN RecQ like helicase (WRN; NCBI Gene ID: 7486); or zinc finger protein Helios (IKZF2; NCBI Gene ID: 22807).Illustrative Mechanisms of Action Immune Checkpoint Modulators

[0220] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with one or more blockers or inhibitors of inhibitory immune checkpoint proteins or receptors and / or with one or more stimulators, activators or agonists of one or more stimulatory immune checkpoint proteins or receptors. Blockade or inhibition of inhibitory immune checkpoints can positively regulate T-cell or NK cell activation and prevent immune escape of cancer cells within the tumor microenvironment. Activation or stimulation of stimulatory immune check points can augment the effect of immune checkpoint inhibitors in cancer therapeutics. In some embodiments, the immune checkpoint proteins or receptors regulate T cell responses (e.g., reviewed in Xu, et al., J Exp Clin Cancer Res. (2018) 37:110). In some embodiments, the immune checkpoint proteins or receptors regulate NK cell responses (e.g., reviewed in Davis, et al., Semin Immunol. (2017) 31:64–75 and Chiossone, et al., Nat Rev Immunol. (2018) 18(11):671-688). Inhibition of regulatory T-cells (Treg) or Treg depletion can alleviate their suppression of antitumor immune responses and have anticancer effects (e.g., reviewed in Plitas and Rudensky, Annu. Rev. Cancer Biol. (2020) 4:459-77; Tanaka and Sakaguchi, Eur. J. Immunol. (2019) 49:1140-1146).

[0221] Examples of immune checkpoint proteins or receptors that can be combined with a compound provided herein, or pharmaceutically acceptable salt thereof, include CD27 (NCBI Gene ID: 939), CD70 (NCBI Gene ID: 970); CD40 (NCBI Gene ID: 958), CD40LG (NCBI Gene ID: 959); CD47 (NCBI Gene ID: 961), SIRPA (NCBI Gene ID: 140885); CD48 (SLAMF2; NCBI Gene ID: 962), transmembrane and immunoglobulin domain containing 2 (TMIGD2, CD28H; NCBI Gene ID: 126259), CD84 (LY9B, SLAMF5; NCBI Gene ID: 8832), CD96 (NCBI Gene ID: 10225), CD160 (NCBI Gene ID: 11126), MS4A1 (CD20; NCBI Gene ID: 931), CD244 (SLAMF4; NCBI Gene ID: 51744); CD276 (B7H3; NCBI Gene ID: 80381); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA; NCBI Gene ID: 64115); immunoglobulin superfamily member 11 (IGSF11, VSIG3; NCBI Gene ID: 152404); natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1, B7H6; NCBI Gene ID: 374383); HERV-H LTR-associating 2 (HHLA2, B7H7; NCBI Gene ID: 11148); inducible T cell co-stimulator (ICOS, CD278; NCBI Gene ID: 29851); inducible T cell co-stimulator ligand (ICOSLG, B7H2; NCBI Gene ID: 23308); TNF receptor superfamilymember 4 (TNFRSF4, OX40; NCBI Gene ID: 7293); TNF superfamily member 4 (TNFSF4, OX40L; NCBI Gene ID: 7292); TNFRSF8 (CD30; NCBI Gene ID: 943), TNFSF8 (CD30L; NCBI Gene ID: 944); TNFRSF10A (CD261, DR4, TRAILR1; NCBI Gene ID: 8797), TNFRSF9 (CD137; NCBI Gene ID: 3604), TNFSF9 (CD137L; NCBI Gene ID: 8744); TNFRSF10B (CD262, DR5, TRAILR2; NCBI Gene ID: 8795), TNFRSF10 (TRAIL; NCBI Gene ID: 8743); TNFRSF14 (HVEM, CD270; NCBI Gene ID: 8764), TNFSF14 (HVEML; NCBI Gene ID: 8740); CD272 (B and T lymphocyte associated (BTLA); NCBI Gene ID: 151888); TNFRSF17 (BCMA, CD269; NCBI Gene ID: 608), TNFSF13B (BAFF; NCBI Gene ID: 10673); TNFRSF18 (GITR; NCBI Gene ID: 8784), TNFSF18 (GITRL; NCBI Gene ID: 8995); MHC class I polypeptide- related sequence A (MICA; NCBI Gene ID: 100507436); MHC class I polypeptide-related sequence B (MICB; NCBI Gene ID: 4277); CD274 (CD274, PDL1, PD-L1; NCBI Gene ID: 29126); programmed cell death 1 (PDCD1, PD1, PD-1; NCBI Gene ID: 5133); cytotoxic T- lymphocyte associated protein 4 (CTLA4, CD152; NCBI Gene ID: 1493); CD80 (B7-1; NCBI Gene ID: 941), CD28 (NCBI Gene ID: 940); nectin cell adhesion molecule 2 (NECTIN2, CD112; NCBI Gene ID: 5819); CD226 (DNAM-1; NCBI Gene ID: 10666); Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155; NCBI Gene ID: 5817); PVR related immunoglobulin domain containing (PVRIG, CD112R; NCBI Gene ID: 79037); T cell immunoreceptor with Ig and ITIM domains (TIGIT; NCBI Gene ID: 201633); T cell immunoglobulin and mucin domain containing 4 (TIMD4; TIM4; NCBI Gene ID: 91937); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3; NCBI Gene ID: 84868); galectin 9 (LGALS9; NCBI Gene ID: 3965); lymphocyte activating 3 (LAG3, CD223; NCBI Gene ID: 3902); signaling lymphocytic activation molecule family member 1 (SLAMF1, SLAM, CD150; NCBI Gene ID: 6504); lymphocyte antigen 9 (LY9, CD229, SLAMF3; NCBI Gene ID: 4063); SLAM family member 6 (SLAMF6, CD352; NCBI Gene ID: 114836); SLAM family member 7 (SLAMF7, CD319; NCBI Gene ID: 57823); UL16 binding protein 1 (ULBP1; NCBI Gene ID: 80329); UL16 binding protein 2 (ULBP2; NCBI Gene ID: 80328); UL16 binding protein 3 (ULBP3; NCBI Gene ID: 79465); retinoic acid early transcript 1E (RAET1E; ULBP4; NCBI Gene ID: 135250); retinoic acid early transcript 1G (RAET1G; ULBP5; NCBI Gene ID: 353091); retinoic acid early transcript 1L (RAET1L; ULBP6; NCBI Gene ID: 154064); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1; NCBI Gene ID: 3811, e.g., lirilumab (IPH- 2102, IPH-4102)); killer cell lectin like receptor C1 (KLRC1, NKG2A, CD159A; NCBI Gene ID: 3821); killer cell lectin like receptor K1 (KLRK1, NKG2D, CD314; NCBI Gene ID: 22914); killer cell lectin like receptor C2 (KLRC2, CD159c, NKG2C; NCBI Gene ID: 3822); killer cell lectin like receptor C3 (KLRC3, NKG2E; NCBI Gene ID: 3823); killer cell lectin like receptor C4(KLRC4, NKG2F; NCBI Gene ID: 8302); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1; NCBI Gene ID: 3802); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2; NCBI Gene ID: 3803); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3; NCBI Gene ID: 3804); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin like receptor D1 (KLRD1; NCBI Gene ID: 3824); killer cell lectin like receptor G1 (KLRG1; CLEC15A, MAFA, 2F1; NCBI Gene ID: 10219); sialic acid binding Ig like lectin 7 (SIGLEC7; NCBI Gene ID: 27036); and sialic acid binding Ig like lectin 9 (SIGLEC9; NCBI Gene ID: 27180).

[0222] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with one or more blockers or inhibitors of one or more T-cell inhibitory immune checkpoint proteins or receptors. Illustrative T-cell inhibitory immune checkpoint proteins or receptors include CD274 (CD274, PDL1, PD-L1); programmed cell death 1 ligand 2 (PDCD1LG2, PD-L2, CD273); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152); CD276 (B7H3); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); PVR related immunoglobulin domain containing (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); lymphocyte activating 3 (LAG3, CD223); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); and killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1). In some embodiments, the compound or pharmaceutically acceptable salt thereof provided herein is administered with one or more agonist or activators of one or more T-cell stimulatory immune checkpoint proteins or receptors. Illustrative T-cell stimulatory immune checkpoint proteins or receptors include without limitation CD27, CD70; CD40, CD40LG; inducible T cell costimulator (ICOS, CD278); inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptorsuperfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7- 1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); CD244 (2B4, SLAMF4), Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155). See, e.g., Xu, et al., J Exp Clin Cancer Res. (2018) 37:110.

[0223] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with one or more blockers or inhibitors of one or more NK-cell inhibitory immune checkpoint proteins or receptors. Illustrative NK-cell inhibitory immune checkpoint proteins or receptors include killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin like receptor C1 (KLRC1, NKG2A, CD159A); killer cell lectin like receptor D1 (KLRD1, CD94), killer cell lectin like receptor G1 (KLRG1; CLEC15A, MAFA, 2F1); sialic acid binding Ig like lectin 7 (SIGLEC7); and sialic acid binding Ig like lectin 9 (SIGLEC9). In some embodiments the compound or pharmaceutically acceptable salt thereof provided herein is administered with one or more agonist or activators of one or more NK-cell stimulatory immune checkpoint proteins or receptors. Illustrative NK-cell stimulatory immune checkpoint proteins or receptors include CD16, CD226 (DNAM-1); CD244 (2B4, SLAMF4); killer cell lectin like receptor K1 (KLRK1, NKG2D, CD314); SLAM family member 7 (SLAMF7). See, e.g., Davis, et al., Semin Immunol. (2017) 31:64–75; Fang, et al., Semin Immunol. (2017) 31:37-54; and Chiossone, et al., Nat Rev Immunol. (2018) 18(11):671-688.

[0224] In some embodiments the one or more immune checkpoint inhibitors comprise a proteinaceous (e.g., antibody or fragment thereof, or antibody mimetic) inhibitor of PD-L1 (CD274), PD-1 (PDCD1), CTLA4, or TIGIT. In some embodiments the one or more immune checkpoint inhibitors comprise a small organic molecule inhibitor of PD-L1 (CD274), PD-1 (PDCD1), CTLA4, or TIGIT. In some embodiments the one or more immune checkpoint inhibitors comprise a proteinaceous (e.g., antibody or fragment thereof, or antibody mimetic) inhibitor of LAG3.

[0225] Examples of inhibitors of CTLA4 that can be co-administered include ipilimumab, tremelimumab, BMS-986218, AGEN1181, zalifrelimab (AGEN1884), BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002 (ipilimumab biosimilar), BCD-145, APL-509, JS-007, BA- 3071, ONC-392, AGEN-2041, HBM-4003, JHL-1155, KN-044, CG-0161, ATOR-1144, PBI- 5D3H5, BPI-002, as well as multi-specific inhibitors FPT-155 (CTLA4 / PD-L1 / CD28), PF- 06936308 (PD-1 / CTLA4), MGD-019 (PD-1 / CTLA4), KN-046 (PD-1 / CTLA4), MEDI-5752 (CTLA4 / PD-1), XmAb-20717 (PD-1 / CTLA4), and AK-104 (CTLA4 / PD-1).

[0226] Examples of inhibitors of PD-L1 (CD274) or PD-1 (PDCD1) that can be co-administered include pembrolizumab, nivolumab, cemiplimab, pidilizumab, AMP-224, MEDI0680 (AMP- 514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS-936559, cosibelimab (CK-301), sasanlimab (PF-06801591), tislelizumab (BGB-A317), GLS-010 (WBP-3055), AK-103 (HX- 008), AK-105, CS-1003, HLX-10, retifanlimab (MGA-012), BI-754091, balstilimab (AGEN- 2034), AMG-404, toripalimab (JS-001), cetrelimab (JNJ-63723283), genolimzumab (CBT-501), LZM-009, prolgolimab (BCD-100), lodapolimab (LY-3300054), SHR-1201, camrelizumab (SHR-1210), Sym-021, budigalimab (ABBV-181), PD1-PIK, BAT-1306, avelumab (MSB0010718C), CX-072, CBT-502, dostarlimab (TSR-042), MSB-2311, JTX-4014, BGB- A333, SHR-1316, CS-1001 (WBP-3155, envafolimab (KN-035), sintilimab (IBI-308), HLX-20, KL-A167, STI-A1014, STI-A1015 (IMC-001), BCD-135, FAZ-053, TQB-2450, MDX1105-01, GS-4224, GS-4416, INCB086550, MAX10181, zimberelimab (AB122), spartalizumab (PDR- 001), and compounds disclosed in WO2018195321, WO2020014643, WO2019160882, or WO2018195321, as well as multi-specific inhibitors FPT-155 (CTLA4 / PD-L1 / CD28), PF- 06936308 (PD-1 / CTLA4), MGD-013 (PD-1 / LAG-3), FS-118 (LAG-3 / PD-L1), RO-7247669 (PD-1 / LAG-3), MGD-019 (PD-1 / CTLA4), KN-046 (PD-1 / CTLA4), MEDI-5752 (CTLA4 / PD- 1), RO-7121661 (PD-1 / TIM-3), RG7769 (PD-1 / TIM-3), TAK-252 (PD-1 / OX40L), XmAb-20717 (PD-1 / CTLA4), AK-104 (CTLA4 / PD-1), FS-118 (LAG-3 / PD-L1), FPT-155 (CTLA4 / PD- L1 / CD28), GEN-1046 (PD-L1 / 4-1BB), bintrafusp alpha (M7824; PD-L1 / TGFβ-EC domain), CA-170 (PD-L1 / VISTA), CDX-527 (CD27 / PD-L1), LY-3415244 (TIM3 / PDL1), and INBRX- 105 (4-1BB / PDL1). In some embodiments the PD-L1 inhibitor is a small molecule inhibitor, such as CA-170, GS-4224, GS-4416 and lazertinib (GNS-1480; PD-L1 / EGFR).

[0227] Examples of inhibitors of TIGIT that can be co-administered include tiragolumab (RG-6058), vibostolimab, domvanalimab (AB154), AB308, BMS-986207, AGEN-1307, COM-902, or etigilimab.

[0228] Examples of inhibitors of LAG3 that can be co-administered include leramilimab (LAG525).

[0229] Inhibition of regulatory T-cell (Treg) activity or Treg depletion can alleviate their suppression of antitumor immune responses and have anticancer effects. See, e.g., Plitas and Rudensky, Annu. Rev. Cancer Biol. (2020) 4:459-77; Tanaka and Sakaguchi, Eur. J. Immunol. (2019) 49:1140-1146. In some embodiments, a compound of Formula (I), (Ia), (Ib), or (Ic) provided herein, or pharmaceutically acceptable salt thereof, provided herein is administered with one or more inhibitors of Treg activity or a Treg depleting agent. Treg inhibition or depletion can augment the effect of immune checkpoint inhibitors in cancer therapeutics.

[0230] In some embodiments compound or pharamaceutically acceptable salt thereof provided herein is administered with one or more Treg inhibitors. In some embodiments the Treg inhibitor can suppress the migration of Tregs into the tumor microenvironment. In some embodiments Treg inhibitor can reduce the immunosuppressive function of Tregs. In some embodiments, the Treg inhibitor can modulate the cellular phenotype and induce production of proinflammatory cytokines. Exemplary Treg inhibitors include, without limitation, CCR4 (NCBI Gene ID: 1233) antagonists and degraders of Ikaros zinc-finger proteins (e.g., Ikaros (IKZF1; NCBI Gene ID: 10320), Helios (IKZF2; NCBI Gene ID: 22807), Aiolos (IKZF3; NCBI Gene ID: 22806), and Eos (IKZF4; NCBI Gene ID: 64375).

[0231] Examples of Helios degraders that can be co-administered include without limitation I-57 (Novartis) and compounds disclosed in WO2019038717, WO2020012334, WO20200117759, and WO2021101919.

[0232] In some embodiments a compound or pharmaceutically acceptable salt thereof provided herein is administered with one or more Treg depleting agents. In some embodiments the Treg depleting agent is an antibody. In some embodiments the Treg depleting antibody has antibody- dependent cytotoxic (ADCC) activity. In some embodiments, the Treg depleting antibody is Fc- engineered to possess an enhanced ADCC activity. In some embodiments the Treg depleting antibody is an antibody-drug conjugate (ADC). Illustrative targets for Treg depleting agents include without limitation CD25 (IL2RA; NCBI Gene ID: 3559), CTLA4 (CD152; NCBI Gene ID: 1493); GITR (TNFRSF18; NCBI Gene ID: 8784); 4-1BB (CD137; NCBI Gene ID: 3604), OX-40 (CD134; NCBI Gene ID: 7293), LAG3 (CD223; NCBI Gene ID: 3902), TIGIT (NCBI Gene ID: 201633), CCR4 (NCBI Gene ID: 1233), and CCR8 (NCBI Gene ID: 1237).

[0233] In some embodiments the Treg inhibitor or Treg depleting agent that can be co- administered comprises an antibody or antigen-binding fragment thereof that selectively binds to a cell surface receptor selected from the group consisting of C-C motif chemokine receptor 4 (CCR4), C-C motif chemokine receptor 7 (CCR7), C-C motif chemokine receptor 8 (CCR8), C- X-C motif chemokine receptor 4 (CXCR4; CD184), TNFRSF4 (OX40), TNFRSF18 (GITR, CD357), TNFRSF9 (4-1BB, CD137), cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152), programmed cell death 1 (PDCD1, PD-1), Sialyl Lewis x (CD15s), CD27, ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1; CD39), protein tyrosine phosphatase receptor type C (PTPRC; CD45), neural cell adhesion molecule 1 (NCAM1; CD56), selectin L (SELL; CD62L), integrin subunit alpha E (ITGAE; CD103), interleukin 7 receptor (IL7R; CD127), CD40 ligand (CD40LG; CD154), folate receptor alpha (FOLR1), folate receptor beta (FOLR2), leucine rich repeat containing 32 (LRRC32; GARP), IKAROS family zinc finger 2 (IKZF2; HELIOS), inducible T cell costimulatory (ICOS; CD278), lymphocyte activating 3 (LAG3; CD223), transforming growth factor beta 1 (TGFB1), hepatitis A virus cellular receptor 2 (HAVCR2; CD366; TIM3), T cell immunoreceptor with Ig and ITIM domains (TIGIT), TNF receptor superfamily member 1B (CD120b; TNFR2), IL2RA (CD25) or a combination thereof.

[0234] Examples of Treg depleting anti-CCR8 antibodies that can be administered include without limitation JTX-1811 (GS-1811) (Jounce Therapeutics, Gilead Sciences), BMS-986340 (Bristol Meyers Squibb), S-531011 (Shionogi), FPA157 (Five Prime Therapeutics), SRF-114 (Surface Oncology), HBM1022 (Harbor BioMed), IO-1 (Oncurious), and antibodies disclosed in WO2021163064, WO2020138489, and WO2021152186.

[0235] Examples of Treg depleting anti-CCR4 antibodies that can be administered include mogamulizumab.

[0236] Inhibiting, depleting, or reprogramming of non-stimulatory myeloid cells in the tumor microenvironment can enhance anti-cancer immune responses (see, e.g., Binnewies et al., Nat. Med. (2018) 24(5): 541-550; WO2016049641). Illustrative targets for depleting or reprogramming non-stimmulatory myeloid cells include triggering receptors expressed on myeloid cells, TREM-1 (CD354, NCBI Gene ID: 54210) and TREM-2 (NCBI Gene ID: 54209). In some embodiments a compound or pharmaceutically acceptable salt thereof provided herein is administered with one or more myeloid cell depleting or reprogramming agents, such as an anti-TREM-1 antibody (e.g. PY159; antibodies disclosed in WO2019032624) or an anti-TREM-2 antibody (e.g., PY314; antibodies disclosed in WO2019118513).Cluster of Differentiation Agonists or Activators

[0237] In some embodiments, a compound of Formula (I), (Ia), (Ib), or (Ic) provided herein, or pharmaceutically acceptable salt thereof, is administered with agents targeting a cluster of differentiation (CD) marker. Exemplary CD marker targeting agents that can be co-administered include without limitation A6, AD-IL24, neratinib, tucatinib (ONT 380), mobocertinib (TAK- 788), tesevatinib, trastuzumab (HERCEPTIN®), trastuzumab biosimimar (HLX-02), margetuximab, BAT-8001, pertuzumab (Perjeta), pegfilgrastim, RG6264, zanidatamab (ZW25), cavatak, AIC-100, tagraxofusp (SL-401), HLA-A2402 / HLA-A0201 restricted epitope peptide vaccine, dasatinib, imatinib, nilotinib, sorafenib, lenvatinib mesylate, ofranergene obadenovec, cabozantinib malate, AL-8326, ZLJ-33, KBP-7018, sunitinib malate, pazopanib derivatives, AGX-73, rebastinib, NMS-088, lucitanib hydrochloride, midostaurin, cediranib, dovitinib, sitravatinib, tivozanib, masitinib, regorafenib, olverembatinib dimesylate (HQP-1351), cabozantinib, ponatinib, and famitinib L-malate, CX-2029 (ABBV-2029), SCB-313, CA-170, COM-701, CDX-301, GS-3583, asunercept (APG-101), APO-010, and compounds disclosed in WO2016196388, WO2016033570, WO2015157386, WO199203459, WO199221766, WO2004080462, WO2005020921, WO2006009755, WO2007078034, WO2007092403, WO2007127317, WO2008005877, WO2012154480, WO2014100620, WO2014039714, WO2015134536, WO2017167182, WO2018112136, WO2018112140, WO2019155067, WO2020076105, PCT / US2019 / 063091, WO19173692, WO2016179517, WO2017096179, WO2017096182, WO2017096281, WO2018089628, WO2017096179, WO2018089628, WO2018195321, WO2020014643, WO2019160882, WO2018195321, WO200140307, WO2002092784, WO2007133811, WO2009046541, WO2010083253, WO2011076781, WO2013056352, WO2015138600, WO2016179399, WO2016205042, WO2017178653, WO2018026600, WO2018057669, WO2018107058, WO2018190719, WO2018210793, WO2019023347, WO2019042470, WO2019175218, WO2019183266, WO2020013170, WO2020068752, Cancer Discov. 2019 Jan 9(1):8; and Gariepy J., et al. 106th Annu Meet Am Assoc Immunologists (AAI) (May 9-13, San Diego, 2019, Abst 71.5).

[0238] In some embodiments the CD marker targeting agents that can be co-administered include small molecule inhibitors, such as PBF-1662, BLZ-945, pemigatinib (INCB-054828), rogaratinib (BAY-1163877), AZD4547, roblitinib (FGF-401), quizartinib dihydrochloride, SX- 682, AZD-5069, PLX-9486, avapritinib (BLU-285), ripretinib (DCC-2618), imatinib mesylate, JSP-191, BLU-263, CD117-ADC, AZD3229, telatinib, vorolanib, GO-203-2C, AB-680, PSB- 12379, PSB-12441, PSB-12425, CB-708, HM-30181A, motixafortide (BL-8040), LY2510924,burixafor (TG-0054), X4P-002, mavorixafor (X4P-001-IO), plerixafor, CTX-5861, and REGN- 5678 (PSMA / CD28).

[0239] In some embodiments the CD marker targeting agent that can be co-administered include small molecule agonists, such as interleukin 2 receptor subunit gamma, eltrombopag, rintatolimod, poly-ICLC (NSC-301463), Riboxxon, Apoxxim, RIBOXXIM®, MCT-465, MCT- 475, G100, PEPA-10, eftozanermin alfa (ABBV-621), E-6887, motolimod, resiquimod, selgantolimod (GS-9688), VTX-1463, NKTR-262, AST-008, CMP-001, cobitolimod, tilsotolimod, litenimod, MGN-1601, BB-006, IMO-8400, IMO-9200, agatolimod, DIMS-9054, DV-1079, lefitolimod (MGN-1703), CYT-003, and PUL-042.

[0240] In some embodiments the CD marker targeting agent that can be co-administered include antibodies, such as tafasitamab (MOR208; MorphoSys AG), Inebilizumab (MEDI-551), obinutuzumab, IGN-002, rituximab biosimilar (PF-05280586), varlilumab (CDX-1127), AFM-13 (CD16 / CD30), AMG330, otlertuzumab (TRU-016), isatuximab, felzartamab (MOR-202), TAK- 079, TAK573, daratumumab (DARZALEX®), TTX-030, selicrelumab (RG7876), APX-005M, ABBV-428, ABBV-927, mitazalimab (JNJ-64457107), lenziluma, alemtuzuma, emactuzumab, AMG-820, FPA-008 (cabiralizumab), PRS-343 (CD-137 / Her2), AFM-13 (CD16 / CD30), belantamab mafodotin (GSK-2857916), AFM26 (BCMA / CD16A), simlukafusp alfa (RG7461), urelumab, utomilumab (PF-05082566), AGEN2373, ADG-106, BT-7480, PRS-343 (CD- 137 / HER2), FAP-4-IBBL (4-1BB / FAP), ramucirumab, CDX-0158, CDX-0159 and FSI-174, relatlimab (ONO-4482), LAG-525, MK-4280, fianlimab (REGN-3767), INCAGN2385, encelimab (TSR-033), atipotuzumab, BrevaRex (Mab-AR-20.5), MEDI-9447 (oleclumab), CPX- 006, IPH-53, BMS-986179, NZV-930, CPI-006, PAT-SC1, lirilumab (IPH-2102), lacutamab (IPH-4102), monalizumab, BAY-1834942, NEO-201 (CEACAM 5 / 6), Iodine (131I) apamistamab (131I-BC8 (lomab-B)), MEDI0562 (tavolixizumab), GSK-3174998, INCAGN1949, BMS-986178, GBR-8383, ABBV-368, denosumab, BION-1301, MK-4166, INCAGN-1876, TRX-518, BMS-986156, MK-1248, GWN-323, CTB-006, INBRX-109, GEN- 1029, pepinemab (VX-15), vopratelimab (JTX-2011), GSK3359609, cobolimab (TSR-022), MBG-453, INCAGN-2390, and compounds disclosed in WO^2017096179, WO2017096276, WO2017096189, and WO2018089628.

[0241] In some embodiments the CD marker targeting agent that can be co-administered include cell therapies, such as CD19-ARTEMIS, TBI-1501, CTL-119 huCART-19 T cells, l iso-cel, lisocabtagene maraleucel (JCAR-017), axicabtagene ciloleucel (KTE-C19, Yescarta®),axicabtagene ciloleucel (KTE-X19), US7741465, US6319494, UCART-19, tabelecleucel (EBV- CTL), T tisagenlecleucel-T (CTL019), CD19CAR-CD28-CD3zeta-EGFRt-expressing T cells, CD19 / 4-1BBL armored CAR T cell therapy, C-CAR-011, CIK-CAR.CD19, CD19CAR-28-zeta T cells, PCAR-019, MatchCART, DSCAR-01, IM19 CAR-T, TC-110, anti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia, Universiti Kebangsaan Malaysia), anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia / Non-Hodgkin's lymphoma, University Hospital Heidelberg), anti-CD19 CAR T-cell therapy (silenced IL-6 expression, cancer, Shanghai Unicar- Therapy Bio-medicine Technology), MB-CART2019.1 (CD19 / CD20), GC-197 (CD19 / CD7), CLIC-1901, ET-019003, anti-CD19-STAR-T cells, AVA-001, BCMA-CD19 cCAR (CD19 / APRIL), ICG-134, ICG-132 (CD19 / CD20), CTA-101, WZTL-002, dual anti-CD19 / anti- CD20 CAR T-cells (chronic lymphocytic leukemia / B-cell lymphomas), HY-001, ET-019002, YTB-323, GC-012 (CD19 / APRIL), GC-022 (CD19 / CD22), CD19CAR-CD28-CD3zeta-EGFRt- expressing Tn / mem, UCAR-011, ICTCAR-014, GC-007F, PTG-01, CC-97540, GC-007G, TC- 310, GC-197, tisagenlecleucel-T, CART-19, tisagenlecleucel (CTL-019)), anti-CD20 CAR T-cell therapy (non-Hodgkin's lymphoma), MB-CART2019.1 (CD19 / CD20), WZTL-002 dual anti- CD19 / anti-CD20 CAR-T cells, ICG-132 (CD19 / CD20), ACTR707 ATTCK-20, PBCAR-20A, LB-1905, CIK-CAR.CD33, CD33CART, dual anti-BCMA / anti-CD38 CAR T-cell therapy, CART-ddBCMA, MB-102, IM-23, JEZ-567, UCART-123, PD-1 knockout T cell therapy (esophageal cancer / NSCLC), ICTCAR-052, Tn MUC-1 CAR-T, ICTCAR-053, PD-1 knockout T cell therapy (esophageal cancer / NSCLC), AUTO-2, anti-BCMA CAR T-cell therapy, Descartes-011, anti-BCMA / anti-CD38 CAR T-cell therapy, CART-ddBCMA, BCMA-CS1 cCAR, CYAD-01 (NKG2D LIGAND MODULATOR), KD-045, PD-L1 t-haNK, BCMA-CS1 cCAR, MEDI5083, anti-CD276 CART, and therapies disclosed in WO2012079000 or WO2017049166. Cluster of Differentiation 47 (CD47) Inhibitors

[0242] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIIa), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), or (IVa-2), provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of CD47 (IAP, MER6, OA3; NCBI Gene ID: 961). Examples of CD47 inhibitors include anti-CD47 mAbs (Vx-1004), anti-human CD47 mAbs (CNTO-7108), CC-90002, CC-90002-ST-001, humanized anti-CD47 antibody or a CD47-blocking agent, NI-1701, NI-1801, RCT-1938, ALX148, SG-404, SRF-231, and TTI-621. Additional exemplary anti-CD47 antibodies include CC-90002, magrolimab (Hu5F9-G4), AO-176 (Vx-1004), letaplimab (IBI-188) (letaplimab), lemzoparlimab(TJC-4), SHR-1603, HLX-24, LQ-001, IMC-002, ZL-1201, IMM-01, B6H12, GenSci-059, TAY- 018, PT-240, 1F8-GMCSF, SY-102, KD-015, ALX-148, AK-117, TTI-621, TTI-622, or compounds disclosed in WO199727873, WO199940940, WO2002092784, WO2005044857, WO2009046541, WO2010070047, WO2011143624, WO2012170250, WO2013109752, WO2013119714, WO2014087248, WO2015191861, WO2016022971, WO2016023040, WO2016024021, WO2016081423, WO2016109415, WO2016141328, WO2016188449, WO2017027422, WO2017049251, WO2017053423, WO2017121771, WO2017194634, WO2017196793, WO2017215585, WO2018075857, WO2018075960, WO2018089508, WO2018095428, WO2018137705, WO2018233575, WO2019027903, WO2019034895, WO2019042119, WO2019042285, WO2019042470, WO2019086573, WO2019108733, WO2019138367, WO2019144895, WO2019157843, WO2019179366, WO2019184912, WO2019185717, WO2019201236, WO2019238012, WO2019241732, WO2020019135, WO2020036977, WO2020043188, and WO2020009725. In some embodiments, the CD47 inhibitor is RRx-001, DSP-107, VT-1021, IMM-02, SGN-CD47M, or SIRPa‐Fc‐CD40L (SL- 172154). In some embodiments the CD47 inhibitor is magrolimab.

[0243] In some embodiments, the CD47 inhibitor is a bispecific antibodies targeting CD47, such as IBI-322 (CD47 / PD-L1), IMM-0306 (CD47 / CD20), TJ-L1C4 (CD47 / PD-L1), HX-009 (CD47 / PD-1), PMC-122 (CD47 / PD-L1), PT-217, (CD47 / DLL3), IMM-26011 (CD47 / FLT3), IMM-0207 (CD47 / VEGF), IMM-2902 (CD47 / HER2), BH29xx (CD47 / PD-L1), IMM-03 (CD47 / CD20), IMM-2502 (CD47 / PD-L1), HMBD-004B (CD47 / BCMA), HMBD-004A (CD47 / CD33), TG-1801 (NI-1701), or NI-1801. SIRPα Targeting Agents

[0244] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with a SIRPα targeting agent (NCBI Gene ID: 140885; UniProt P78324). Examples of SIRPα targeting agents that can be co-administered include SIRPα inhibitors, such as AL-008, RRx-001, and CTX-5861, and anti-SIRPα antibodies, such as FSI- 189 (GS-0189), ES-004, BI-765063, ADU1805, CC-95251, Q-1801 (SIRPα / PD-L1). Additional SIRPα-targeting agents of use are described, for example, in WO200140307, WO2002092784, WO2007133811, WO2009046541, WO2010083253, WO2011076781, WO2013056352, WO2015138600, WO2016179399, WO2016205042, WO2017178653, WO2018026600,WO2018057669, WO2018107058, WO2018190719, WO2018210793, WO2019023347, WO2019042470, WO2019175218, WO2019183266, WO2020013170 and WO2020068752. FLT3R Agonists

[0245] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with a FLT3R agonist. In some embodiments, the compound provided herein, or pharmaceutically acceptable salt thereof, is administered with a FLT3 ligand. In some embodiments, the compound provided herein, or pharmaceutically acceptable salt thereof, is administered with a FLT3L-Fc fusion protein, e.g., as described in WO2020263830. In some embodiments the compound provided herein, or pharmaceutically acceptable salt thereof, is administered with GS-3583 or CDX-301. In some embodiments the compound provided herein, or pharmaceutically acceptable salt thereof, is administered with GS-3583. TNF Receptor Superfamily (TNFRSF) Member Agonists or Activators

[0246] In some embodiments, a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an agonist of one or more TNF receptor superfamily (TNFRSF) members, e.g., an agonist of one or more of TNFRSF1A (NCBI Gene ID: 7132), TNFRSF1B (NCBI Gene ID: 7133), TNFRSF4 (OX40, CD134; NCBI Gene ID: 7293), TNFRSF5 (CD40; NCBI Gene ID: 958), TNFRSF6 (FAS, NCBI Gene ID: 355), TNFRSF7 (CD27, NCBI Gene ID: 939), TNFRSF8 (CD30, NCBI Gene ID: 943), TNFRSF9 (4-1BB, CD137, NCBI Gene ID: 3604), TNFRSF10A (CD261, DR4, TRAILR1, NCBI Gene ID: 8797), TNFRSF10B (CD262, DR5, TRAILR2, NCBI Gene ID: 8795), TNFRSF10C (CD263, TRAILR3, NCBI Gene ID: 8794), TNFRSF10D (CD264, TRAILR4, NCBI Gene ID: 8793), TNFRSF11A (CD265, RANK, NCBI Gene ID: 8792), TNFRSF11B (NCBI Gene ID: 4982), TNFRSF12A (CD266, NCBI Gene ID: 51330), TNFRSF13B (CD267, NCBI Gene ID: 23495), TNFRSF13C (CD268, NCBI Gene ID: 115650), TNFRSF16 (NGFR, CD271, NCBI Gene ID: 4804), TNFRSF17 (BCMA, CD269, NCBI Gene ID: 608), TNFRSF18 (GITR, CD357, NCBI Gene ID: 8784), TNFRSF19 (NCBI Gene ID: 55504), TNFRSF21 (CD358, DR6, NCBI Gene ID: 27242), and TNFRSF25 (DR3, NCBI Gene ID: 8718).

[0247] Example anti-TNFRSF4 (OX40) antibodies that can be co-administered include MEDI6469, MEDI6383, tavolixizumab (MEDI0562), MOXR0916, PF-04518600, RG-7888, GSK-3174998, INCAGN1949, BMS-986178, GBR-8383, ABBV-368, and those described in WO2016179517, WO2017096179, WO2017096182, WO2017096281, and WO2018089628.

[0248] Example anti-TNFRSF5 (CD40) antibodies that can be co-administered include RG7876, SEA-CD40, APX-005M, and ABBV-428.

[0249] In some embodiments, the anti-TNFRSF7 (CD27) antibody varlilumab (CDX-1127) is co-administered.

[0250] Example anti-TNFRSF9 (4-1BB, CD137) antibodies that can be co-administered include urelumab, utomilumab (PF-05082566), AGEN-2373, and ADG-106.

[0251] In some embodiments the anti-TNFRSF17 (BCMA) antibody GSK-2857916 is co-administered.

[0252] Example anti-TNFRSF18 (GITR) antibodies that can be co-administered include MEDI1873, FPA-154, INCAGN-1876, TRX-518, BMS-986156, MK-1248, GWN-323, and those described in WO2017096179, WO2017096276, WO2017096189, and WO2018089628. In some embodiments, an antibody, or fragment thereof, co-targeting TNFRSF4 (OX40) and TNFRSF18 (GITR) is co-administered. Such antibodies are described, e.g., in WO2017096179 and WO2018089628.

[0253] Bi-specific antibodies targeting TNFRSF family members that can be co-administered include PRS-343 (CD-137 / HER2), AFM26 (BCMA / CD16A), AFM-13 (CD16 / CD30), odronextamab (REGN-1979; CD20 / CD3), AMG-420 (BCMA / CD3), INHIBRX-105 (4- 1BB / PDL1), FAP-4-IBBL (4-1BB / FAP), plamotamab (XmAb-13676; CD3 / CD20), RG-7828 (CD20 / CD3), CC-93269 (CD3 / BCMA), REGN-5458 (CD3 / BCMA), and IMM-0306 (CD47 / CD20). TGFβ Antagonists

[0254] In some embodiments, a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with a TGFβ antagonist. In some embodiments, the TGFβ antagonistis a TGFβ -specific antibody. TGFβ -specific antibodies can be prepared and characterized using methods known to those of skill in the art, such as those described in PCT International Application Publication No. WO 2018 / 129329 and in U.S. Patent No. 9,518,112. In some embodiments, the TGFβ antagonist binds to a TGFβ latency-associated peptide (LAP), e.g., TGFβ 1-LAP. TGFβ 1-LAP-specific antibodies can be prepared and characterized using methods known to those of skill in the art, such as those described in U.S. Patent No. 8,198,412 or U.S. Patent No. 10,017,567. In some embodiments, the TGFβ antagonist binds to TGFβ (e.g., TGFβ 1) in a context independent manner (e.g., independent of the presentation of TGF β in a specific tissue or organ). In some embodiments, the TGFβ antagonist binds to TGFβ (e.g., TGFβ 1) in a context-dependent manner. In some embodiments, the TGFβ antagonist blocks activation of latent TGFβ (e.g., latent TGFβ 1) that is localized in extracellular matrix, e.g., in connective tissue of the liver. In some embodiments, the TGFβ antagonist blocks activation of latent TGFβ (e.g., latent TGFβ 1) that is localized in the thymus, a lymph node, or in a tumor microenvironment (e.g., in a patient having liver cancer). In some embodiments, the TGFβ antagonist blocks activation of latent TGFβ (e.g., latent TGFβ 1) by Latent TGFβ Binding Protein (LTBP). In some embodiments, the TGFβ antagonist blocks activation of latent TGFβ (e.g., latent TGFβ 1) by Glycoprotein-A Repetitions Predominant protein (GARP), as described, e.g., in U.S. Patent No. 10,000,572. In some embodiments, the TGFβ antagonist is ARGX-115. In some embodiments, the TGFβ antagonist is SK-181. In some embodiments, the TGFβ antagonist is an anti-latency- associated peptide (LAP) antibody that specifically binds to a LAP-TGFβ complex. In some embodiments, the anti-LAP antibody specifically binds to LAP-TGFβ complexes in extracellular matrix (ECM), e.g., of connective tissue in the liver. In some embodiments, the anti-LAP antibody specifically binds to LAP-TGFβ complexes on the surfaces of certain immunosuppressive cell types, such as regulatory T cells (Tregs), tumor-associated macrophages, or myeloid-derived suppressor cells, e.g., in a tumor microenvironment. In some embodiments, the anti-LAP antibody is a TLS-01 antibody. In some embodiments, the anti-LAP antibody specifically binds to LAP- TGFβ complexes in any context. In some embodiments, the anti-LAP antibody is a TLS-02 antibody. In some embodiments, the TGFβ antagonist comprises a TGFβ receptor. In some embodiments, the TGFβ antagonist is a TGFβ receptor-Fc fusion protein. In some embodiments, the TGFβ antagonist is an antibody comprising a TGFβ receptor. TGFβ antagonists comprising a TGFβ receptor that can be useful in connection with the compositions and methods providedherein have been described, e.g., in PCT International Publication Nos. WO 2019 / 113123 A1 and WO 2019 / 113464 A1. Bi-Specific T-Cell Engagers

[0255] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with a bi-specific T-cell engager (e.g., not having an Fc) or an anti- CD3 bi-specific antibody (e.g., having an Fc). Illustrative anti-CD3 bi-specific antibodies or BiTEs that can be co-administered include duvortuxizumab (JNJ-64052781; CD19 / CD3), AMG- 211 (CEA / CD3), AMG-160 (PSMA / CD3), RG7802 (CEA / CD3), ERY-974 (CD3 / GPC3), PF- 06671008 (Cadherins / CD3), APVO436 (CD123 / CD3), flotetuzumab (CD123 / CD3), odronextamab (REGN-1979; CD20 / CD3), MCLA-117 (CD3 / CLEC12A), JNJ-0819 (heme / CD3), JNJ-7564 (CD3 / heme), AMG-757 (DLL3-CD3), AMG-330 (CD33 / CD3), AMG- 420 (BCMA / CD3), AMG-427 (FLT3 / CD3), AMG-562 (CD19 / CD3), AMG-596 (EGFRvIII / CD3), AMG-673 (CD33 / CD3), AMG-701 (BCMA / CD3), AMG-757 (DLL3 / CD3), AMG-211 (CEA / CD3), blinatumomab (CD19 / CD3), huGD2-BsAb (CD3 / GD2), ERY974 (GPC3 / CD3), GEMoab (CD3 / PSCA), RG6026 (CD20 / CD3), RG6194 (HER2 / CD3), PF- 06863135 (BCMA / CD3), SAR440234 (CD3 / CDw123), JNJ-9383 (MGD-015), AMG-424 (CD38 / CD3), tidutamab (XmAb-18087 (SSTR2 / CD3)), JNJ-63709178 (CD123 / CD3), MGD-007 (CD3 / gpA33), MGD-009 (CD3 / B7H3), IMCgp100 (CD3 / gp100), XmAb-14045 (CD123 / CD3), XmAb-13676 (CD3 / CD20), tidutamab (XmAb-18087; SSTR2 / CD3), catumaxomab (CD3 / EpCAM), REGN-4018 (MUC16 / CD3), mosunetuzumab (RG-7828; CD20 / CD3), CC- 93269 (CD3 / BCMA), REGN-5458 (CD3 / BCMA), GRB-1302 (CD3 / Erbb2), GRB-1342 (CD38 / CD3), GEM-333 (CD3 / CD33). As appropriate, the anti-CD3 binding bi-specific molecules may or may not have an Fc. Illustrative bi-specific T-cell engagers that can be co- administered target CD3 and a tumor-associated antigen as described herein, including, e.g., CD19 (e.g., blinatumomab); CD33 (e.g., AMG330); CEA (e.g., MEDI-565); receptor tyrosine kinase- like orphan receptor 1 (ROR1) (Gohil, et al., Oncoimmunology. (2017) May 17;6(7):e1326437); PD-L1 (Horn, et al., Oncotarget. 2017 Aug 3;8(35):57964-57980); and EGFRvIII (Yang, et al., Cancer Lett. 2017 Sep 10;403:224-230).Bi-and Tri-Specific Natural Killer (NK)-Cell Engagers

[0256] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with a bi-specific NK-cell engager (BiKE) or a tri-specific NK-cell engager (TriKE) (e.g., not having an Fc) or bi-specific antibody (e.g., having an Fc) against an NK cell activating receptor, e.g., CD16A, C-type lectin receptors (CD94 / NKG2C, NKG2D, NKG2E / H and NKG2F), natural cytotoxicity receptors (NKp30, NKp44 and NKp46), killer cell C-type lectin-like receptor (NKp65, NKp80), Fc receptor FcγR (which mediates antibody- dependent cell cytotoxicity), SLAM family receptors (e.g., 2B4, SLAM6 and SLAM7), killer cell immunoglobulin-like receptors (KIR) (KIR-2DS and KIR-3DS), DNAM-1 and CD137 (41BB). Illustrative anti-CD16 bi-specific antibodies, BiKEs or TriKEs that can be co-administered include AFM26 (BCMA / CD16A) and AFM-13 (CD16 / CD30). As appropriate, the anti-CD16 binding bi-specific molecules may or may not have an Fc. Illustrative bi-specific NK-cell engagers that can be co-administered target CD16 and one or more tumor-associated antigens as described herein, including, e.g., CD19, CD20, CD22, CD30, CD33, CD123, EGFR, EpCAM, ganglioside GD2, HER2 / neu, HLA Class II and FOLR1. BiKEs and TriKEs are described, e.g., in Felices, et al., Methods Mol Biol. (2016) 1441:333–346; Fang, et al., Semin Immunol. (2017) 31:37-54. MCL1 apoptosis regulator, BCL2 family member (MCL1) Inhibitors

[0257] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of MCL1 apoptosis regulator, BCL2 family member (MCL1, TM; EAT; MCL1L; MCL1S; Mcl-1; BCL2L3; MCL1-ES; bcl2-L-3; mcl1 / EAT; NCBI Gene ID: 4170). Examples of MCL1 inhibitors include tapotoclax (AMG-176), AMG-397, S- 64315, AZD-5991, 483-LM, A-1210477, UMI-77, JKY-5-037, PRT-1419, GS-9716, and those described in WO2018183418, WO2016033486, and WO2017147410. SHP2 Inhibitors

[0258] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptablesalt thereof, is administered with an inhibitor of protein tyrosine phosphatase non-receptor type 11 (PTPN11; BPTP3, CFC, JMML, METCDS, NS1, PTP-1D, PTP2C, SH-PTP2, SH-PTP3, SHP2; NCBI Gene ID: 5781). Examples of SHP2 inhibitors include TNO155 (SHP-099), RMC- 4550, JAB-3068, RMC-4630, and those described in WO2018172984 and WO2017211303. Hematopoietic Progenitor Kinase 1 (HPK1) Inhibitors and Degraders

[0259] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1, HPK1; NCBI Gene ID: 11184). Examples of Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors include without limitation, those described in WO2020092621, WO2018183956, WO2018183964, WO2018167147, WO2018049152, WO2020092528, WO2016205942, WO2016090300, WO2018049214, WO2018049200, WO2018049191, WO2018102366, WO2018049152, and WO2016090300. Apoptosis Signal-Regulating Kinase (ASK) Inhibitors

[0260] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an ASK inhibitor, e.g., mitogen-activated protein kinase kinase kinase 5 (MAP3K5; ASK1, MAPKKK5, MEKK5; NCBI Gene ID: 4217). Examples of ASK1 inhibitors include those described in WO2011008709 (Gilead Sciences) and WO 2013112741 (Gilead Sciences). Bruton Tyrosine Kinase (BTK) Inhibitors

[0261] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of Bruton tyrosine kinase (BTK, AGMX1, AT, ATK, BPK, IGHD3, IMD1, PSCTK1, XLA; NCBI Gene ID: 695). Examples of BTK inhibitors include (S)-6-amino-9-(1-(but-2-ynoyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one, acalabrutinib (ACP-196), zanubrutinib (BGB-3111), CB988, HM71224, ibrutinib, M-2951(evobrutinib), M7583, tirabrutinib (ONO-4059), PRN-1008, spebrutinib (CC-292), TAK-020, vecabrutinib, ARQ-531, SHR-1459, DTRMWXHS-12, PCI-32765, and TAS-5315. Cyclin-dependent Kinase (CDK) Inhibitors

[0262] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of cyclin dependent kinase 1 (CDK1, CDC2; CDC28A; P34CDC2; NCBI Gene ID: 983); cyclin dependent kinase 2 (CDK2, CDKN2; p33(CDK2); NCBI Gene ID: 1017); cyclin dependent kinase 3 (CDK3, ; NCBI Gene ID: 1018); cyclin dependent kinase 4 (CDK4, CMM3; PSK-J3; NCBI Gene ID: 1019); cyclin dependent kinase 6 (CDK6, MCPH12; PLSTIRE; NCBI Gene ID: 1021); cyclin dependent kinase 7 (CDK7, CAK; CAK1; HCAK; MO15; STK1; CDKN7; p39MO15; NCBI Gene ID: 1022), or cyclin dependent kinase 9 (CDK9, TAK; C-2k; CTK1; CDC2L4; PITALRE; NCBI Gene ID: 1025). Inhibitors of CDK 1, 2, 3, 4, 6, 7 and / or 9, include abemaciclib, alvocidib (HMR-1275, flavopiridol), AT-7519, dinaciclib, ibrance, FLX-925, LEE001, palbociclib, samuraciclib, ribociclib, rigosertib, selinexor, UCN-01, SY1365, CT-7001, SY-1365, G1T38, milciclib, trilaciclib, simurosertib hydrate (TAK931), and TG-02. Discoidin Domain Receptor (DDR) Inhibitors

[0263] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is combined with an inhibitor of discoidin domain receptor tyrosine kinase 1 (DDR1, CAK, CD167, DDR, EDDR1, HGK2, MCK10, NEP, NTRK4, PTK3, PTK3A, RTK6, TRKE; NCBI Gene ID: 780); and / or discoidin domain receptor tyrosine kinase 2 (DDR2, MIG20a, NTRKR3, TKT, TYRO10, WRCN; NCBI Gene ID: 4921). Examples of DDR inhibitors include dasatinib and those disclosed in WO2014 / 047624 (Gilead Sciences), US 2009-0142345 (Takeda Pharmaceutical), US 2011-0287011 (Oncomed Pharmaceuticals), WO 2013 / 027802 (Chugai Pharmaceutical), and WO2013 / 034933 (Imperial Innovations). Targeted E3 Ligase Ligand Conjugates

[0264] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf),(IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with a targeted E3 ligase ligand conjugate. Such conjugates have a target protein binding moiety and an E3 ligase binding moiety (e.g., an inhibitor of apoptosis protein (IAP) (e.g., XIAP, c-IAP1, c-IAP2, NIL-IAP, Bruce, and surviving) E3 ubiquitin ligase binding moiety, Von Hippel-Lindau E3 ubiquitin ligase (VHL) binding moiety, a cereblon E3 ubiquitin ligase binding moiety, mouse double minute 2 homolog (MDM2) E3 ubiquitin ligase binding moiety),and can be used to promote or increase the degradation of targeted proteins, e.g., via the ubiquitin pathway. In some embodiments the targeted E3 ligase ligand conjugates comprise a targeting or binding moiety that targets or binds a protein described herein, and an E3 ligase ligand or binding moiety. In some embodiments the targeted E3 ligase ligand conjugates comprise a targeting or binding moiety that targets or binds a protein selected from Cbl proto- oncogene B (CBLB; Cbl-b, Nbla00127, RNF56; NCBI Gene ID: 868) and hypoxia inducible factor 1 subunit alpha (HIF1A; NCBI Gene ID: 3091). In some embodiments the targeted E3 ligase ligand conjugates comprise a kinase inhibitor (e.g., a small molecule kinase inhibitor, e.g., of BTK and an E3 ligase ligand or binding moiety. See, e.g., WO2018098280. In some embodiments the targeted E3 ligase ligand conjugates comprise a binding moiety targeting or binding to Interleukin-1 (IL-1) Receptor-Associated Kinase-4 (IRAK-4); Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and / or B-RAF), c-Met / p38, or a BRD protein; and an E3 ligase ligand or binding moiety. See, e.g., WO2019099926, WO2018226542, WO2018119448, WO2018223909, WO2019079701. Additional targeted E3 ligase ligand conjugates that can be co-administered are described, e.g., in WO2018237026, WO2019084026, WO2019084030, WO2019067733, WO2019043217, WO2019043208, and WO2018144649. Histone Deacetylase (HDAC) Inhibitors

[0265] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of a histone deacetylase, e.g., histone deacetylase 9 (HDAC9, HD7, HD7b, HD9, HDAC, HDAC7, HDAC7B, HDAC9B, HDAC9FL, HDRP, MITR; Gene ID: 9734). Examples of HDAC inhibitors include abexinostat, ACY-241, AR-42, BEBT- 908, belinostat, CKD-581, CS-055 (HBI-8000), CUDC-907 (fimepinostat), entinostat, givinostat, mocetinostat, panobinostat, pracinostat, quisinostat (JNJ-26481585), resminostat, ricolinostat, SHP-141, valproic acid (VAL-001), vorinostat, tinostamustine, remetinostat, and entinostat.Indoleamine-pyrrole-2,3-dioxygenase (IDO1) inhibitors

[0266] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; NCBI Gene ID: 3620). Examples of IDO1 inhibitors include BLV-0801, epacadostat, linrodostat (F- 001287, BMS-986205), GBV-1012, GBV-1028, GDC-0919, indoximod, NKTR-218, NLG-919- based vaccine, PF-06840003, pyranonaphthoquinone derivatives (SN-35837), resminostat, SBLK-200802, and shIDO-ST, EOS-200271, KHK-2455, and LY-3381916. Janus Kinase (JAK) Inhibitors

[0267] In some embodiments, a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of Janus kinase 1 (JAK1, JAK1A, JAK1B, JTK3; NCBI Gene ID: 3716); Janus kinase 2 (JAK2, JTK10, THCYT3; NCBI Gene ID: 3717); and / or Janus kinase 3 (JAK3, JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK; NCBI Gene ID: 3718). Examples of JAK inhibitors include AT9283, AZD1480, baricitinib, BMS-911543, fedratinib, filgotinib (GLPG0634), gandotinib (LY2784544), INCB039110 (itacitinib), lestaurtinib, momelotinib (CYT0387), ilginatinib maleate (NS-018), pacritinib (SB1518), peficitinib (ASP015K), ruxolitinib, tofacitinib (formerly tasocitinib), INCB052793, and XL019. Lysyl Oxidase-Like Protein (LOXL) Inhibitors

[0268] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of a LOXL protein, e.g., LOXL1 (NCBI Gene ID: 4016), LOXL2 (NCBI Gene ID: 4017), LOXL3 (NCBI Gene ID: 84695), LOXL4 (NCBI Gene ID: 84171), and / or LOX (NCBI Gene ID: 4015). Examples of LOXL2 inhibitors include the antibodies described in WO 2009017833 (Arresto Biosciences), WO 2009035791 (Arresto Biosciences), and WO 2011097513 (Gilead Biologics).Matrix Metalloprotease (MMP) Inhibitors

[0269] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of a matrix metallopeptidase (MMP), e.g., an inhibitor of MMP1 (NCBI Gene ID: 4312), MMP2 (NCBI Gene ID: 4313), MMP3 (NCBI Gene ID: 4314), MMP7 (NCBI Gene ID: 4316), MMP8 (NCBI Gene ID: 4317), MMP9 (NCBI Gene ID: 4318); MMP10 (NCBI Gene ID: 4319); MMP11 (NCBI Gene ID: 4320); MMP12 (NCBI Gene ID: 4321), MMP13 (NCBI Gene ID: 4322), MMP14 (NCBI Gene ID: 4323), MMP15 (NCBI Gene ID: 4324), MMP16 (NCBI Gene ID: 4325), MMP17 (NCBI Gene ID: 4326), MMP19 (NCBI Gene ID: 4327), MMP20 (NCBI Gene ID: 9313), MMP21 (NCBI Gene ID: 118856), MMP24 (NCBI Gene ID: 10893), MMP25 (NCBI Gene ID: 64386), MMP26 (NCBI Gene ID: 56547), MMP27 (NCBI Gene ID: 64066) and / or MMP28 (NCBI Gene ID: 79148). Examples of MMP9 inhibitors include marimastat (BB-2516), cipemastat (Ro 32-3555), GS-5745 (andecaliximab), and those described in WO 2012027721 (Gilead Biologics). RAS and RAS Pathway Inhibitors

[0270] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of KRAS proto-oncogene, GTPase (KRAS; a.k.a., NS; NS3; CFC2; RALD; K-Ras; KRAS1; KRAS2; RASK2; KI-RAS; C-K-RAS; K-RAS2A; K- RAS2B; K-RAS4A; K-RAS4B; c-Ki-ras2; NCBI Gene ID: 3845); NRAS proto-oncogene, GTPase (NRAS; a.k.a., NS6; CMNS; NCMS; ALPS4; N-ras; NRAS1; NCBI Gene ID: 4893) or HRAS proto-oncogene, GTPase (HRAS; a.k.a., CTLO; KRAS; HAMSV; HRAS1; KRAS2; RASH1; RASK2; Ki-Ras; p21ras; C-H-RAS; c-K-ras; H-RASIDX; c-Ki-ras; C-BAS / HAS; C- HA-RAS1; NCBI Gene ID: 3265). The Ras inhibitors can inhibit Ras at either the polynucleotide (e.g., transcriptional inhibitor) or polypeptide (e.g., GTPase enzyme inhibitor) level. In some embodiments, the inhibitors target one or more proteins in the Ras pathway, e.g., inhibit one or more of EGFR, Ras, Raf (A-Raf, B-Raf, C-Raf), MEK (MEK1, MEK2), ERK, PI3K, AKT and mTOR. Illustrative K-Ras inhibitors that can be co-administered include sotorasib (AMG-510), COTI-219, ARS-3248, WDB-178, BI-3406, BI-1701963, SML-8-73-1 (G12C), adagrasib (MRTX-849), ARS-1620 (G12C), SML-8-73-1 (G12C), Compound 3144 (G12D), Kobe0065 / 2602 (Ras GTP), RT11, MRTX-849 (G12C) and K-Ras(G12D)-selective inhibitorypeptides, including KRpep-2and KRpep-2d. Illustrative KRAS mRNA inhibitors include anti- KRAS U1 adaptor, AZD-4785, siG12D-LODER™, and siG12D exosomes. Illustrative MEK inhibitors that can be co-administered include binimetinib, cobimetinib, PD-0325901, pimasertib, RG-7304, selumetinib, trametinib, and those described below and herein. Illustrative Raf dimer inhibitors that can be co-administered include BGB-283, HM-95573, LXH-254, LY-3009120, RG7304 and TAK-580. Illustrative ERK inhibitors that can be co-administered include LTT-462, LY-3214996, MK-8353, ravoxertinib and ulixertinib. Illustrative Ras GTPase inhibitors that can be co-administered include rigosertib. Illustrative PI3K inhibitors that can be co-administered include idelalisib (Zydelig®), alpelisib, buparlisib, pictilisib, inavolisib (RG6114), ASN-003. Illustrative AKT inhibitors that can be co-administered include capivasertib and GSK2141795. Illustrative PI3K / mTOR inhibitors that can be co-administered include dactolisib, omipalisib, voxtalisib. gedatolisib, GSK2141795, GSK-2126458, inavolisib (RG6114), sapanisertib, ME- 344, sirolimus (oral nano-amorphous formulation, cancer), racemetyrosine (TYME-88 (mTOR / cytochrome P450 3A4)), temsirolimus (TORISEL®, CCI-779), CC-115, onatasertib (CC-223), SF-1126, and PQR-309 (bimiralisib). In some embodiments, Ras-driven cancers (e.g., NSCLC) having CDKN2A mutations can be inhibited by co-administration of the MEK inhibitor selumetinib and the CDK4 / 6 inhibitor palbociclib. See, e.g., Zhou, et al., Cancer Lett. 2017 Nov 1;408:130-137. Also, K-RAS and mutant N-RAS can be reduced by the irreversible ERBB1 / 2 / 4 inhibitor neratinib. See, e.g., Booth, et al., Cancer Biol Ther. 2018 Feb 1;19(2):132-137. Mitogen-activated Protein Kinase (MEK) Inhibitors

[0271] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of mitogen-activated protein kinase kinase 7 (MAP2K7, JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7, SAPKK-4, SAPKK4; NCBI Gene ID: 5609). Examples of MEK inhibitors include antroquinonol, binimetinib, cobimetinib (GDC-0973, XL-518), MT-144, selumetinib (AZD6244), sorafenib, trametinib (GSK1120212), uprosertib + trametinib, PD-0325901, pimasertib, LTT462, AS703988, CC-90003, and refametinib. Phosphatidylinositol 3-kinase (PI3K) Inhibitors

[0272] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf),(IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of a phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, e.g., phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA, CLAPO, CLOVE, CWS5, MCAP, MCM, MCMTC, PI3K, PI3K-alpha, p110-alpha; NCBI Gene ID: 5290); phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta (PIK3CB, P110BETA, PI3K, PI3KBETA, PIK3C1; NCBI Gene ID: 5291); phosphatidylinositol- 4,5-bisphosphate 3-kinase catalytic subunit gamma (PIK3CG, PI3CG, PI3K, PI3Kgamma, PIK3, p110gamma, p120-PI3K; Gene ID: 5494); and / or phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta (PIK3CD, APDS, IMD14, P110DELTA, PI3K, p110D, NCBI Gene ID: 5293). In some embodiments the PI3K inhibitor is a pan-PI3K inhibitor. Examples of PI3K inhibitors include ACP-319, AEZA-129, AMG-319, AS252424, AZD8186, BAY 10824391, BEZ235, buparlisib (BKM120), BYL719 (alpelisib), CH5132799, copanlisib (BAY 80-6946), duvelisib, GDC-0032, GDC-0077, GDC-0941, GDC-0980, GSK2636771, GSK2269557, idelalisib (Zydelig®), INCB50465, IPI-145, IPI-443, IPI-549, KAR4141, LY294002, LY3023414, MLN1117, OXY111A, PA799, PX-866, RG7604, rigosertib, RP5090, RP6530, SRX3177, taselisib, TG100115, TGR-1202 (umbralisib), TGX221, WX-037, X-339, X-414, XL147 (SAR245408), XL499, XL756, wortmannin, ZSTK474, and the compounds described in WO2005113556 (ICOS), WO 2013 / 052699 (Gilead Calistoga), WO2013116562 (Gilead Calistoga), WO2014100765 (Gilead Calistoga), WO2014100767 (Gilead Calistoga), and WO2014201409 (Gilead Sciences). Spleen Tyrosine Kinase (SYK) Inhibitors

[0273] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an inhibitor of spleen associated tyrosine kinase (SYK, p72-Syk, NCBI Gene ID: 6850). Examples of SYK inhibitors include 6-(1H-indazol-6-yl)-N-(4- morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine, BAY-61-3606, cerdulatinib (PRT-062607), entospletinib, fostamatinib (R788), HMPL-523, NVP-QAB 205 AA, R112, R343, tamatinib (R406), gusacitinib (ASN-002), and those described in US8450321 (Gilead Connecticut) and US20150175616.Toll-Like Receptor (TLR) Agonists

[0274] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an agonist of a toll-like receptor (TLR), e.g., an agonist of TLR1 (NCBI Gene ID: 7096), TLR2 (NCBI Gene ID: 7097), TLR3 (NCBI Gene ID: 7098), TLR4 (NCBI Gene ID: 7099), TLR5 (NCBI Gene ID: 7100), TLR6 (NCBI Gene ID: 10333), TLR7 (NCBI Gene ID: 51284), TLR8 (NCBI Gene ID: 51311), TLR9 (NCBI Gene ID: 54106), and / or TLR10 (NCBI Gene ID: 81793). Example TLR7 agonists that can be co-administered include DS-0509, GS-9620 (vesatolimod), vesatolimod analogs, LHC-165, TMX-101 (imiquimod), GSK- 2245035, resiquimod, DSR-6434, DSP-3025, IMO-4200, MCT-465, MEDI-9197, 3M-051, SB- 9922, 3M-052, Limtop, TMX-30X, TMX-202, RG-7863, RG-7795, BDB-001, DSP-0509, and the compounds disclosed in US20100143301 (Gilead Sciences), US20110098248 (Gilead Sciences), and US20090047249 (Gilead Sciences), US20140045849 (Janssen), US20140073642 (Janssen), WO2014056953 (Janssen), WO2014076221 (Janssen), WO2014128189 (Janssen), US20140350031 (Janssen), WO2014023813 (Janssen), US20080234251 (Array Biopharma), US20080306050 (Array Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma), US20120082658 (Ventirx Pharma), US20120219615 (Ventirx Pharma), US20140066432 (Ventirx Pharma), US20140088085 (Ventirx Pharma), US20140275167 (Novira Therapeutics), and US20130251673 (Novira Therapeutics). An TLR7 / TLR8 agonist that can be co-administered is NKTR-262. Example TLR8 agonists that can be co-administered include E-6887, IMO-4200, IMO-8400, IMO-9200, MCT-465, MEDI-9197, motolimod, resiquimod, GS-9688, VTX-1463, VTX-763, 3M-051, 3M- 052, and the compounds disclosed in US20140045849 (Janssen), US20140073642 (Janssen), WO2014 / 056953 (Janssen), WO2014 / 076221 (Janssen), WO2014 / 128189 (Janssen), US20140350031 (Janssen), WO2014 / 023813 (Janssen), US20080234251 (Array Biopharma), US20080306050 (Array Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma), US20120082658 (Ventirx Pharma), US20120219615 (Ventirx Pharma), US20140066432 (Ventirx Pharma), US20140088085 (Ventirx Pharma), US20140275167 (Novira Therapeutics), and US20130251673 (Novira Therapeutics). Example TLR9 agonists that can be co-administered include AST-008, CMP-001, IMO-2055, IMO-2125, litenimod, MGN-1601, BB-001, BB-006, IMO-3100, IMO-8400, IR-103, IMO-9200, agatolimod, DIMS-9054, DV-1079, DV-1179, AZD-1419, leftolimod (MGN-1703),CYT-003, CYT-003-QbG10 and PUL-042. Examples of TLR3 agonist include rintatolimod, poly-ICLC, RIBOXXON®, Apoxxim, RIBOXXIM®, IPH-33, MCT-465, MCT-475, and ND- 1.1. Tyrosine-kinase Inhibitors (TKIs)

[0275] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with a tyrosine kinase inhibitor (TKI). TKIs may target epidermal growth factor receptors (EGFRs) and receptors for fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF). Examples of TKIs include without limitation afatinib, ARQ-087 (derazantinib), asp5878, AZD3759, AZD4547, bosutinib, brigatinib, cabozantinib, cediranib, crenolanib, dacomitinib, dasatinib, dovitinib, E-6201, erdafitinib, erlotinib, gefitinib, gilteritinib (ASP-2215), FP-1039, HM61713, icotinib, imatinib, KX2-391 (Src), lapatinib, lestaurtinib, lenvatinib, midostaurin, nintedanib, ODM-203, osimertinib (AZD-9291), ponatinib, poziotinib, quizartinib, radotinib, rociletinib, sulfatinib (HMPL-012), sunitinib, famitinib L-malate, (MAC-4), tivoanib, TH-4000, and MEDI-575 (anti-PDGFR antibody). Exemplary EGFR targeting agents include neratinib, tucatinib (ONT-380), tesevatinib, mobocertinib (TAK-788), DZD-9008, varlitinib, abivertinib (ACEA-0010), EGF816 (nazartinib), olmutinib (BI-1482694), osimertinib (AZD-9291), AMG-596 (EGFRvIII / CD3), lifirafenib (BGB-283), vectibix, lazertinib (LECLAZA®), and compounds disclosed in Booth, et al., Cancer Biol Ther. 2018 Feb 1;19(2):132-137. Antibodies targeting EGFR include without limitation modotuximab, cetuximab sarotalocan (RM-1929), seribantumab, necitumumab, depatuxizumab mafodotin (ABT-414), tomuzotuximab, depatuxizumab (ABT-806), and cetuximab. Chemotherapeutic Agents

[0276] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with a chemotherapeutic agent or anti-neoplastic agent.

[0277] As used herein, the term “chemotherapeutic agent” or “chemotherapeutic” (or “chemotherapy” in the case of treatment with a chemotherapeutic agent) is meant to encompass any non-proteinaceous (e.g., non-peptidic) chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include but not limited to: alkylating agents such as thiotepaand cyclophosphamide (CYTOXAN®); alkyl sulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodepa, carboquone, meturedepa, and uredepa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimemylolomelamine; acetogenins, e.g., bullatacin and bullatacinone; a camptothecin, including synthetic analog topotecan; bryostatin, callystatin; CC- 1065, including its adozelesin, carzelesin, and bizelesin synthetic analogs; cryptophycins, particularly cryptophycin 1 and cryptophycin 8;dolastatin; duocarmycin, including the synthetic analogs KW-2189 and CBI-TMI; eleutherobin; 5-azacytidine; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cyclophosphamide, glufosfamide, evofosfamide, bendamustine, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, and uracil mustard; nitrosoureas such as carmustine, chlorozotocin, foremustine, lomustine, nimustine, and ranimustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gammaII and calicheamicin phiI1), dynemicin including dynemicin A, bisphosphonates such as clodronate, an esperamicin, neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromomophores, aclacinomycins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carrninomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino- doxorubicin, and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, and zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5- FU); folic acid analogs such as demopterin, methotrexate, pteropterin, and trimetrexate; purine analogs such as cladribine, pentostatin, fludarabine, 6-mercaptopurine, thiamiprine, and thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, and testolactone; anti- adrenals such as aminoglutethimide, mitotane, and trilostane; folic acid replinishers such as frolinic acid; radiotherapeutic agents such as Radium-223; trichothecenes, especially T-2 toxin, verracurin A, roridin A, and anguidine; taxoids such as paclitaxel (TAXOL®), abraxane, docetaxel (TAXOTERE®), cabazitaxel, BIND-014, tesetaxel; sabizabulin (Veru-111); platinum analogs such as cisplatin and carboplatin, NC-6004 nanoplatin; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; hestrabucil; bisantrene; edatraxate;defofamine; demecolcine; diaziquone; elformthine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; leucovorin; lonidamine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; losoxantrone; fluoropyrimidine; folinic acid; podophyllinic acid; 2-ethylhydrazide; procarbazine; polysaccharide-K (PSK); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; trabectedin, triaziquone; 2,2',2''-trichlorotriemylamine; urethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (“Ara-C”); cyclophosphamide; thiopeta; chlorambucil; gemcitabine (GEMZAR®); 6- thioguanine; mercaptopurine; methotrexate; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitroxantrone; vancristine; vinorelbine (NAVELBINE®); novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeoloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DFMO); retinoids such as retinoic acid; capecitabine; NUC-1031; FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin); FOLFIRI (folinic acid, 5-fluorouracil, irinotecan); FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, irinotecan), FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, oxaliplatin), and pharmaceutically acceptable salts, acids, or derivatives of any of the above. Such agents can be conjugated onto an antibody or any targeting agent described herein to create an antibody-drug conjugate (ADC) or targeted drug conjugate. Anti-hormonal Agents

[0278] Also included in the definition of “chemotherapeutic agent” are anti-hormonal agents such as anti-estrogens and selective estrogen receptor modulators (SERMs), inhibitors of the enzyme aromatase, anti-androgens, and pharmaceutically acceptable salts, acids or derivatives of any of the above that act to regulate or inhibit hormone action on tumors.

[0279] Examples of anti-estrogens and SERMs include tamoxifen (including NOLVADEXTM), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (FARESTON®).

[0280] Inhibitors of the enzyme aromatase regulate estrogen production in the adrenal glands. Examples include 4(5)-imidazoles, aminoglutethimide, megestrol acetate (MEGACE®), exemestane, formestane, fadrozole, vorozole (RIVISOR®), letrozole (FEMARA®), and anastrozole (ARIMIDEX®).

[0281] Examples of anti-androgens include apalutamide, abiraterone, enzalutamide, flutamide, galeterone, nilutamide, bicalutamide, leuprolide, goserelin, ODM-201, APC-100, ODM-204, enobosarm (GTX-024), darolutamide, and IONIS-AR-2.5Rx (antisense).

[0282] An example progesterone receptor antagonist includes onapristone. Additional progesterone targeting agents include TRI-CYCLEN LO (norethindrone + ethinyl estradiol), norgestimate + ethinylestradiol (Tri-Cyclen) and levonorgestrel. Anti-Angiogenic Agents

[0283] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an anti-angiogenic agent. Anti-angiogenic agents that can be co- administered include retinoid acid and derivatives thereof, 2-methoxyestradiol, ANGIOSTATIN®, ENDOSTATIN®, regorafenib, necuparanib, suramin, squalamine, tissue inhibitor of metalloproteinase-1, tissue inhibitor of metalloproteinase-2, plasminogen activator inhibitor-1, plasminogen activator inbibitor-2, cartilage-derived inhibitor, paclitaxel (nab- paclitaxel), platelet factor 4, protamine sulphate (clupeine), sulphated chitin derivatives (prepared from queen crab shells), sulphated polysaccharide peptidoglycan complex (sp-pg), staurosporine, modulators of matrix metabolism including proline analogs such as l-azetidine-2-carboxylic acid (LACA), cishydroxyproline, d,I-3,4-dehydroproline, thiaproline, α,α'-dipyridyl, beta- aminopropionitrile fumarate, 4-propyl-5-(4-pyridinyl)-2(3h)-oxazolone, methotrexate, mitoxantrone, heparin, interferons, 2 macroglobulin-serum, chicken inhibitor of metalloproteinase-3 (ChIMP-3), chymostatin, beta-cyclodextrin tetradecasulfate, eponemycin, fumagillin, gold sodium thiomalate, d-penicillamine, beta-1-anticollagenase-serum, alpha-2- antiplasmin, bisantrene, lobenzarit disodium, n-2-carboxyphenyl-4-chloroanthronilic acid disodium or “CCA”, thalidomide, angiostatic steroid, carboxy aminoimidazole, metalloproteinase inhibitors such as BB-94, inhibitors of S100A9 such as tasquinimod . Other anti-angiogenesis agents include antibodies, preferably monoclonal antibodies against these angiogenic growth factors: beta-FGF, alpha-FGF, FGF-5, VEGF isoforms, VEGF-C, HGF / SF, and Ang-1 / Ang-2. Examples for anti-VEGFA antibodies that can be co-administered include bevacizumab, vanucizumab, faricimab, dilpacimab (ABT-165; DLL4 / VEGF), or navicixizumab (OMP-305B83; DLL4 / VEGF).Anti-fibrotic Agents

[0284] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an anti-fibrotic agent. Anti-fibrotic agents that can be co- administered include the compounds such as beta-aminoproprionitrile (BAPN), as well as the compounds disclosed in US4965288 relating to inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen and US4997854 relating to compounds which inhibit LOX for the treatment of various pathological fibrotic states, which are herein incorporated by reference. Further exemplary inhibitors are described in US4943593 relating to compounds such as 2-isobutyl-3-fluoro-, chloro-, or bromo- allylamine, US5021456, US5059714, US5120764, US5182297, US5252608 relating to 2-(1- naphthyloxymemyl)-3-fluoroallylamine, and US 20040248871, which are herein incorporated by reference.

[0285] Exemplary anti-fibrotic agents also include the primary amines reacting with the carbonyl group of the active site of the lysyl oxidases, and more particularly those which produce, after binding with the carbonyl, a product stabilized by resonance, such as the following primary amines: emylenemamine, hydrazine, phenylhydrazine, and their derivatives; semicarbazide and urea derivatives; aminonitriles such as BAPN or 2-nitroethylamine; unsaturated or saturated haloamines such as 2-bromo-ethylamine, 2-chloroethylamine, 2-trifluoroethylamine, 3- bromopropylamine, and p-halobenzylamines; and selenohomocysteine lactone.

[0286] Other anti-fibrotic agents are copper chelating agents penetrating or not penetrating the cells. Exemplary compounds include indirect inhibitors which block the aldehyde derivatives originating from the oxidative deamination of the lysyl and hydroxylysyl residues by the lysyl oxidases. Examples include the thiolamines, particularly D-penicillamine, and its analogs such as 2-amino-5-mercapto-5-methylhexanoic acid, D-2-amino-3-methyl-3-((2-acetamidoethyl)dithio) butanoic acid, p-2-amino-3-methyl-3-((2-aminoethyl)dithio)butanoic acid, sodium-4-((p-1- dimethyl-2-amino-2-carboxyethyl)dithio)butane sulphurate, 2-acetamidoethyl-2- acetamidoethanethiol sulphanate, and sodium-4-mercaptobutanesulphinate trihydrate.Anti-Inflammatory Agents

[0287] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an anti-inflammatory agent. Example anti-inflammatory agents include without limitation inhibitors of one or more of arginase (ARG1 (NCBI Gene ID: 383), ARG2 (NCBI Gene ID: 384)), carbonic anhydrase (CA1 (NCBI Gene ID: 759), CA2 (NCBI Gene ID: 760), CA3 (NCBI Gene ID: 761), CA4 (NCBI Gene ID: 762), CA5A (NCBI Gene ID: 763), CA5B (NCBI Gene ID: 11238), CA6 (NCBI Gene ID: 765), CA7 (NCBI Gene ID: 766), CA8 (NCBI Gene ID: 767), CA9 (NCBI Gene ID: 768), CA10 (NCBI Gene ID: 56934), CA11 (NCBI Gene ID: 770), CA12 (NCBI Gene ID: 771), CA13 (NCBI Gene ID: 377677), CA14 (NCBI Gene ID: 23632)), prostaglandin-endoperoxide synthase 1 (PTGS1, COX-1; NCBI Gene ID: 5742), prostaglandin-endoperoxide synthase 2 (PTGS2, COX-2; NCBI Gene ID: 5743), secreted phospholipase A2, prostaglandin E synthase (PTGES, PGES; Gene ID: 9536), arachidonate 5- lipoxygenase (ALOX5, 5-LOX; NCBI Gene ID: 240), soluble epoxide hydrolase 2 (EPHX2, SEH; NCBI Gene ID: 2053) and / or mitogen-activated protein kinase kinase kinase 8 (MAP3K8, TPL2; NCBI Gene ID: 1326). In some embodiments, the inhibitor is a dual inhibitor, e.g., a dual inhibitor of COX-2 / COX-1, COX-2 / SEH, COX-2 / CA, COX-2 / 5-LOX.

[0288] Examples of inhibitors of prostaglandin-endoperoxide synthase 1 (PTGS1, COX-1; NCBI Gene ID: 5742) that can be co-administered include mofezolac, GLY-230, and TRK-700.

[0289] Examples of inhibitors of prostaglandin-endoperoxide synthase 2 (PTGS2, COX-2; NCBI Gene ID: 5743) that can be co-administered include diclofenac, meloxicam, parecoxib, etoricoxib, AP-101, celecoxib, AXS-06, diclofenac potassium, DRGT-46, AAT-076, meisuoshuli, lumiracoxib, meloxicam, valdecoxib, zaltoprofen, nimesulide, anitrazafen, apricoxib, cimicoxib, deracoxib, flumizole, firocoxib, mavacoxib, NS-398, pamicogrel, parecoxib, robenacoxib, rofecoxib, rutecarpine, tilmacoxib, and zaltoprofen. Examples of dual COX1 / COX2 inhibitors that can be co-administered include HP-5000, lornoxicam, ketorolac tromethamine, bromfenac sodium, ATB-346, HP-5000. Examples of dual COX-2 / carbonic anhydrase (CA) inhibitors that can be co-administered include polmacoxib and imrecoxib.

[0290] Examples of inhibitors of secreted phospholipase A2, prostaglandin E synthase (PTGES, PGES; Gene ID: 9536) that can be co-administered include LY3023703, GRC 27864, and compounds described in WO2015158204, WO2013024898, WO2006063466, WO2007059610,WO2007124589, WO2010100249, WO2010034796, WO2010034797, WO2012022793, WO2012076673, WO2012076672, WO2010034798, WO2010034799, WO2012022792, WO2009103778, WO2011048004, WO2012087771, WO2012161965, WO2013118071, WO2013072825, WO2014167444, WO2009138376, WO2011023812, WO2012110860, WO2013153535, WO2009130242, WO2009146696, WO2013186692, WO2015059618, WO2016069376, WO2016069374, WO2009117985, WO2009064250, WO2009064251, WO2009082347, WO2009117987, and WO2008071173. Metformin has further been found to repress the COX2 / PGE2 / STAT3 axis, and can be co-administered. See, e.g., Tong, et al., Cancer Lett. (2017) 389:23-32; and Liu, et al., Oncotarget. (2016) 7(19):28235-46.

[0291] Examples of inhibitors of carbonic anhydrase (e.g., one or more of CA1 (NCBI Gene ID: 759), CA2 (NCBI Gene ID: 760), CA3 (NCBI Gene ID: 761), CA4 (NCBI Gene ID: 762), CA5A (NCBI Gene ID: 763), CA5B (NCBI Gene ID: 11238), CA6 (NCBI Gene ID: 765), CA7 (NCBI Gene ID: 766), CA8 (NCBI Gene ID: 767), CA9 (NCBI Gene ID: 768), CA10 (NCBI Gene ID: 56934), CA11 (NCBI Gene ID: 770), CA12 (NCBI Gene ID: 771), CA13 (NCBI Gene ID: 377677), CA14 (NCBI Gene ID: 23632)) that can be co-administered include acetazolamide, methazolamide, dorzolamide, zonisamide, brinzolamide and dichlorphenamide. A dual COX- 2 / CA1 / CA2 inhibitor that can be co-administered includes CG100649.

[0292] Examples of inhibitors of arachidonate 5-lipoxygenase (ALOX5, 5-LOX; NCBI Gene ID: 240) that can be co-administered include meclofenamate sodium, zileuton.

[0293] Examples of inhibitors of soluble epoxide hydrolase 2 (EPHX2, SEH; NCBI Gene ID: 2053) that can be co-administered include compounds described in WO2015148954. Dual inhibitors of COX-2 / SEH that can be co-administered include compounds described in WO2012082647. Dual inhibitors of SEH and fatty acid amide hydrolase (FAAH; NCBI Gene ID: 2166) that can be co-administered include compounds described in WO2017160861.

[0294] Examples of inhibitors of mitogen-activated protein kinase kinase kinase 8 (MAP3K8, tumor progression loci-2, TPL2; NCBI Gene ID: 1326) that can be co-administered include GS- 4875, GS-5290, BHM-078 and those described in WO2006124944, WO2006124692, WO2014064215, WO2018005435, Teli, et al., J Enzyme Inhib Med Chem. (2012) 27(4):558-70; Gangwall, et al., Curr Top Med Chem. (2013) 13(9):1015-35; Wu, et al., Bioorg Med Chem Lett. (2009) 19(13):3485-8; Kaila, et al., Bioorg Med Chem. (2007) 15(19):6425-42; and Hu, et al., Bioorg Med Chem Lett. (2011) 21(16):4758-61.Tumor Oxygenation Agents

[0295] In some embodiments a compound of Formula (I), (Ia), (Ib), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIj), (IIk), (IIIa), (IIIa-1), (IIIa-2), (IIIa-3), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IVa), (IVa-1), (IVa-2), (V), (Va), (VI), or (VIa), provided herein, or pharmaceutically acceptable salt thereof, is administered with an agent that promotes or increases tumor oxygenation or reoxygenation, or prevents or reduces tumor hypoxia. Illustrative agents ...

Claims

  1. The compound or pharmaceutically acceptable salt, wherein the compound is, , or.

2. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

3. The pharmaceutical composition of claim 2, further comprising an additional therapeutic agent.

4. A method of treating an IKFZ2 protein associated disease or condition comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claims 2 or 3.

5. The method of claim 4, wherein the IKFZ2 associated disease or condition is cancer.

6. The method of claim 5, wherein the cancer is a hematological cancer selected from acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), B-cell ALL, myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), undifferentiated leukemia, small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), T-cell lymphoma, B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), Waldestrom’s macroglobulinemia (WM)) and multiple myeloma (MM).

7. The method of claim 5, wherein the cancer is a solid tumor and is selected from lung cancer, colorectal cancer, stomach cancer, renal cancer, ovarian cancer, testicular cancer, uterine cancer, urinary bladder cancer, breast cancer, prostate cancer, cervical cancer, pancreatic cancer and head and neck cancer.

8. The method of any one of claims 4 to 7, wherein the compound or pharmaceutically acceptable salt thereof is administered in combination with an additional therapeutic agent or therapeutic modality.

9. The pharmaceutical composition of claim 3 or the method of claim 8, wherein the additional therapeutic agent or additional therapeutic modality comprises one, two, three, or four additional therapeutic agents and / or therapeutic modalities.

10. The pharmaceutical composition of claim 3, or the method of claim 9, wherein the additional therapeutic agent or therapeutic modalities are selected from an immune checkpoint modulator, an antibody-drug conjugate (ADC), an antiapoptotic agent, a targeted anticancer therapeutic, a chemotherapeutic agent, surgery, or radiation therapy.

11. The pharmaceutical composition or method of claim 10, wherein the immune checkpoint modulator is selected from an anti-PD-(L)1 antibody, an anti-TIGIT antibody, an anti-CTLA4 antibody, an anti-CCR8 antibody, an anti-TREM1 antibody, an anti-TREM2 antibody, a CD47 inhibitor, a DGKa inhibitor, an HPK1 inhibitor, a FLT3 agonist, an adenosine receptor antagonist, a CD39 inhibitor, a CD73 inhibitor, an IL-2 variant (IL-2v), and a CAR-T cell therapy.

12. The pharmaceutical composition or method of claim 11, wherein the anti-PD-(L)1 antibody is selected from pembrolizumab, nivolumab, cemiplimab, pidilizumab, spartalizumab, atezolizumab, avelumab, durvalumab, cosibelimab, sasanlimab, tislelizumab, retifanlimab, balstilimab, toripalimab, cetrelimab, genolimzumab, prolgolimab, lodapolimab, camrelizumab, budigalimab, avelumab, dostarlimab, envafolimab, sintilimab, and zimberelimab.

13. The pharmaceutical composition or method of claim 11, wherein the anti-TIGIT antibody is selected from tiragolumab, vibostolimab, domvanalimab, AB308, AK127, BMS-986207, and etigilimab.

14. The pharmaceutical composition or method of claim 11, wherein the anti-CTLA4 antibody is selected from ipilimumab, tremelimumab, and zalifrelimab.

15. The pharmaceutical composition or method of claim 11, wherein the CD47 inhibitor is selected from magrolimab, letaplimab, lemzoparlimab, AL-008, RRx-001, CTX-5861, FSI-189 (GS-0189), ES-004, BI-765063, ADU1805, CC-95251, and Q-1801.

16. The pharmaceutical composition or method of claim 11, wherein the adenosine receptor antagonist is etrumadenant (AB928), taminadenant, TT-10, TT-4, or M1069.

17. The pharmaceutical composition or method of claim 11, wherein the CD39 inhibitor is TTX-030.

18. The pharmaceutical composition or method of claim 11, wherein the CD73 inhibitor is quemliclustat (AB680), uliledlimab, mupadolimab, ORIC-533, ATG-037, PT-199, AK131, NZV930, BMS-986179, or oleclumab.

19. The pharmaceutical composition or method of claim 11, wherein the IL-2v is aldesleukin (Proleukin), bempegaldesleukin (NKTR-214), nemvaleukin alfa (ALKS-4230), THOR-202 (SAR-444245), BNT-151, ANV-419, XTX-202, RG-6279 (RO-7284755), NL-201, STK-012, SHR-1916, or GS-4528.

20. The pharmaceutical composition or method of claim 11, wherein the ADC is selected from sacituzumab govitecan, datopotamab deruxtecan, enfortumab vedotin, and trastuzumab deruxtecan.

21. The pharmaceutical composition or method of claim 11, wherein the additional therapeutic agent is selected from idealisib, sacituzumab govitecan, magrolimab, GS-0189, GS-3583, zimberelimab, GS-4224, GS-9716, GS-6451, GS-1811 (JTX-1811), quemliclustat (AB680), etrumadenant (AB928), domvanalimab, AB308, PY159, PY314, AGEN-1223, AGEN-2373, axicabtagene ciloleucel and brexucabtagene autoleucel.

22. Use of the compound of claim 1 or pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of an IKFZ2 associated disease or condition.

Images